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Cannabinoid 2 Receptor Agonists Modulate Neuropathic Pain
and Cytokine Production

By

Jenny Linn Wilkerson

Abstract
The focus of the work in this dissertation is to elucidate the efficacy of
cannabinoid 2 receptor agonists, specifically targeting the spinal cord, for the
treatment of chronic neuropathic pain. Chemical structures for all cannabinoid
compounds utilized are displayed (Supplemental Figure A-1). As an orientation
for the reader, the organization of this dissertation consists of five components;
chapters 1 through 5. In the first chapter, a background is developed to acquaint
one with the topics of chronic pain, and the use of cannabinergic compounds for
chronic pain relief. This chapter is in the form of a review, and specifically
addresses (1) the underlying differences in physiological processes during
periods of acute pain compared to chronic pain, (2) the role of spinal cord glial
cells under conditions of chronic inflammation, reflecting what is seen under
chronic pain conditions, (3) the endogenous cannabinoid system, (4) evidence
that specifically targeting the cannabinoid 2 receptor in the spinal cord may
eventually be ideal for the treatment of chronic pain, and (5) the current clinical
trial endeavors utilizing cannabinoid 2 receptor agonists. Following the review,
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evidence will be presented in support of the stated specific aims. Specific aim 1
of this dissertation will be in the form of two published manuscripts.
The first manuscript, Chapter 2, explores the efficacy of one of the most widely
utilized cannabinoid 2 receptor agonists, AM1241 following a peri-spinal,
intrathecal injection. I display a dose-dependent effect, and the timecourse of the
compound’s

ability

to

reverse

pain

symptoms.

Further,

using

immunohistochemical techniques I detail a novel method of quantifying discrete
anatomical changes in the immunostaining of inflammatory markers via the use
of a computer assisted analysis of the entire spectral range of a variety of
fluorescently-tagged antibodies. I refer to this method as ‘spectral analysis’. This
spectral analysis approach is more sensitive and accuate than conventional
methods. Finally, this manuscript examines changes in critical factors known to
mediate pathological pain in both the dorsal horn of the spinal cord and the
dorsal root ganglia.
The second manuscript, Chapter 3, explores the efficacy of a novel cannabinoid
2 receptor agonist AM1710 belonging to a chemically distinct classification of
cannabinoid-like compounds following a peri-spinal, intrathecal injection. As in
the first manuscript, for this compound, I display a dose-dependent effect, and
the time course of the compound’s ability to reverse pain symptoms. Additionally,
spectral analysis methods are utilized to examine AM1710’s ability to alter levels
of critical factors known to mediate pathological pain, in both the spinal cord
dorsal horn and the dorsal root ganglia. Finally, this manuscript characterizes
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AM1710’s ability to act through anti-inflammatory pathways via peri-spinal glial
cells within the meninges surrounding the spinal cord to block the development of
neuropathic pain in a purely immune-mediated model of chronic pain.
Specific aim 2 is in the form of a fourth manuscript to be submitted for peerreview in The Journal of Pain. The studies presented here within Chapter 4, are
completed and provide evidence for AM1710’s specificity to act via a restricted
cannabinoid type 2 receptor, and not on the other classical cannabinoid receptor,
the cannabinoid type 1 receptor. Further, the use of transgenic mice that lack
functional cannabinoid 1 receptors uncovers a potentially novel and protective
role of the endocannabinoid system under chronic pain conditions.
Chapter 5 consists of a discussion of the main points from all the prior chapters
to support the overarching thesis that the use of cannabinoid 2 receptor agonists
is effective for the treatment of neuropathic pain. Additionally presented is a
critique of some of the methods used to conduct experiments, and a supporting
rationale for why these methods were selected. This dissertation concludes with
potential future directions of this work, to further elucidate the endocannabinoid
system for pain control.
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Abstract
Under normal conditions, acute pain processing consists of well-characterized
neuronal

signaling

events.

When

dysfunctional

pain

signaling

occurs,

pathological pain ensues. Glial activation and their released factors participate in
the mediation of pathological pain. The use of cannabinoid compounds for pain
relief is currently an area of great interest for both basic scientists and
physicians. These compounds, bind mainly either the cannabinoid receptor
subtype 1 (CB1R) or cannabinoid receptor subtype 2 (CB2R), and are able to
modulate pain. Although cannabinoids were initially only thought to modulate
pain via neuronal mechanisms within the central nervous system, strong
evidence now supports that CB2R cannabinioid compounds are capable of
modulating the activity or function of glia, (e.g. astrocytes and microglia) for pain
relief. However, the mechanisms underlying cannabinoid receptor-mediated pain
4

relief remain largely unknown. An emerging body of evidence supports that CB 2R
agonist compounds may prove to be powerful novel therapeutic candidates for
the treatment of chronic pain.
Keywords: review, endocannabinoid, MAGL, DRG, IL-1β, spinal cord, microglia,
astrocytes, CB2R
Chronic pathological pain is one of the most common reasons to seek medical
attention and is reaching worldwide epidemic proportions [1]. Chronic pain
becomes pathological as a consequence of abnormal pain signaling and is often
manifested in numerous diseases, such as diabetes, arthritis, amyotrophic lateral
sclerosis (ALS), multiple sclerosis (MS), and cancer [2-6]. Glial cells, which
include oligodendrocytes, astrocytes and microglia, have been found to play key
roles when chronic pain becomes pathological. Given less is known about the
involvement of oligodendrocytes, this review will focus primarily on astrocytes
and microglial cells in chronic pain processing.
Cannabinoid compounds are emerging as novel therapeutic targets for the
treatment of chronic neuropathic pain [7]. These compounds, with subsequent
CB1 and CB2 receptor (CB1R and CB2R, respectively) activation, are able to
modulate pain through a number of mechanisms involving alterations in
microglial functions [8]. This review will first discuss how normal pain becomes
pathological and the role of activated glia in mediating such pain. These sections
will be followed by addressing cannabinoid-mediated modulation of glial
proinflammatory factors, which are known to produce chronic neuropathic pain in
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animal models. An emphasis will be made on the CB2R. Given this review
focuses on the action of the CB2R, a discussion is included on the current states
of clinical trials examining the potential efficacy of CB2R agonists as pain
therapeutics.

1.1 Normal vs. pathological pain
1.1.1 Acute Pain Signaling
Acute pain processing is distinct from the etiology underlying chronic pathological
pain. Distinguishing the cellular responses and underlying signaling cascades
that are unique to pathological pain may prove critical in understanding why
many neuronally-targeted treatments do not prove to be effective in relieving
chronic pathological pain in the clinical setting. In acute pain, such as that caused
by high intensity stimuli from mechanical stimulation (e.g. pinprick), unmyelinated
C and lightly myelinated Aδ nociceptive nerve fiber terminals in the body
depolarize and transduce this information into action potentials that travel
through the peripheral axon to the dorsal root ganglia (DRG). The centrally
projecting terminals of these nociceptors predominantly enter the spinal cord
dorsal horn to reach the superficial (laminae I - II) and deeper lamina IV-V, and
synapse onto second order pain projection neurons located in lamina I, IV and V
[9-11]. The classical neurotransmitter primarily responsible for synaptic
communication between nociceptors and pain projection neurons is the
excitatory amino acid glutamate. Glutamate then binds and activates the
ionotropic α-amino-3hydroxyl-5-methyl-4-isoxazolepropionic acid (AMPA) and
kainate receptors as well as metabotropic glutamate receptors (mGluR 1, 3, 5
6

and 7) [12]. Additionally, a number of nociceptive-related neuropeptides acting in
the spinal cord dorsal horn have been identified to play key roles in pain
neurotransmission. For example, the classic neuropeptide, substance P, is
released from primary nociceptive afferents [13]. Substance P then binds and
activates its receptor, neurokinin 1 (NK1), which is present in high concentrations
on dorsal horn lamina I neurons. Both substance P and its NK1 receptor are
widely known to play a significant role in nociceptive processing [14]. These
spinal cord nociceptive neurotransmitters, along with their receptors, are critical
for activating second order neurons, which communicate to supraspinal painprocessing centers and elicit reflexive and protective responses to avoid potential
or further tissue damage.

1.1.2 Central Sensitization
However, under some circumstances, incoming nociceptive signaling is
prolonged leading to clinical manifestations of pathological neuronal signaling.
Examples of such pathological states are hyperalgesia, which is decreased
threshold to nociceptive stimuli, and dynamic tactile allodynia, which is increased
sensitivity to non-nociceptive light touch. Both pain states often occur in regions
beyond the tissue-injured site. The underlying neurobiological events initiated by
prolonged nociceptive signaling include increased synaptic function triggered
within the central nervous system. Specifically, these events are known to occur
within the dorsal horn of the spinal cord, and culminate in a process termed,
spinal sensitization of pain projection neurons [15, 16]. Once triggered, this
central sensitization is sustained despite the termination of noxious input.
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Experimentally, continued activity is substantially extended following the end of
the stimulus application [17, 18]. These seminal early studies suggested that pain
may be experienced even in the absence of peripheral noxious stimuli.
Pathological pain results from inflammation and/or trauma to peripheral nerve(s),
tissue(s), or the central nervous system (CNS), and may arise as a complication
to numerous medical conditions. Various animal models have been developed to
induce conditions similar to those observed clinically. Neuropathic pain is
commonly studied in models of peripheral nerve injury/inflammation. Models of
diabetic neuropathy, chemotherapy-induced pain, post-surgical pain, and
osteoarthritis pain are well-established examples, and reports of these are cited
throughout this review. Although distinct in disease etiology, peripheral
neuropathies share in the manifestation of pathological pain. This pathological
processing is initially triggered by incoming noxious signals from nociceptors
leading to central sensitization. One classically known mechanism for spinal
sensitization involves excitation of pain projection neurons in the superficial
laminae of the spinal cord dorsal horn as well as wide dynamic range neurons
(WDR) located in deeper lamina IV and V that process the rapid and intense
nerve depolarizations. Following prolonged and significant depolarization by the
actions of glutamate and substance P, spinal pain projection neurons become
sensitized, leading to the activation of N-Methyl-D-Aspartic Acid (NMDA)
receptors that are normally inactive due to a Mg2+ plug within the cation channel.
Prolonged depolarization induces Mg2+ release followed by enhanced influx of
Ca2+ [19, 20]. A cascade of intracellular events occurs, which ultimately leads to
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post-synaptic enhancement of AMPA and mGlu receptor action, thereby
increasing synaptic efficacy [21].

1.1.3 Sensory Changes in Pathological Pain
Increasing synaptic efficacy exerts profound changes in dorsal horn sensory
processing [16, 22]. Indeed, enhanced synaptic efficacy, initiated by low intensity
mechanosensitive Aβ fibers, occurs at synapses on pain projection neurons in
the dorsal horn [23], creating the perceptual equivalent of a noxious stimulus.
Activated low-intensity Aβ fibers, that carry non-painful information such as light
touch, are now capable of activating high intensity nociceptive neurons resulting
in the clinical phenomenon known as allodynia. That is, non-painful light touch is
coded as painful, leading to a pain sensation that occurs in the absence of
noxious input. Despite the fact that the stimulus is initiated in the periphery, its
manifestation is a consequence of central changes like sensitization in the spinal
cord [15]. Both allodynia and hyperalgesia are a hallmark of pathological pain
[15, 16].

1.2 The role of glia in pathological pain
1.2.1 Glial activation
While it is clear that neuronal processes are critical for spinal sensitization
leading to pathological pain signaling, non-neuronal glial mechanisms are also
important [24]. Under persistent pathological conditions, the availability of
neuropeptides, such as substance P and amino acid neurotransmitters like
glutamate are increased and able to bind their receptors not only on neurons, but
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also on astrocytes as well as parenchymal and perivascular microglia. Glial
“activation” ensues and sets in motion a cascade of excitatory signaling events
[25].
At the onset and during pathological pain conditions, multiple signaling cascades
within glia are triggered including the activation of p38 mitogen activated protein
kinase (p-p38MAPK) and the c-Jun N-terminal kinase (JNK) pathways via
phosphorylation events. Consequently, downstream cascades are initiated,
including NF-κβ activation, a cytokine nuclear transcription factor, and lead to the
subsequent production of pro-inflammatory cytokines such as interleukin-1β (IL1β) and tumor necrosis factor-α (TNF-α), as well as chemokines (chemoattractant cytokines) [25-30]. It is important to note that multiple signaling
pathways can activate NF-κβ leading to altered gene expression. For example,
glially released TNF-α, when bound to its receptor, leads to phosphorylation of
p38MAPK (p-p38MAPK) and NF-κβ activation. Alternatively, IL-1β, when bound
to its receptor, can directly activate NF-κβ [31, 32]. In the spinal cord, IL-1β and
TNF-α can further directly excite neurons because neurons express receptors for
these cytokines. Indirect neuronal stimulation occurs by cytokine-induced release
of additional excitatory mediators such as prostaglandins and nitric oxide (NO). It
has been reported that spinal p38MAPK, JNK and the extracellular signalregulated kinase, ERK1/2, also referred to as MAPK3/1, are critical mediators of
pathological pain in animal models [33-37]. For example, sciatic nerve ligation
(SNL), a well characterized rodent model of peripheral nerve injury, leads to
increased p38MAPK in spinal astrocytes and microglia, and upon spinal
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pharmacological blockade with the p-p38MAPK inhibitor SB203580, p38MAPK
activation with associated neuropathic pain is diminished [34]. Although very little
is known about oligodendrocyte signaling in chronic pain, emerging evidence
suggests that these cells are not merely passive observers to chronic pain, but
rather these cells may also up-regulate (phosphorylated) p-AKT, a factor that has
been found to mediate apoptosis, cell migration and motility in the dorsal horn of
the spinal cord. Phosphorylated-AKT may be critical to the previously discussed
spinal cord neuronal sensitization process [38].
It is notable that activated microglia respond to and produce inducible nitric oxide
synthase (iNOS), and likewise activated astrocytes release NO [39, 40]. The
production of NO by both neurons and glia is characteristic of neuroinflammation
[41-44]. Thus, upon spinal glial activation from NO (among several other
activating factors), intracellular signaling cascades lead to increases in cytokines
and diffusible factors that further activate neighboring neurons and glia. That is,
IL-1β and TNF-α lead to a feed-forward loop of further JNK and MAPK signaling,
NF-κβ activation, and increased NO, cytokine, and chemokine production, which
all contribute to ongoing pathological pain.
While microglia and immune-like astrocytes respond to spinal IL-1β and TNF-α
resulting in pathological pain, increased peripheral immune cell (neutrophils,
lymphocytes, monocytes, macrophages) migration to critical regions of
nociceptive processing, such as the DRG and the spinal cord dorsal horn also
occurs in response to cytokines [39, 45-47]. The specific underlying mechanisms
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are poorly understood. What is known, however, is that cellular enrichment at
these critically important anatomical sites takes place via increased immune cell
actin remodeling and proliferation in response to chemotactic signaling [45, 48,
49].

1.2.2 Glial morphology and activation markers
Activated glial cells typically undergo changes in morphology, proliferation and
migration, termed gliosis. For example, astrocytes up-regulate vimentin and glial
fibrillary acidic protein (GFAP), and become highly arborized with thickened
processes [50]. These changes in morphology and increased GFAP expression
are often considered a sign of spinal cord pathogenesis during the expression of
neuropathic pain in animal models, and are thought to be indicative of CNS
inflammatory processes [26, 50, 51]. A report examining cellular enrichment of
the spinal cord in a peripheral nerve injury rat-model of pain identified that
microglial cells are more proliferative and undergo more clustering than
astrocytes [52]. Microglia, when activated, typically up-regulate the cellular
makers, ionized calcium binding adaptor molecule-1 (Iba-1), and CD11b/c, also
known as OX42 [52-57]. However, the up-regulation of these proteins is not
always indicative of proinflammatory phenotypic processes of glial cells. For
example, activated microglia can additionally express ED2, a classic antiinflammatory marker, suggesting that activated microglia are not solely engaged
in proinflammatory processes [58, 59].
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Although these cellular changes have been widely documented in animal models
of chronic pain, less is known about whether glial activation always reflects
inflammation and whether it contributes to chronic pain in humans. What is
known is that gliosis occurs within the spinal cord of patients with neuroimmune
diseases such as ALS, MS, and spodylytic myopathy [60, 61]. It is noteworthy
that these patients often report chronic pain symptoms [4, 6]. Furthermore, post
mortem tissue analysis from these patients often reveals gliosis concominant
with the disease, and as such, these glial changes may contribute to chronic pain
in these patients. However, the role of these cellular markers in animal models of
chronic pain are not fully understood, as reports show a disconnection between
glial marker up-regulation, proinflammatory signaling markers, and behavior
associated with pain. For example, while fluorocitrate attenuated up-regulation of
GFAP in mice with the chronic constriction injury of the sciatic nerve (CCI),
another commonly used model of chronic neuropathic pain, chronic pain
symptoms remained unchanged [53]. Additionally, in separate studies utilizing a
paw incision model of postsurgical pain, chronic morphine administered
subcutaneously delayed the normal resolution of allodynia and hyperalgesia,
which

was

observed

with

saline-injected

controls.

Tissues

from

the

corresponding groups in this study were analyzed for GFAP, Iba-1, p-ERK and pp38MAPK, with saline injected animals showing clear behavioral resolution,
which was absent in the morphine treated groups. Strikingly, no differences in
GFAP or Iba-1 immunoreactivity were observed between saline or chronic
morphine-treated groups. However, p-ERK and p-38MAPK were increased in the
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chronic morphine treated groups, corresponding to their behavioral profile [62].
Conversely, perivascular microglia have been shown to remain in an activated
state as assessed by immunohistochemical detection of ED2 during the
presence of pain reversal [63]. From these studies, and as noted previously, the
presence or absence of glial activation, per se, is too simplistic to fully
understand a glial role in chronic pain. It is possible that microglia can remain
activated while producing and releasing anti-inflammatory factors that ultimately
lead to pain suppression [64, 65].

1.2.3 Downstream glial signaling of cytokines
Both IL-1β and TNF-α induce chemotactic activity on CNS microglia and
astrocytes. Indeed, once activated, microglia and astrocytes are well known to
undergo migration and proliferation in the spinal cord under conditions of chronic
pain [52]. Recently, it has been shown that an increase in glial cell numbers
occurs within the ipsilateral dorsal horn of the spinal cord following unilateral
peripheral nerve injury [66].
During pathological pain states, peripheral immune cells additionally migrate to
critical CNS pain processing sites. However, the contribution of peripheral vs.
CNS immune cell actions with subsequent cytokine signaling to neuropathic pain
is not fully understood. Rat spinal cord meninges contain peripheral
immunocompentent cells such as macrophages, and following in vitro stimulation
of isolated meninges with the administration of the HIV-1 envelope glycoprotein
gp120, IL-1β and TNF-α were released [67]. These data suggest that meningeal

14

cells, characterized to include peripheral immune cells like macrophages,
contribute to ongoing spinal cord glial activation via proinflammatory cytokine
actions. Given these compelling data, we explored the possibility that
anatomically intact meninges contain macrophages that express IL-1β. Here, we
utilized immunofluorescent histochemical procedures followed by detection with
confocal microscopy and demonstrated that IL-1β is indeed present within the
meningial layers surrounding the spinal cord of neuropathic rats (Figure 1.1.
A,B,C). Histologically, these data confirm prior reports showing, via in situ
hybridization, that IL-1β mRNA was co-labeled with Iba-1 [68], indicating
infiltrating monocytes/ macrophages. Within deeper dorsal horn laminae, IL-1β is
co-labeled with Iba-1 that also identifies microglia (Figure 1.1 D, E, F). While we
found some co-labeling of IL-1β with GFAP, no co-labeling with NF-H (data not
shown) within the dorsal horn of the spinal cord was observed. Given the
evidence that immune cell and glial-derived IL-1β (as well as other cytokines
discussed, above) has a critical role in animal models of pathological pain,
treatments focused on targeting neurons alone is now thought to be an
incomplete approach. Immune and glial cells within the CNS may serve as novel
targets to modulate enduring pathological pain.
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Figure 1.1 Qualitative confocal images of cellular immunostaining.
A, Immunostaining of Iba-1 (red) for infiltrating macrophages and microglia in the meninges and
superficial white matter of the spinal cord in a rat with ongoing neuropathy. B, Immunostaining
with IL-1β (green). C, Arrows indicate yellow co-labeling of IL-1β and Iba-1 positive cells and not
with GFAP (blue). D, Immunostaining of Iba-1 (red) in the deeper laminae of the spinal cord
dorsal horn in a rat with ongoing neuropathy. E, Immunostaining with IL-1β (green). F, Arrows
indicate yellow co-labeling of IL-1β and Iba-1 positive cells and not with GFAP (blue). G, DRG
immunostaining of GFAP positive satellite cells (red) and neurons stained for neurofilamentheavy (NF-H, white) from a rat with ongoing neuropathy. H, DRG immunostaining for IL-1β
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(green). I, Arrows indicate yellow DRG IL-1β and GFAP colabeling with DAPI nuclear labeling
(blue). J, Immunostaining of Iba-1 (red) in meninges and superficial laminae of the dorsal horn
spinal cord in a rat with ongoing neuropathy. K, Immunostaining of MAGL (green). L, Arrows
indicate yellow co-labeling of MAGL and Iba-1 positive cells, and not with GFAP (blue). Scale
bars for all images indicate 20 μm.

1.2.4 Glia in DRG
Glial satellite cells in the DRG are also important in mediating pathological pain in
addition to spinal cord glial cytokine actions. Satellite glia completely surround
DRG neurons and together form a functional unit [69]. Glial satellite cells become
activated and contribute to pathological pain in response to peripheral injury by
several possible mechanisms [69-72]. For example, glial satellite cells generate
cytokines, including IL-1β, and TNF-α, which have been characterized to activate
peripheral immune cells [70, 72-74]. DRG invasion by peripheral immune cells
[75-77] occurs as a consequence of peripheral nerve injury [29, 78, 79]. Neuroimmune activity is a potential mechanism because DRG neurons have receptors
for these cytokines, and when stimulated, lead to the production of the
chemokine monocyte chemotractant protein -1 (MCP-1), which induces
peripheral immune cell migration to the DRG [49, 79]. In addition, neuroactive IL1β and other immune signals released from satellite glia act in a paracrine
fashion to stimulate neighboring sensory ganglia and their axons, creating
allodynia [69, 72, 80-82]. Indeed, stimulating sensory neurons in the DRG with
IL-1β leads to further axonal release of substance P [83] within the dorsal horn of
the spinal cord. IL-1β acts in a p-p38MAPK dependent manner in the DRG [80],
and increased p-p38MAPK expression is well-characterized in the DRG following
peripheral nerve injury that produces pathological pain [80, 84, 85]. Here we
show an example of DRG IL-1β in close proximity with sensory neurons. IL-1β is
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co-labeled with GFAP-positive satellite cells within a DRG from an animal with
ongoing CCI-induced neuropathy is shown (Fig. 1 G,H,I). The actions of gliallyreleased cytokines such as IL-1β on nearby neuronal processing in both spinal
cord and DRG indicate that, not only neuronal, but also glial systems are altered
during conditions that lead to and promote chronic pain. These data strongly
suggests that in order to efficiently control chronic or pathological pain associated
with numerous disease states, including diabetic neuropathy and cancer,
promising therapeutics will need to address this underlying glial contribution.

1.2.5 Modulating glial activation for pain relief
Several compounds specifically targeting glial activation have been developed
with the potential for the treatment of pain. While a full discussion of such
compounds is beyond the scope of this review (for review, see [86]), one
example drug is discussed here to underscore the supposition that altering glial
activation states is a highly promising approach to control pathological pain. An
example of a compound that targets microglial activation is minocycline, a wellcharacterized microglial inhibitor [87]. In numerous animal models, minocycline
robustly produces anti-allodynia and analgesia [53, 87-89]. However, globally
disrupting the function of microglia as well as peripheral immune cells may
produce unintended side-effects, such as increased susceptibility to CNS
infection [90]. An alternative approach using cannabinoid-related compounds
appears to be very promising for clinical pain relief. Cannabinoids may act in an
anti-inflammatory manner, and these anti-inflammatory actions may have a glial
role [7, 91]. Intriguingly, the cannabinoid receptor subtype 2, CB2R, has been
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identified primarily on microglia [92]. Published reports strongly suggest that
activation of this receptor subtype leads to pain control [93, 94]. In the remainder
of this review we will provide a brief overview of cannabinoids, specifically
discussing published data in support of cannabinoid-related compounds for pain
control with a glial-centric view.

1.3 The endocannabinoid system
1.3.1 Components of the endocannabinoid system
The endogenous cannabinoid (endocannabinoid) system is comprised of multiple
components, including receptors, ligands, and degradative enzymes. Each will
be discussed in turn, below. Within the past 6 years, an explosion of reports has
occurred on the endocannabinoid system and its potential role in modulating
numerous disease processes, including those associated with pathological pain
conditions. This is due, in part, following the identification of cells that express
cannabinoid receptors and subsequent signaling mechanisms. In general,
endocannabinoid signaling was thought to involve only neurons [95-97]. Glia in
the CNS had no role. However, immune cells, including microglia are now known
to be involved in endocannabinoid signaling cascades (discussed further, below).
While the underlying mechanisms involved in mediating the therapeutic effects of
the endocannabinoid system are still a mystery, new breakthroughs have
elucidated the bioavailability of endocannabinoids and cannabinoid receptor
action with regard to the mediation of pain processing.
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The two widely acknowledged cannabinoid receptors are the CB1R and the
CB2R. Both have shown great potential for the development of therapeutics
targeted at pain control. The putative cannabinoid receptor subtype of the
‘orphan’ receptor, GPR55 [98], remains controversial as several reports indicate
opposite pharmacological profiles [99-102]. Research targeting this receptor with
cannabinoid ligands has just begun to gain momentum, [99, 103-105]. However,
there are reports that at least five distinct cannabinoid receptors have been
identified [8]. The most well-characterized cannabinoid receptor, the CB1R is
primarily found on neurons within the heart, small intestine, urinary bladder and
vas deferens in the periphery and, within the CNS, has the highest
concentrations in the cerebellum, hippocampus, basal ganglia and cerebral
cortex [106-108]. However, the CB2R has a distinctly different distribution and is
primarily found on immune cells [109-111]. Current evidence demonstrates that
the endocannabinoid system may have potential as a target for pain control, and
thus the remainder of this review will focus on the endocannabinoid system
relative to pain therapeutics.

1.3.2 Classical cannabinoid receptor signaling
Both the CB1R and CB2R belong to the G-protein coupled receptor (GPCR)
superfamily, and couple to the inhibitory Gi/o and Gi, respectively. Activation of
either receptor leads to p42/44 MAPK signaling and inhibits adenylate cyclase,
limiting the ATP production of cyclic AMP (cAMP), and leading to lessened
activity of protein kinase A (PKA) [106, 112, 113]. CB1R activation, but not CB2R
activation, can modulate ionic Ca2+ and K+ channels, which is blocked with
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pertussis toxin, indicating that the CB1R Gi/o proteins are directly responsible for
modulation of these ion channels [106, 114-116]. Evidence exists that CB1R
activation can activate p38MAPK in vitro [117, 118]. However, this is a
paradoxical finding- because activation of p38MAPK can lead to increased pain
signaling, which opposes the therapeutic efficacy of CB 1R agonists for pain
control. A mechanism for these findings has not been elucidated, but may include
or be wholly dependent on, non-cannabinoid receptor signaling cascades. No
similar in vivo report exists detailing p38MAPK activation from CB1R activation.
Although a few of the above mentioned signaling properties of the CB 1R have
proven to be sufficient in leading to pain control, the practical implications of
CB1R agonists in a clinical setting are limited. The CB1R was first discovered as
the receptor for the major psychoactive ingredient in Cannabis sativa, Δ 9tetrahydrocannabinol (THC) which was first isolated in 1965 [119-121]. The
attractiveness for clinical application of compounds selectively acting on the
CB1R is limited by the development of tolerance [122] and its psychotropic
effects [7, 123], which include cognitive impairment [124], catalepsy [125-127],
hypothermia [127-129], and negative impacts on learning and memory [128,
129]. This is in contrast to the effects of cannabidiol, another active compound of
marijuana [130]. Cannabidiol does not produce unwanted CNS side-effects by
itself, but it is not widely thought to act robustly at either the CB 1R or the CB2R
due to low binding affinities observed in vitro [130]. Despite low CB1R and CB2R
binding properties that cannabidiol possesses, it remains as a promising
therapeutic for chronic pain treatment based on its anti-inflammatory actions.
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In vivo, cannabidiol within the CNS may still produce CB2R activation resulting in
anti-inflammatory properties. It was recently demonstrated in a mouse model of
diabetic neuropathy that intranasal administration of cannabidiol produces antiinflammatory actions via down-regulation of p-p38MAPK in spinal glia [131]. In
this animal model, spinal glia are characterized to become activated and
contribute to neuropathic conditions resulting in mechanical sensitivity and
thermal hyperalgesia through the activation of proinflammatory signaling
cascades like p38MAPK [132-134]. Cannabidiol is sufficient to produce
neuropathic pain relief that is dependent on CB2R activation [131]. These data
demonstrate that there is a critical link between cannabidiol’s therapeutic action,
which includes a CB2R role, to spinal glial activation and pain control.

1.3.3 Cannabinoid 2 receptors
The CB2R is predominantly found on immune cells, such as lymphocytes,
neutrophils, and macrophages, with the highest peripheral concentrations in the
spleen, lymph nodes and testes [92, 109-111]. Within the CNS, the CB2R is
found primarily on microglia, and some neurons specifically within the
hippocampus, cortex and substantia nigra [108, 135, 136]. However, the spinal
cord and DRG distribution of the CB2R is an area of much debate, as the current
literature frequently reports conflicting data. One report suggests the CB 2R is
expressed only on neurons [139], while a separate report reveals CB2R
expression on microglia, and to a lesser extent on neurons [96], and yet another
report demonstrates CB2R on microglia with no neuronal expression [138]. The
discrepancy between studies identifying the CB2R expression on specific cell
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types may be partially due to the recent discovery of two separate isoforms of the
CB2R. The most prevalent isoform of the CB2R within the periphery, termed
“CB2B”, is found extensively within the spleen, and to a lesser degree, in the
liver, intestines, and leukocytes. The shorter isoform, “CB2A”, is predominately
found within the brain, testes, and to a lesser degree in the spleen, kidney,
muscle and leukocytes [137]. As most commercially available antibodies for the
CB2R utilize CB2R isolated from spleen, it is possible that the CB2B isoform,
found in much greater abundance within the spleen than the CB2A isoform, is the
isoform

recognized

by

most

commercially

available

antibodies

for

immunohistochemistry. For example, Wotherspoon and colleagues, utilizing
immunohistochemistry and CB2R null mice, showed that CB2R expression was
induced by nerve ligation and was localized to the spinal cord superficial lamina
ipsilateral to the nerve damage, while null CB2R mice revealed no up-regulation
[138]. The authors suggest that CB2R was expressed on sensory afferent
terminals because co-localization with growth associated protein-43 and the
neuropeptide

galanin,

was

observed.

However,

Romero-Sandoval

and

colleagues demonstrated, also through immunohistochemistry, that the CB 2R
was primarily found on parenchymal and perivascular microglial cells. The
authors additionally noted very limited and sparse staining in neurons [91, 94,
139]. Lastly, in a study using in situ hybridization (ISH), CB2R mRNA was present
on immunohistochemically-identified microglia [135].
Based on the above-noted discrepancies of the cellular localization of the CB 2R
in the spinal cord, one possible consideration should be the animal model that is
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utilized. It has been demonstrated that the CB2R may not be up-regulated in the
dorsal horn of the spinal cord in inflammatory pain models, but rather in chronic
neuropathic pain models [135]. This suggests that the degree of CB2R upregulation in chronic pain is heavily dependent on the model. The type of the
injury induced in a specific model may dictate the overall receptor up-regulation
and the cellular co-localization of the CB2R. The CB2R isoform distribution within
the spinal cord and DRG under basal and chronic inflammatory pain conditions
has not been systematically examined. Given these potential confounds,
identifying the cellular distribution of the CB2R within the spinal cord remains
elusive.

1.3.4 Bioavailability of endocannabinoids
The endogenous cannabinoid system is also comprised of a number of
endogenous ligands for the CB1R and CB2R, which includes anandamide (AEA),
2-arachadonyl glyercol (2-AG), as well as degradative enzymes [140-143]. The
endocannabinoids AEA and 2-AG are produced and released from neurons and
microglia [92], which are controlled by enzymatic hydrolysis of fatty acid amide
hydrolase (FAAH) and monoacylglycerol lipase (MAGL), respectively [140, 142].
The enzyme MAGL has been identified on presynaptic axon terminals in brain,
suggesting it can terminate 2-AG activity in presynaptic nerve terminals [141,
143] of centrally projecting afferent nociceptors in the spinal cord dorsal horn.
Interestingly, it has been found that microglia release 2-AG, and functional MAGL
has been described in primary microglial cell cultures [144]. Recently, a novel
isoform of MAGL has been described in BV-2 microglial cell cultures, although it
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is uncertain if this isoform occurs within microglial cells in vivo [145]. To date,
MAGL cellular co-expression utilizing immunohistological techniques has not
been performed on pain-relevant spinal cord dorsal horn regions or spinal cord
tissue. We show here, utilizing confocal microscopy, that within the meningial
layer surrounding the spinal cord taken from behaviorally verified neuropathic
rats, MAGL is co-labeled with Iba-1 positive infiltrating monocytes. In superficial
laminae, MAGL is co-labeled with either resident microglia or infiltrating
monocytes/macrophages (Figure 1.1 J,K,L). We additionally observed in the
deeper dorsal horn laminae, that MAGL is co-labeled with Iba-1 positive
microglia, and morphologically identifiable neuronal cell bodies (data not shown).

1.3.5 The implications of the endocannabinoid system in pain modulation
Following

peripheral

nerve

or

tissue

injury,

increased

expression

of

endocannabinoids, CB2R, FAAH and MAGL occurs in DRG and spinal cord [92,
107, 146]. For example, AEA and 2-AG are up-regulated in DRG following L5
spinal nerve ligation (SNL), a well-described animal model that leads to
neuropathic pain [107]. Additionally, in a paw incision model of pain, 2-AG, widely
characterized to produce analgesia, was found to be up-regulated in the
ipsilateral lumbar spinal cord on days 3 and 9, and in the contralateral lumbar
spinal cord on days 1 and 9 after surgery [63]. These data suggest that
endocannabinoid compounds may act to counterbalance the cytokine actions
known to mediate neuropathic pain.
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Recent studies show that exogenous application of the endocannabinoids, AEA
and 2-AG, lead to pain control. Exogenous AEA administered spinally reverses
carageenan-induced nociception [147], and exogenous 2-AG injected into the
hindpaw blocks nociceptive responses due to formalin injection [148, 149].
Paradoxically, administration of exogenous AEA to the hindpaw or high
intrathecal doses, produces nociceptive behavior, and in both cases, is mediated
by the ionotropic transient receptor potential cation channel, superfamily V
subtype 1 (TRPV-1) [147, 150]. Several reports detail that the actions of AEA
may be mediated by TRPV-1, and as such, caution must be taken when
assigning endocannabinoid actions to only the CB1R or the CB2R.
Manipulating the enzymes responsible for the bioavailability of AEA or 2-AG is
additionally effective for pain control. Altering endocannabinoid levels by
inhibiting the actions of MAGL and/or FAAH increases available endogenous
AEA and 2-AG and results in therapeutic actions. Following localized
administration of MAGL inhibitors (JZL184, URB602) into rat hindpaws increases
local levels of 2-AG, with simultaneous attenuation of formalin-induced pain in
rats [148, 149]. Additionally, systemic administration of FAAH inhibitors (PF3845, URB597), MAGL inhibitors (JZL184, URB602) or the dual FAAH/MAGL
inhibitor, JZL195, increases CNS levels of AEA and 2-AG, with attenuation of
CCI-induced pain in mice [151, 152]. Specifically, the pharmacological FAAH
inhibitor, PF-3845 decreased allodynia and hyperalgesia in CCI-induced
neuropathic mice without the development of tolerance [127]. Numerous studies
have demonstrated that MAGL inhibitors increase 2-AG accumulation [127, 151,
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153]. However, recent studies indicate that following challenge with CB 1R
agonists,

increased

2-AG

availability

leads

to

CB1R

down-regulation,

desensitization and lessened CB1R effects [125, 127]. These data suggest that
significantly increasing the levels of 2-AG may not be a clinically viable approach
for treating chronic pain conditions.
Although pain behavior is suppressed following exogenous administration of 2AG and AEA or by increased levels of endocannabinods via enzyme inhibitors,
the exact mechanisms of these cannabinoids underlying the modulation of
inflammation and pain is not well understood. Studies are currently underway by
several groups to elucidate the mechanisms whereby the endocannabinoid
system is able to lead to pain control [63, 127, 151, 152]. Alkaitis and colleagues,
utilizing dual CB1R and CB2R antagonists, AM281 and AM630 respectively,
recently found that the endocannabinoid system plays critical roles in the
resolution of allodynia from surgical hindpaw incision, an animal model of postsurgical pain [63]. In addition, blocking the activation of both the CB 1R and the
CB2R resulted in increased p-p38MAPK levels in this model of post-surgical pain,
suggesting that constitutive endocannabinoid actions play a role in modulating pp38MAPK. These findings support that the endocannabinoid system alters
factors which are critical mediators of inflammatory processes underlying pain
responses in a wide range of medical conditions where chronic pain is a
component. Although speculative, CB2R actions during chronic pain may be
primed for enhanced activity to ultimately produce pain modulation following
CB2R stimulation, as down-regulation and desensitization previously noted to
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occur with the CB1R has not been observed with the CB2R [7, 93, 154].
Numerous synthetic CB2R agonists are currently being explored as potential
therapeutic interventions for the treatment of chronic pain.

1.4 Well-characterized CB2R synthetic compounds
Growing evidence that CB2R agonism appears to lack the adverse CNS effects
that activated CB1R exerts has fueled the development of clinically-viable CB2R
agonists. Therefore, a strong research effort in pursuit of the development and
characterization of synthetic CB2R agonists with modified chemical structures to
facilitate selective binding to the CB2R over the CB1R is ongoing. The remainder
of this review will address the current evidence of synthetic CB2R selective
compounds for the treatment of different animal models of pathological pain. This
is not an exhaustive review of all studies, but rather an overview. Additional
reviews detailing the chemistry, bioavailability, efficacy, and kinetics of specific
drug compounds are available elsewhere [7, 155, 156].
Synthetic agonists selective for CB2R have been shown to produce antiinflammatory effects with modulation of signaling cascades favorable for
controlling chronic pain. Caution must be used in assuming that specific antiinflammatory effects seen with a particular CB2R agonist will additionally be seen
with all other CB2R agonists, as the binding site for different compounds may not
be the same. This factor may further influence the cellular signaling pathways
that occur downstream of cannabinoid receptor binding, and the compound’s
ultimate intracellular fate, such as degradation by MAGL as opposed to FAAH.

28

Therefore, each selected CB2R agonist and its observed actions are presented in
a table (Table 1.1). The most recent findings for each compound are
summarized. JWH-015 is a CB2R selective agonist from the aminoalkylindole
classification of CB2R agonists with a 27-fold affinity for the CB2R over the CB1R
[157, 158]. Collectively, the aminoalkylindoles represent the most studied group
of synthetic CB2R agonists. Romero-Sandoval and colleagues have recently
used a well-characterized in vitro model of inflammation to examine the antiinflammatory actions of JWH-015. Lipopolysaccharide (LPS), an outer cell-wall
particle of gram-negative bacteria which strongly activates innate immune cells,
was given to macrophages in cell culture. It was demonstrated that incubation
with JWH-015 leads to a decrease in phosphorylated extracellular signalregulated kinase-1 (P-ERK) that is mediated by mitogen-activated kinasephosphatase (MKP) 1 and 3 [91]. MKP-3 is a selective negative modulator of the
ERK-2 signaling pathway through negative feedback loop mechanisms, while in
the same in vitro studies, neither JNK nor p38MAPK signaling was affected [159].
CB2R agonist treatment failed to suppress LPS-stimulated increases in p-ERK-2
in the presence of MKP-3 inhibitors, supporting the possibility that CB2R agonists
exert anti-inflammatory actions via MKP-3 signaling [91]. These data support that
CB2R activation, by binding highly selective synthetic agonists, may control
proinflammatory processes.
Other CB2R agonists that produce therapeutic effects to control chronic pain are
described below. The compound AM1241, a CB2R selective agonist also from
the aminoalkylindole class, has a 36-fold affinity for the CB2R>CB1R [156, 160,
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161]. Despite the fact that it has been described as a protean agonist because it
exerts different inverse agonist properties [161], it is widely characterized as an
effective compound for pain suppression. For example, AM1241 has been found
to be effective in treating experimental models of bone cancer pain. Acute and
sustained intraperitoneal (i.p.) administration of AM1241 to mice decreased pain
symptoms and additionally lessened the amount of bone loss during bone
cancer-induced neuropathic pain. The authors suggest that these observations
were mediated via the CB2R, as acute behavioral effects observed were not
present with the addition of SR144528, a CB2R antagonist [162]. In a separate
study using two models of bone cancer pain, systemic administration of AM1241
was efficacious in reducing pain symptoms and was reliant on spinal CB 2R.
Interestingly, the authors concluded that the actions of opioid receptors were
necessary to achieve these analgesic effects, as the administration of naloxone,
a short-acting opioid antagonist in a replicate experiment, blocked the
development of AM1241-mediated analgesia [163]. The involvement of
endogenous opioids was further supported in mediating CB 2R analgesia by an
earlier study using non-neuropathic naïve rats [164]. However, Rahn and
colleagues have recently demonstrated that the anti-nociceptive effects of
systemic AM1241 in naïve rats are not dependent on the actions of opioid
receptors or downstream effects [165]. In this study, the reported dose of
AM1241 utilized by Ibrahim and colleagues, 0.1 mg/kg i.p, did not achieve
reliable effects, and so higher doses of AM1241, up to 1 mg/kg were evaluated.
Additionally, in the SNL model of neuropathic pain, the effects of AM1241
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following i.p. administration were not blocked by naloxone suggesting that
AM1241 does not act via opioid receptors to exert analgesic effects [166] (Table
1.1). The discrepancy between these studies suggests that bone cancer pain
may uniquely involve endorphin-endocannabinoid interactions while other
discrete peripheral nerve lesions or naïve conditions may involve only the
endocannabinoid system.
Spinal sensitization is a key component of chronic pathological pain. Thus,
compounds developed for chronic pain control will require centrally-mediated
actions and may be insufficient if they do not cross the blood brain barrier
because their actions will be sequestered to peripheral sites of pain processing.
A growing body of evidence supports that spinal administration of AM1241
produces significant control over pathological pain in several models using
peripheral manipulations. For example, intrathecal (peri-spinal, i.t.) AM1241
reverses allodynia induced by either SNL or intra-paw injection of complete
Freund’s adjuvant (CFA), a model of local inflammatory pain [166]. Additionally,
i.t. AM1241 has been found to reverse CCI-induced allodynia [167] and leads to
a corresponding decrease in spinal cord astrocyte activation of these previously
neuropathic animals [168]. In separate studies that used SNL to induce
peripheral neuropathy in rats, both astrocyte and microglial phenotypic markers
of activation were decreased following either i.t. administration of JWH-015 [94]
or i.p. administration of GW405833 [169], a partial CB2R agonist. Taken together,
these reports demonstrate that CB2R agonists are able to alter spinal glial
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activation states and create in vivo anti-inflammatory effects suitable for pain
control.
The ability for CB2R agonists to be administered without the development of
tolerance or reliance on μ-opioid actions within the spinal cord has been studied
utilizing GW405833. This compound is also classified as an aminoalkylindole,
and is additionally known as L-768,242. Conflicting reports of GW405833’s
affinity for the CB2R over the CB1R exist [156]. However, it is generally accepted
that at the human CB2R the compound displays a 1,200-fold affinity for the CB2R
over the CB1R, and at the rat CB2R there is a 78-fold affinity for the CB2R over
the CB1R [170]. Leichsenring and colleagues recently demonstrated that chronic
repeated i.p. injection of GW405833 was able to provide sustained reversal from
allodynia following SNL. That is, animals did not develop tolerance to this
compound, which was in stark contrast to treatment with the mixed CB 1R/CB2R
agonist, WIN55,212-22 [169]. Additionally, allodynia returned after intermittent
treatment of GW405833. The authors also performed immunohistochemistry and,
as previously noted, found diminished astrocyte and microglial activation.
However, after cessation of GW405833 treatment, astrocyte and microglial
activation returned, which occurred in parallel with the return of allodynia. In
addition to the above mentioned benefits of CB 2R agonist actions, it has recently
been reported that GW405833 can reverse CCI-induced increased helplessness
responses, as assessed in the forced swim test for rats, which is a model that
may elucidate depression-like symptoms in animals [171]. Furthermore,
GW405833 is efficacious in treating knee pain, however, these studies indicate
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that GW405833 may have partial agonist actions at the TRPV-1 [172]. While
endocannabinoids are capable of acting at the TRPV-1 receptor at high doses
that subsequently lead to TRPV-1 desensitization [173, 174], the report by
Schuleret and colleagues is the first electrophysiological demonstration of CB 2R
agonist actions on neuronal TRPV-1 ion channels. Further research is needed to
understand if the downstream signaling following GW405833 binding to neuronal
TRPV-1 may enhance this CB2R agonist compound’s anti-nociceptive actions.

1.5 Newer CB2R agonist compounds
Several newer classes of CB2R agonists have been developed to examine
therapeutic efficacy for chronic pain relief. AM1714 and AM1710 are members of
the novel cannabilactone classification [156, 175]. AM1710’s pharmacological
profile has recently been characterized both in vitro and in vivo [168, 176].
AM1710 does not cross the blood brain barrier, and is 57-fold more selective for
the CB2R over the CB1R [176]. Systemic i.p. AM1710 in naïve rats was able to
produce anti-nociceptive mechanical responses when a 100-fold dose range
(from 0.1mg/kg – 10mg/kg) was examined. At the 0.1 mg/kg dose, AM1710’s
effects were altered only by the administration of a CB 2R antagonist, but not the
administration of a CB1R antagonist. However, at the dose of 5 mg/kg, both
CB1R and CB2R antagonists diminished AM1710’s anti-nociceptive actions. The
doses of either 0.1 mg/kg or 10 mg/kg AM1710 did not produce behaviors
typically associated with CB1R activation. This was in stark contrast to the
observed CB1R induced effects from the mixed CB1R/CB2R agonist, WIN 55,2122. Anti-nociceptive effects of 5 mg/kg AM1710 were observed for as long as 120
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minutes after i.p. injection, while no effects at 0.1 mg/kg were observed at the
same timepoint, showing a dose effect on the duration of AM1710 efficacy [176].
In separate studies, i.t. injection of AM1710 reverses CCI-induced allodynia for
approximately 3 hours [167, 168]. Additionally i.t. pretreatment with AM1710
blocks the development of allodynia in a rat model of sterile spinal cord
inflammation using i.t. administration of the HIV-1 envelope glycoprotein, gp120
[168]. Separately, Rahn and colleagues have shown that AM1714 is capable of
reversing chemotherapy-induced pain [176] while AM1710 prevented pain in the
same model [177]. NESS400, a novel CB2R agonist, decreased spinal astrocyte
and microglial activation and reversed signs of neuropathic pain behavior
following i.p. administration [178]. MDA19 is also a novel CB2R agonist with
moderate selectivity for the CB2R over the CB1R (approximately 14-fold), and
displays properties of a protean agonist in vitro [179], like AM1241. MDA19 was
found to reverse both the spinal nerve ligation and chemotherapy-induced
models of chronic pain (Table 1).
Abbott Laboratories has developed two novel compounds, A-796260 and A836339, both of which are selective for the CB2R over the CB1R [180-182]. A796260, when given to rats i.p., was able to produce relief from local
inflammatory pain, neuropathic pain, postoperative pain, and osteoarthritis pain.
These effects were due only to the actions of the CB2R, and not CB1R or µ-opioid
receptor actions, and without the development of CB 1R mediated psychotropic
effects. It was found in vitro that A-836339 could act as a CB1R agonist, and
studies in vivo revealed that high doses of A-836339 produced CB1R mediated
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psychotropic effects [182]. Further studies with A-836339 reveal that this
compound was also efficacious in animal models of inflammatory, neuropathic,
postoperative, and osteoarthritis pain, when administered locally to the hindpaw,
intra-DRG, and intrathecally. As before, the actions of A-836339 at these sites
were due primarily to the CB2R, and not μ-opioid receptor agonism [166] (Table
1.1).
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Table 1.1
CB2R agonist effects from animal and clinical studies. For the compound/ produced by column, *
indicates compounds that are also examined in clinical trials. For the CB2R >CB1R selective
column, human binding (h), rat binding (r). For in vivo models of pain, the abbreviations are as
follows: local inflammatory pain models of lipopolysaccharide (LPS), complete Freund’s adjuvant
(CFA). The systemic visceral model of pain: intraperitoneal acetic acid (i.p. acetic acid).
Neuropathic pain models: chronic constriction injury (CCI), sciatic nerve ligation (SNL),
intraperitoneal chemotherapy induced pain (i.p. paxlitaxol), bone cancer induced pain (bone
cancer), osteoarthritis induction via knee joint synovium injection (knee joint osteoarthritis). Other
models of pain utilized are noted as: post-operative model of surgical pain (PSP), and intrathecal
administration of the HIV-1 envelope glycoprotein, gp120 (i.t. gp120).

Several independent groups have developed and characterized additional
promising CB2R selective compounds. The Lichtman laboratory has recently
synthesized an ethyl sulfonamide THC analog: O-3223. This compound is also a
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novel CB2R agonist with a 79-fold affinity for the CB2R over the CB1R, and
administration of this compound in naïve mice did not produce the psychotropic
effects associated with CB1R activation [183]. In vivo anti-nociceptive effects of
this compound were determined to be reliant on CB2R, but not CB1R function.
Pre-treatment with i.p. O-3223 was efficacious in lowering the amount of edema
in the paws of mice given the immune stimulant LPS, and i.p. O-3223 reversed
hyperalgesia in a mouse model of sciatic nerve ligation [183]. CBS0550 is a
novel CB2R agonist with high selectivity for the CB2R, and when given orally to
rats, was efficacious in reversing yeast cell-wall induced local inflammatory pain
[184]. Taken together, these studies reflect just a sample of the efforts being
made toward identifying optimal CB2R compounds for pain therapeutics (Table
1.1).

1.6 Clinical use of CB2R agonists
The current clinical trials using cannabinoid compounds for the treatment of
chronic pain have examined mixed CB1R/ CB2R agonists, or CB1R agonists.
Sativex, Marinol/Dronabinol, and Nabilone, all containing THC derivatives, have
reached late stage or regulatory approval in various countries [185, 186]. To
date, only three CB2R compounds have entered into clinical trials for human
evaluation. First noted by Beltramo [155], the progress of CB2Rs in clinical trials
has not been swift. Glenmark Pharmaceuticals reported in a press release (April
13th, 2009), that its CB2R compound, GRC10693, successfully completed a
phase I clinical trial, showing good tolerance and no serious adverse events in
the 80 healthy patients enrolled. This safety profile of GRC10693 was observed
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with the highest dose of GRC10693 evaluated – 1200 mg. Glenmark
Pharmaceuticals states that GRC10693 shows a CB2R selectivity of >4700-fold
over the CB1R. Additionally, peripheral and oral administration of GRC10693
showed efficacy in modulating the in vivo animal models of systemic acetic acidinduced visceral pain and hindpaw carageenan-induced local inflammation, as
well as CCI [187, 188]. However, the company has decided to not move forward
with phase II clinical trials, as it is currently contemplating licensing the
compound

to

other

pharmaceutical

companies

(http://www.glenmarkpharma.cz/clin2.php?lang=en). Early clinical trials showed a
safety and tolerability profile of Pharmos Scientific’s Cannabinor CB2R selective
compound, but it lacked reliable analgesia. Cannabinor is no longer being
developed

as

an

i.v.

therapeutic

(http://www.pharmoscorp.com/development/cannabinor.html). Glaxo-Smith-Klein
reports numerous phase I and II trials for its CB2R agonist GW842166X.
GW842166X was described as highly selective for the CB 2R over the CB1R, with
the ability to cross the blood brain barrier in animals. Additionally, this compound
showed efficacy in the CFA inflammatory model of pain, without the development
of tolerance [189] (Table 1.1). Interestingly, the only completed phase I clinical
trial examined the distribution of radiolabeled GW842166X (specifically,
[11c]GW842166X)

via

positron

emission

tomography

(PET)

analysis,

(http://clinicaltrials.gov/ct2/show/NCT00511524?term=GW842166X&rank=2).
The rationale was to identify whether this compound was able to cross the blood
brain barrier in 6 healthy males. All other phase I studies of this compound were
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terminated prior to study completion. Glaxo-Smith-Klein reports a total of 3 phase
II clinical studies, all aimed at oral dosing, with all reaching completion. The first
phase II study examined molar tooth extraction with enrollment in European
sites. The other two studies, also with European enrollment sites, examined
GW842166X efficacy in osteoarthritis pain (Table 1.1). Reports from these
studies have not been released, and all were completed by September, 2009.
The outcomes from the above-noted early clinical trials, specifically those of
Cannabinor from Pharmos Scientific, suggest that there may be intrinsic
differences between the cellular mechanisms within the human patient that has
suffered with pain for an indeterminate amount of time. Further, intrinsic
physiological differences may also exist, even in a closely monitored animal
model of pain. One potential explanation may lie within the previously described
spinal cord mechanisms underlying the maintenance of chronic pain. The clinical
studies described did not administer these CB2R agonist compounds to the
spinal cord. The restriction of these compounds to peripheral sites, (i.e., poor
blood brain barrier permeability) is desired to ensure that even minuscule CB 1R
non-specific binding within the CNS does not occur. This is thought to be an
optimal approach to avoid off-target (i.e., CB1R) psychotropic effects. However, it
may be that the administration of these compounds to reach the spinal cord is
necessary to produce enduring pain relief due to the potential spinal glial
mechanisms underlying chronic pathological pain. Indeed, the argument can be
made that these compounds, lipophilic in nature, do possess the ability to
penetrate the blood brain barrier. Additionally, it may be that these compounds,
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acting as very weak CB1R agonists within the CNS, at levels that do not produce
psychotropic or motor side effects, are beneficial in producing pain relief.

1.7 Summary
CB2R agonists are emerging as favorable therapeutics over CB 1R for the
treatment of chronic pain, as these compounds produce relief from pain
symptoms without the commonly reported CB1R-related side-effects, like
catalepsy and motor ataxia. CB2R agonists may exert their actions independently
from μ-opioid receptor actions, and no evidence currently exists related to the
development of tolerance or addiction following CB2R agonist administration.
While CB2R agonists appear to be highly promising as a new avenue for pain
therapeutics, the actual direct CNS and DRG effects of CB 2R agonists on the
endocannabinoid system are largely unknown. In addition, the CNS role in pain
modulation of the endocannabinoid system is itself currently not fully understood
and is an area of intense research. The findings discussed in this review suggest
that CB2R ligands hold promise as future therapeutics to treat chronic pain
problems. However, greater research efforts are required to yield new clinically
useful CB2R ligands, as the evidence and outcomes from clinical trials is limited
regarding the efficacy of these compounds. Although speculative, spinal CB2R
activation in humans may be necessary to reverse ongoing chronic pathological
pain. This approach would preferentially target activated glia which are critical
modulators of chronic neuropathic pain. Targeting glial cells, including microglial
cells, with CB2R ligands may hold the key to unlocking an efficacious treatment
for chronic pain patients.
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Abstract
During pathological pain, the actions of the endocannabinoid system, including
the cannabinoid 2 receptor, leads to effective anti-allodynia and modifies a
variety of spinal microglial and astrocyte actions. Here, following spinal
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administration of the cannabinoid 2 receptor compound, AM1241, we examined
immunoreactive alterations in proinflammatory markers, activated p38 mitogenactivated protein kinase, interleukin-1 β, the anti-inflammatory cytokine,
interleukin-10, as well as degradative endocannabinoid enzymes, and markers
for activated glia in neuropathic rats. In these studies the dorsal horn of the spinal
cord and dorsal root ganglia were examined. AM1241 produced profound antiallodynia and correspondingly restored basal immunoreactive levels of p38mitogen activated kinase, interleukin-1β, interleukin-10, and the endocannabinoid
enzyme monoacylglycerol lipase. In addition, astrocyte activation markers in the
dorsal root ganglia and the spinal cord were reset to basal values. In contrast,
spinal AM1241 did not suppress the increased microglial activation observed in
neuropathic rats. The differences in fluorescent markers were determined within
discrete anatomical regions by applying spectral analysis methods, which
virtually eliminated non-specific signal during the quantification of specific
immunofluorescent intensity. These findings provided reliable expression profiles
and support that intrathecal AM1241 controls pathological pain though antiinflammatory mechanisms by modulating critical glial factors, and additionally
decreases expression levels of endocannabinoid degradative enzymes.
Keywords: CCI, paraffin immunohistochemistry, MAGL, DRG, pain
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2.1 Introduction
Microglia and astrocytes (glia) play a crucial role in the development and
maintenance of chronic neuropathic pain in various animal models [24].
Increased glial activation is well known to occur in the dorsal horn of the spinal
cord in animal models of peripheral neuropathy, as demonstrated by increased
production of glial fibrillary acidic protein (GFAP) in astrocytes and ionized
calcium binding adaptor molecule -1 (Iba-1) in microglia [50, 93]. When strongly
activated, glia can increase expression of proinflammatory factors such as
phosphorylated p38 mitogen-activated protein kinase (p-p38MAPK) that can lead
to production and release of proinflammatory cytokines such as interleukin-1β
(IL-1β) and tumor necrosis factor- α (TNF-α), which subsequently bind and
activate their respective receptors on nearby neurons and glia [25, 29, 190]. The
cellular anatomical localization of p-p38MAPK is predominantly expressed and is
functionally important in spinal cord microglia and corresponding satellite cells in
dorsal root ganglia (DRG) during neuropathic pain [191-195]. IL-1β mRNA and
protein are upregulated within spinal cord homogenates of rats with pathological
pain [196]. However, immunohistochemical detection of increased IL-1β protein,
as well as alterations in the anti-inflammatory cytokine, interleukin-10 (IL-10), in
intact spinal cord dorsal horn from rats with peripheral neuropathy has not yet
been characterized. One goal of these studies is to quantify immunoreactivity
(IR) for IL-1β as well as IL-10 in sections of the intact dorsal horn from rats with
chronic peripheral neuropathy. In addition, changes in immunoreactive pp38MAPK levels were examined to verify prior reports that increases in p-
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p38MAPK occurs in combination with increased proinflammatory cytokine
expression. Peripheral neuropathy is assessed by the presence of allodynia,
characterized as a sensitivity to light mechanical touch that is not present under
healthy conditions.
AM1241 is a widely characterized cannabinoid agonist that controls hyperalgesia
(exaggerated nociceptive thresholds) and allodynia following intraperitoneal [197,
198], intravenous [199], intra-dorsal root ganglia (DRG), or intrathecal (i.t.) [166]
injection. In the current studies, we sought to determine the timecourse and
dose-dependent changes in allodynia produced by unilateral chronic constriction
injury (CCI) of the rat sciatic nerve following i.t. AM1241 administration to avoid
known peripheral actions of the compound. The development of bilateral
allodynia following unilateral CCI has been documented in numerous studies
[200-206]. We therefore followed not only bilateral sensory behavioral changes,
but also quantitative changes in the bilateral immunoreactivity of: (1) cytokines,
(2)

p-p38MAPK,

(3)

enzymes

responsible

for

the

bioavailability

of

endocannabinoids characterized to exert analgesic properties [151, 207, 208],
and (4) activated astrocytes and microglia in spinal cord and DRG.
Existing evidence shows that AM1241 acts as an agonist at the cannabinoid type
2 receptor (CB2R) that results in suppression of nociceptive responses [165], and
prevents neuropathic and inflammatory pain [155, 198, 209, 210], with selectivity
demonstrated not only by utilizing pharmacological CB2R antagonists, but also by
examining AM1241 analgesic efficacy in CB2R knockout mice [197, 211]. CB2R’s
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are characterized on microglia and macrophages in cell culture [92, 212, 213]
and in the rodent spinal cord following peripheral nerve damage [94, 135] or in
transgenic mice over-expressing the CB2R [93], as well as in the human central
nervous system (CNS) under inflammatory diseased conditions. Given AM1241
can act on CB2R’s expressed on spinal microglia, the potential additional (1)
cytokine and (2) p-p38MAPK role in AM1241’s efficacy in producing spinal antiinflammatory actions concurrent with anti-allodynia may be identified in these
studies.
Related to these goals, we examined two methods to analyze immunofluorescent
images of spinal cord tissue sections to identify the most sensitive procedure for
detecting and quantifying differences in specific immunoreactive protein markers.
In this context, an alternative method that utilizes spectral analysis procedures,
demonstrated here, can be advantageous over conventional methods of image
analysis.

2.2 Materials and methods
2.2.1 Animals
A total of 52 pathogen-free adult male Sprague Dawley rats (300-400 gram;
Harlan Labs, Madison, WI) were used in all experiments. Rats were doublehoused in a temperature and light-controlled (12 hour light/dark; lights on at 6:00
AM) environment, with standard rodent chow and water available ad libitum. All
procedures were approved by the Institutional Animal Care and Use Committee
(IACUC) of the University of New Mexico Health Sciences Center.
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2.2.2 Drugs
The CB2R agonist used in these experiments was (R,S)-(2-iodo-5-nitrophenyl)(1-[(1-methylpiperidin-2-yl)methyl]-1H-indol-3yl)-methanone (AM1241) from the
aminoalkyndole classification [161]. Water soluble hydrochloride salt of racemic
AM1241 was generously gifted (A. Makriyannis, Center for Drug Discovery,
Northeastern University). Initial doses of AM1241 were based on those
previously reported for intravenous (i.v.) injection [199] and pilot studies. A 1000fold dose range of AM1241, dissolved in sterile saline (Hospira Inc, Lake Forest,
IL) was tested (10 μg - .01 μg in 10 μl) or equivolume sterile saline as vehicle. Of
note, fully solubilized AM1241 resulted in a clear solution.

2.2.3 Behavioral assessment of allodynia
Baseline (BL) responses to light mechanical touch were assessed using the von
Frey test after animals were habituated to the testing environment, as previously
described [214, 215]. Briefly, rats were placed atop 2 mm bars with 8 mm
spacing between parallel bars for approximately 45 minutes for 5 days. All
behavioral testing was performed during the first half of the light cycle in a sound,
light, and temperature controlled room. The von Frey test utilizes a series of
calibrated monofilaments, (3.61 – 5.18 log stimulus intensity; North Coast
Medical, Morgan Hills, CA) applied randomly to the left and right plantar surface
of the hindpaw for 8 seconds. Lifting, licking or shaking the paw was considered
a response. Following chronic constriction injury (CCI) or sham surgery, animals
were behaviorally tested on Day 3 and 10. On Day 10 post-surgery after
behavioral assessment, all animals received an i.t. AM1241 or vehicle injection
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followed by behavioral reassessment at 30 min intervals for 5 hr and again at 24
hrs. Testing was performed in a blinded fashion.

2.2.4 Chronic constriction injury (CCI) surgery
Following BL behavioral assessment, the surgical procedure for chronic
constriction of the sciatic nerve was completed as previously described [216].
Briefly, isoflurane (induction 5% vol. followed by 2.5% in oxygen), anesthetized
rats had their mid- to lower back and the dorsal left thigh shaved and cleaned
with diluted Bacti-Stat AE, (EcoLab HealthCare Division, Mississauga, Ontario,
Canada). Using aseptic procedures, the sciatic nerve was carefully isolated, and
loosely ligated with 4 segments of chromic gut sutures (Ethicon, Somerville, NJ)
with each suture approximately 1mm apart. Sham surgery was identical to CCI
surgery but without the nerve ligation. The overlying muscle was sutured closed
with two 3-0 sterile silk sutures (Ethicon, Somerville, NJ), and animals recovered
from anesthesia within approximately 5 minutes.

2.2.5 Intrathecal (i.t.) injection
AM1241 was administered via acute i.t. catheter. Injections were performed as
previously described [217]. Briefly, rats were anesthetized with isoflurane and an
18-gauge sterile, hypodermic needle, with the plastic hub removed was inserted
between lumbar vertebrae L5 and L6. The PE-10 injection catheter was marked
between 7.7-7.8 cm from an open end, with the other end inserted into a 30gauge needle. A sterile Hamilton syringe was fitted with the 30-gauge needle and
the attached PE-10 catheter, and collectively referred to as an injection catheter.
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Either 10 μl drug or equivolume vehicle was withdrawn from respective vials via
the open end of the PE-10 injection catheter, which was gently inserted into the
L5 and L6-placed 18-gauge needle and threaded rostrally to the 7.7 cm marking
on the injection catheter. The resulting position of the inserted tip of the PE-10
catheter occurs at the i.t. lumbosacral enlargement (~L4-L5). During this time,
light tail twitching and a small amount of cerebrospinal fluid efflux from the 18gauge needle was typically observed indicating successful i.t. catheter
placement. Drug or vehicle was injected during a 10 second interval. Upon
completion of injection, the PE-10 i.t. catheter was removed followed by removal
of the 18-gauge needle. A 100% motor recovery rate was observed from this
injection procedure.

2.2.6 Immunohistochemical procedures
Following behavioral assessment at indicated timepoints (Figure 2.3, 2.4)
animals were overdosed with an intraperitoneal injection (8 - 1.3 cc) of sodium
phenobarbital (Sleepaway, Fort Dodge Animal Health, Fort Dodge, IA) and
perfused transcardially with saline followed by 4% paraformaldehyde. Whole
vertebral columns with intact spinal cords (cervical 2 through sacral 1 spinal
column segments) were removed, and underwent overnight fixation in 4%
paraformaldehyde at 4°C. This tissue collection procedure ensured that all
relevant anatomical components, including the spinal cord, DRG, and related
meninges, were intact within the vertebral column, allowing important spatial
relationships to remain for examining corresponding functional interactions at
individual and specific spinal cord levels. All specimens underwent EDTA (Sigma
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Aldrich, St. Louis, MO) decalcification for 30 days, and spinal cord sections were
subsequently paraffin processed and embedded in Paraplast Plus Embedding
Media (McCormick Scientific, St. Louis, MO) as previously described [218]. Four
adjacent tissue sections (7μm) were mounted on a vectabond-treated slide
(Vector Labs, Burlingame, CA), and allowed to adhere to the slide overnight at
40°C.
Approximately 130 slides per L4-L6 lumbar spinal cord, and 40 slides per lumbar
L5 DRG, were generated in this manner for each animal. Two slides from an
animal’s lumbar spinal cord and two slides of DRG were randomly chosen for
each staining procedure. The 7-um sections then underwent deparaffinization,
and rehydration via descending alcohols to PBS (1X, pH 7.4). Sections were then
processed with microwave antigen retrieval procedures (citrate buffer pH 6.0, or
tris-based buffer, pH 9.0; BioCare Medical, Concord, CA).

2.2.7 Antibody staining
Slides were incubated with 5% normal donkey serum (NDS), in PBS (1X, pH 7.4)
for 2 hours, followed by overnight primary antibody (Table 1) incubation in a
humidity chamber at 3° C. Slides underwent secondary antibody incubation
(Table 1) for 2 hours in a humidity chamber at room temperature, rinsed in PBS,
and then coverslipped with Vectashield containing the nuclear stain 4’,6diamidino-2-phenylindole (DAPI ) (Vector Labs, Burlingame, CA). For detection
of MAGL, phosphorylated p38MAPK, and IL-10 protein, sections were incubated
overnight with primary antibodies, incubated with biotinylated secondary antibody
(Table 1) for 1 hour, and then treated with Vectastain ABC Elite kit (Vector Labs,
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Burlingame, CA) and stained using TSA Plus Fluorescein System (PerkinElmer
Life Sciences, Waltham, MA) and finally coverslipped with Vectashield containing
DAPI. Stained section orientation was kept consistent throughout for proper
identification of ipsilateral and contralateral spinal cord and DRGs. For lumbar
spinal cord, sections were taken from L4-L6, and the dorsal horn analyzed (Fig. 1
A). For DRG material, sections were taken containing the DRG with the
projection to L5, and the most distal portion of the DRG was analyzed (Fig. 1 B).
Low magnification photomicrographs were obtained (Figure 1 A, B) using a Nikon
Optiphot fluorescent microscope equipped with a DP2-BSW (Olympus) camera.
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Table2. 1. List of all antibodies used in this study and designated under the
appropriate column heading. Primary antibodies for polyclonal GFAP (astrocyte
specific glial fibrillary acidic protein, Millipore, Billerica, MA), monoclonal GFAP
(astrocyte specific glial fibrillary acidic protein, Progen, Heidelberg, Germany)
previously used in (Achstatter et al., 1986), Iba-1 (microglia, monocyte specific
calcium channel protein, Wako Chemicals, Osaka, Japan)., FAAH (fatty acid
amide hydrolase, endocannabinoid degredgative enzyme, Cayman Chemicals,
Ann

Arbor,

MI),

Biotechnology,
endocannabinoid
phosphorylated

protein

IL-1β

Santa

Cruz,

dregradative
p38MAPK

(proinflammatory
CA),

MAGL

enzyme,

(activated

cytokine,

Santa

(monoacylglyerol

Abcam,

proinflammatory

lipase,

Cambridge,
cytokine

Cruz

MA),

signaling

pathway, Cell Signaling Technology, Beverly, MA), and IL-10 protein (antiinflammatory cytokine, R&D Systems, Minneapolis, MN) were used. Secondary
antibody incubation was performed with the indicated fluorophore conjugated
secondary antibody. For MAGL, phosphorylated p38MAPK, and IL-10 protein,
after overnight primary incubation, sections were instead incubated with
biotinylated secondary antibody. *All secondary antibodies are from Jackson
Immunoresearch (West Grove, PA).

2.2.8 Immunohistochemical image analysis
2.2.8.1 Image J software analysis
Fluorescent images for standard fluorescence analysis were obtained in the
same manner as detailed above, with DAPI omitted from the Vectasheild
mounting media. This was to ensure that DAPI staining did not potentially
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obscure the fluorescence intensity. Images were taken on an Olympus BX51
microscope (Center Valley, PA) equipped with an Olympus DP72 camera.
Images were then converted to grey scale and analyzed using Image J software
available for free download at http://rsb.info.nih.gov/ij/. Briefly, an outline of the
dorsal horn gray matter was drawn on an image, and holding the area within this
outline consistent, the fluorescent intensity was obtained within this area for each
image. This value was generated for each given tissue section (e.g. ipsilateral
dorsal horn spinal cord) and averaged together (total of 4 tissue sections from a
single animal) for an overall value. Therefore, for each anatomical location (e.g.,
ipsilateral and contralateral dorsal horn spinal cord and DRG), the 4 values
(fluorescent intensity average count/second/ mm2) were averaged to obtain an
individual animal’s overall fluorescent intensity, with 3 animals in each
experimental treatment group, to generate an average for that experimental
condition. Likewise, background values were generated from control tissues
incubated with PBS and the given secondary antibody, and averaged together.
The average background was then subtracted from the above mentioned
average of each experimental treatment group.
2.2.8.2 Spectral analysis of images
All images of the spinal cord dorsal horn and DRGs were captured by a Zeiss
Axioscope Microscope at 20x magnification with a Nuance Spectral Camera
(Cambridge Research & Instrumentation, Woburn, MA). Utilizing the Nuance
computer software, the fluorescent wavelength emission spectra was initially
determined for each fluorophore utilized in the detection of the primary antibody
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of interest (DAPI, 488 nm +/- 10nm; FITC, 575 nm +/- 5nm; Rhodamine Red 600
nm+/- 5nm) by using a control slide with only a drop of the pure fluorophore. This
was performed in the absence of a tissue specimen that may potentially obscure
the measurement of the fluorophore’s emission spectra. Two sets of additional
control slides with tissue sections, one with only PBS without primary but with
secondary antibody treatment, and the other, with primary but without secondary
antibody treatment, were then used to objectively eliminate low intensity
fluorescence and autofluorescence background ‘noise’ from our measurements
(Figure2.1 C). Using control slides, the Nuance software allows the user to set an
acceptable threshold of low-level emission fluorescent intensity (as opposed to
the software’s “autothreshold” option) within and outside the defined wavelength
of interest between tissue samples. The experimenter determined low-level
emission intensity by closely replicating the composite computer image with that
observed through the eyepiece. Emission values that fall below this acceptable
threshold of low-level emission, within and outside the defined wavelength of
interest, were eliminated from our measurements (Figure 2.1 D). This level of
fluorescent threshold for each protein marker was determined by the user finding
the most appropriate wavelength of interest that captures the specific FITC or
Rhodamine Red staining for each protein marker within a tissue (e.g., dorsal horn
spinal cord or DRG). Once the optimal level of fluorescent threshold was
determined for a particular protein marker, this level was held consistent
throughout all of the treatment groups for the image analysis (Figure 2.1 D).
These steps were followed by software conversion of fluorescent wavelength
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intensity for each fluorophore to a numerical value. Autofluorescence was
defined as that emission outside the defined wavelength of interest (e.g. DAPI,
488 nm +/- 10nm; FITC, 575 nm +/- 5nm; Rhodamine Red 600 nm+/- 5nm).
These specific autofluorescent and low-level background emission values were
subtracted from the image (Figure 2.1 E,F), yielding a numerical value of true
fluorescent emission intensity for each fluorophore [219, 220].
Primary antibody staining procedures remained consistent to minimize intensity
variations of each fluorophore (FITC or Rhodamine Red) used to detect the
different primary antibodies of interest. To ensure that fluorophore binding was
not impeded through possible steric hindrance of other proximal fluorophores,
sections were labeled for only one cellular marker of interest on a slide.
The user also determined the minimum number of connected pixels on the
computer screen for image analysis, counted as a region of interest (ROI)
defined in the Nuance software system, which resulted in a software image
containing distinctive morphology (i.e., of cellular bodies and processes, pattern
of protein expression) that was virtually identical to the morphology observed
through the microscope. The number of minimum connected pixels would
therefore be set higher for a protein expressed abundantly by a cell (i.e., GFAP)
than a protein expressed sparsely, leading to a punctuate pattern (i.e., IL-1β).
These conditions resulted in a ROI, and were held consistent for both the
ipsilateral and contralateral tissues in every experimental condition and for each
antibody stain. The total area of each ROI, as measured by mm2, is calculated
and is factored into the overall measurement of fluorescent intensity per second
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of exposure. The average count of fluorescent emission intensity per second
exposure, per mm2 is the analyzed value that we report here. That is, fluorescent
intensity average count/second/mm2, which takes into account the density as
well as the intensity of the fluorophore detected. A total of 4 sections per animal
(N=3) were randomly selected and analyzed in this manner. By applying this
novel method of data acquisition and analysis, experimenter bias is greatly
minimized or even eliminated, yielding greater consistency and objectivity to
fluorescent quantification.
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Figure 2.1 Anatomical location of images acquired and spectral analysis allows for
discrete fluorescence signal detection and analysis.
Anatomical location of images acquired and spectral analysis allows for discrete fluorescence
signal detection and analysis. A, Hematoxylin and eosin staining of the dorsal horn of the spinal
cord and B, dorsal root ganglion (area within black box) is displayed in context to relevant
anatomical structures (the entire spinal cord and partial cauda equina, respectively) at 4x
magnification, and then at 20x magnification. C, Representative fluorescent emission for DAPI
(blue) FITC (light green), GFP (dark green) Rhodamine Red (red) and autofluorescence (double
black). Selection of narrow fluorescent peak emission bands (dotted black box around FITC
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wavelength) allows for analysis of only FITC signal, without autoflourescent or GFP signal
contaminating fluorescent analysis. D, Representative fluorescent emission threshold level of
FITC defined and expanded from dotted black box in A, with the fluorescent threshold of intensity
set (dashed black line), above autofluorescent levels. E, Representative spectral image of dorsal
horn spinal cord as stained for GFAP (red), with autofluorescent signal defined in yellow. F, Same
image in E, with autofluorescent signal removed. In all images the scale bar is equal to 50 µm.

2.2.9 Data analysis
Psychometric behavioral analysis was performed as previously described [215]
to compute the log stiffness that would have resulted in the 50% paw withdrawal
rate. Briefly, thresholds were estimated by fitting a Gaussian integral
psychometric function to the observed withdrawal rates for each of the tested von
Frey hairs, using a maximum-likelihood fitting method [221]. Estimated
thresholds derived from a Gaussian integral function yield a mathematical
continuum and thus are appropriate for parametric statistical analyses [215, 221].
The computer program PsychoFit may be downloaded from L.O. Harvey’s
website (http://psych.colorado.edu/~lharvey). All other data analysis was
performed using the computer program GraphPad Prism version 4.03 (GraphPad
Software Inc., San Diego, CA). For behavioral analysis to assess BL values, a
one-way ANOVA was applied. To examine the presence of allodynia, a repeatedmeasures ANOVA was used at BL, 3 and 10 days after CCI, and indicated times
note above (Behavioral assessment of allodynia). For the initial evaluation of
fluorescence fading (Fig. 3 A, B), the student’s t test with a 95% confidence
interval was utilized. For all other statistical analysis, a two way ANOVA with a
95% confidence interval was performed. Statistical significance was determined
with P-values <0.05. All data is expressed as mean +/- SEM. For post hoc
analysis Bonferroni’s test was performed.
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2.3 Results
2.3.1 Intrathecal injection of AM1241 reverses CCI-induced allodynia in a dosedependent manner
Limited evaluation exists for i.t. spinal application of CB 2R agonists to control
allodynia produced by CCI, a widely used and well-characterized rodent model of
chronic peripheral neuropathy with related pain-like behaviors [216]. We first
examined if the putative CB2R agonist from the aminoalkylindole class, AM1241
(36-fold CB2>CB1) [156, 161], could reverse ongoing allodynia produced by CCI.
Prior to surgical manipulation, all groups exhibited similar bilateral (ipsilateral and
contralateral) BL thresholds (ANOVA, F(6,36) =1.105; p=0.3764 ANOVA, F(6,36)
=2.632; p=0.5884, respectively), (Figure 2.2 A,B). Following CCI, clear bilateral
allodynia developed by Day 3 and continued chronically through Day 10
compared to sham-operated rats (ANOVA, F(6,36) =73.23; p< 0.0001, ANOVA,
F(6,36) = 71.32; p<0.0001 respectively). On Day 10, compared to i.t. control
injected neuropathic rats, AM1241 produced a dose-dependent reversal of
allodynia, with maximal reversal observed at 1.5 hours following the highest
injected dose (10 μg). However, allodynia fully returned by 3 hours after i.t.
AM1241 treatment, with allodynia remaining constant through 24 hours. While
0.1 μg produced attenuated allodynia, 0.01 μg did not alter allodynia for either
the ipsilateral (Figure 2.2 A), (ANOVA, F(6,36) = 138.8; p<0.0001), or contralateral
(Figure 2.2 B) hindpaws (ANOVA, F(6,36) =131.6; p<0.0001). Post hoc analysis
revealed 10 µg AM1241 yielded maximal reversal similar to pretreatment BL
values at 1.5 hours after injection (p>.05).
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Figure 2.2 Intrathecal AM1241, a cannabinoid 2 receptor agonist reverses CCI-induced
allodynia.
Intrathecal AM1241, a cannabinoid 2 receptor agonist reverses CCI-induced allodynia. A, B,
AM1241 reverses CCI-induced allodynia in a dose-dependent manner. Before surgical
manipulation, all AM1241 BL values of experimental groups exhibited similar ipsilateral and
contralateral BL thresholds CCI surgery produced significant bilateral allodynia at days 3 and 10
following injury compared to sham-treated animals. Responses from AM1241 (10 μg) maximally
reversed CCI-induced allodynia, (black squares), at 1.5 hours with allodynia fully returning by 3
hours after intrathecal administration.

2.3.2 Spectral Analysis vs. Standard Image J Fluorescent Analysis
Although previous reports detail an observed increase of IL-1β IR within the
dorsal horn of the spinal cord after nerve ligation with chromic gut or silk sutures
[26], detecting statistically significant changes in IL-1β IR has been problematic.
Meanwhile, the use of spectral analysis procedures in other studies has
demonstrated increased accuracy and sensitivity for the detection of cell specific
markers [220, 222]. We therefore made direct comparisons between standard
fluorescent analysis with Image J software and spectral image analysis software
to identify the most sensitive method to quantify immunoreactive proteins of
interest. Identical slides for both analysis procedures were used to eliminate
potential fluorescent intensity variance between slides. Additionally, FITCconjugated secondary antibody was examined as well as Rhodamine-conjugated
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secondary antibody to identify whether intrinsic differences between different
fluorophores (red vs. green) could yield false positive group differences.
IL-1β IR was examined with standard FITC fluorescent analysis utilizing NIH
Image J software procedures (Figure 2.3 A). While a trend toward differences
was present using Image J software, no statistically significant increase in IL-1β
IR in either the ipsilateral or contralateral dorsal horn was found between nonneuropathic (Sham-Vehicle) and neuropathic CCI-treated rats (student T test
p=0.0620 and p=0.5142, respectively). We utilized FITC-tagged secondary
antibody in these studies because FITC tends to fade at a greater rate than
Rhodamine Red, providing a stringent assessment of potential observed
differences between experimental groups following a subsequent exposure. We
therefore exposed the same tissue sections analyzed in Figure 2.3 A for a
second time (Figure 2.3 B) with double the exposure-duration, but with the light
sensitivity held consistent. Doubling the exposure time provides a rigorous test to
determine whether fading can influence quantitative results. In using Image J,
marginal non-significant fading of fluorescent intensity (Fig. 3 A vs. B) (student T
test p= 0.7418 and p=0.9060, respectively) was present, and no difference in IL1β IR between non-neuropathic and neuropathic rats was detected (student T
test p=0.0648 and p=0.4874, respectively). In the same context, marginal fading
was observed with spectral microscopy exposure between an initial exposure
and a subsequent exposure (data not shown).
Given fluorophore fading was not present upon subsequent exposures, a new set
of FITC stained IL-1β tissues from non-neuropathic (Sham-Vehicle) and
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neuropathic rats (CCI-Vehicle) treatment groups were examined with standard
Image J fluorescence analysis followed by spectral analysis. With Image J, we
found no significant effect of surgery in either ipsilateral or contralateral dorsal
horn (student T test p=0.5604 and p=0.6988, respectively)(Figure 2.3 C).
However, spectral analysis of the identical sections revealed statistically
significant differences in ipsilateral IL-1β IR due to surgical treatment (student T
test p=0.0482 and p=0.0635, respectively) (Figure 2.3 D).
We found similar effects following comparison with a new set of slides from L4-L6
lumbar spinal cord tissue sections treated with IL-1β primary antibody, but
incubated with a secondary antibody conjugated to the Rhodamine Red
fluorophore (Figure 2.3 E,F). That is, the quantitative results between FITC or
Rhodamine Red fluorescent intensity were similar within each method of image
analysis. Specifically, no significant effect from surgical treatment was found
utilizing standard Image J Rhodamine Red fluorescence analysis between
treatment groups, either ipsilaterally or contralaterally (student T test p=0.2918
and p=0.2023, respectively) (Figure 2.3 E), while incorporating spectral analysis
methods of the same tissues revealed strong increases in ipsilateral but not
contralateral IL-1β IR in CCI treated rats (chronic neuropathy) (student T test
p=0.0096 and p=0.1047, respectively) (Figure 2.3 F). Representative tissue
staining for sham and CCI IL-1β are shown, as acquired with standard
fluorescent microscopy (Figure 2.3 G,H) and with spectral fluorescent
microscopy (Figure 2.3 I J). Thus, these findings demonstrate that the use of
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spectral analysis may yield quantitative differences that may have previously
gone undetected utilizing standard immunohistochemistry analysis techniques.
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Figure 2.3 Spectral vs. standard Image J immunofluorescent intensity quantification
comparision.
Spectral vs. standard Image J immunofluorescent intensity quantification comparision. A, Utilizing
standard Image J immunofluorescent quantification, no significant IL-1β IR differences between
CCI-induced neuropathy or non-neuropathic sham-treated rats in either the ipsilateral or
contralateral dorsal horn of the spinal cord. IL-1β IR was observed by FITC labeled secondary
antibody. B, Following a second exposure for image capture, fluorophore fading was virtually
absent thereby lacking potential artificial IR intensity differences between experimental
conditions. C, A comparison of sham and CCI-treated rats with i.t. vehicle using Image J
immunofluorescent quantification resulted in no significant fluorescent intensity differences of
labeled IL-1β IR between groups, in either the ipsilateral or contralateral dorsal horn. D, Utilizing
spectral immunofluorescent quantification, significant differences of fluorescent intensity from
FITC-labeled IL-1β between sham- and CCI-treated rats given i.t. vehicle was observed in the
ipsilateral, but not contralateral dorsal horn spinal cord. E, An examination of fluorescent intensity
between groups with a flourophore of a different spectral signature, Rhodamine Red (600 nm),
using standard Image J immunofluorescent quantification revealed no significant group
differences between sham- and CCI-treated rats despite a trend of increased IL-1β IR in CCItreated rats with i.t. vehicle in either the ipsilateral or contralateral dorsal horn. F, Spectral
immunofluorescent quantification of Rhodamine Red-labeled IL-1β yielded significant group
differences between non-neuropathic sham rats and CCI-treated rats with vehicle in the ipsilateral
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dorsal spinal cord. IL-1β IR increases were absent in the contralateral dorsal horn. G, H,
Representative fluorescent images analyzed with Image J at 20x magnification of IL-1β
fluorescent labeling (red). I, J, Representative spectrally unmixed images at 20x magnification of
IL-1β fluorescent labeling (red) with DAPI nuclear stain (blue). In all images the scale bar is equal
days after CCI or sham surgery.

2.3.3 Behavioral verification of i.t. AM1241 for subsequent spinal cord
immunohistochemistry
In a separate group of rats, intrathecal (i.t.) injection of AM1241 again produced
robust bilateral reversal from allodynia (Figure 2.4 A,B), similar to that observed
in Figure 2.2, Prior to CCI, all groups exhibited similar ipsilateral and contralateral
BL thresholds (ANOVA, F(3,11) =0.9006; p=0.4821, ANOVA, F(3,11) =0.8916;
p=0.4860, respectively). CCI produced significant bilateral allodynia at Day 3 and
continued to Day 10 compared to sham-treated animals (ANOVA, F(3,11) =135.8;
p< 0.0001 and ANOVA, F(3,11) = 149.9; p=0.0001, respectively). Behavioral
responses following i.t. AM1241 (10 μg) produced maximal bilateral reversal of
allodynia (ANOVA, F(3,11) =150.4; p<0.0001 and ANOVA, F(3,11) =72.36;
p<0.0001, respectively). At peak reversal, animals were sacrificed and spinal
tissue was collected to examine bilateral immunoreactivity for proteins including
cytokines

p-p38MAPK,

glial

activation

degradative enzymes.
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markers,

and

endocannabinoid

Figure 2.4 Cytokine, p-p38MAPK, DAPI Immunofluorescent intensity quantification of
Tissues from AM1241-treated rats
Immunofluorescent intensity quantification from 7 μm thick sections of dorsal horn spinal cord
from behaviorally verified rats following i.t. vehicle or AM1241. A, B, Prior to CCI, all groups
exhibited similar ipsilateral and contralateral BL thresholds. CCI produced significant bilateral
allodynia at days 3 and 10 following injury compared to sham-treated animals. Behavioral
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responses following AM1241 (10 μg) produced maximal bilateral reversal of allodynia followed by
tissue collection of immunofluorescent intensity quantification. C, D, IL-10 expression was
bilaterally decreased in CCI-treated rats that received i.t. vehicle compared to control shamtreated rats given either vehicle or AM1241, while IL-10 IR recovered to sham levels in CCI
neuropathic rats given i.t. AM1241. E, F, Compared to sham controls, IL-1β expression was
increased ipsilaterally, but not contralaterally in CCI-treated animals given i.t. vehicle of AM1241.
However, i.t. AM1241 in CCI-treated rats robustly suppressed increases in IL-1β IR. G, H,
Phospho-p38 expression was bilaterally increased in CCI-induced neuropathic rats treated with i.t
vehicle of AM1241. Increased bilateral p-p38MAPK was significantly suppressed in CCI-treated
rats given i.t. AM1241. I, J, No differences in DAPI nuclear stain fluorescent intensity was
observed in either sham control or CCI-treated rats given either i.t. vehicle or AM1241. K, L, M,
Representative spectrally unmixed images at 20x magnification of P-p38 MAPK fluorescent
labeling (green) with DAPI nuclear stain (blue). In all images the scale bar is equal to 50 µm.

2.3.4 Immunohistochemical analysis of dorsal spinal cord
2.3.4.1 IL-10
While spinal CB2R activation controls pain-related behaviors and glial activation
in

neuropathic

rats

[93,

94,

135,

139,

223],

the

underlying

spinal

immunoregulatory signals remain unclear. One of the most effective antiinflammatory cytokines characterized to control pathological pain processing to
date is IL-10 [202, 204, 217, 224-230]. Here, we examined changes in IL-10 IR at
the time of peak AM1241 efficacy. Bilateral IL-10- immunoreactivity (IR) in the
dorsal horn spinal cord was dramatically decreased in CCI-induced neuropathic
rats compared to sham-treated rats (ANOVA, F(1,8)=10.09; p=0.0131; ANOVA,
F(1,8)=7.548; p=0.0252, respectively), (Figure 2.4 C,D). In stark contrast,
treatment with AM1241 resulted in basal levels of IL-10 IR, for both the ipsilateral
and contralateral dorsal spinal cord (ANOVA, F(1,8) =13.19; p=0.0067; ANOVA,
F(1,8) =7.903; p=0.0228, respectively).
2.3.4.2 IL-1β
To replicate our results described in Figure 2.3 (D, F), separate L4-L6 lumbar
spinal cord tissue sections were processed and analyzed. Compared to non-
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neuropathic sham-operated rats given i.t. AM1241 or equivolume vehicle, CCIinduced neuropathy produced a robust unilateral increase in dorsal horn IL-1β IR
(ANOVA, F(1,8) =10.46; p=0.0120), while compared to controls, no differences in
contralateral IL1β were observed (ANOVA, F(1,8) =1.627; p=0.2379), (Figure 2.4
E,F ). Conversely, following AM1241 administration, significantly lower levels of
IL-1β IR were detected (ANOVA, F(1,8) =9.431; p=0.0153). IL-1β IR observed in
the contralateral dorsal horn was not substantially elevated when compared to
vehicle injected animals (ANOVA, F(1,8) =1.321; p=0.2836).
2.3.4.3 p38-MAPK and DAPI
Spinal p-p38MAPK is widely characterized to mediate allodynia through the
actions of spinal IL-1β [27, 194, 231]. Therefore, p-p38MAPK was examined.
Compared to non-neuropathic sham-operated rats given i.t. AM1241 or
equivolume vehicle, CCI-induced neuropathy produced a robust p-p38MAPK
bilateral IR increase in the spinal cord dorsal horn (ANOVA, F(1,8) =223.1;
p<0.0001; ANOVA, F(1,8) =148.0; p<0.0001, respectively), (Figure 2.4 G,H). In
contrast, tissues from rats treated with i.t. AM1241 revealed dramatically lower
levels of p-p38MAPK IR that were close to or similar to spinal cord tissues from
non-neuropathic sham-treated rats (ANOVA, F(1,8) =85.82; p<0.0001; ANOVA,
F(1,8) =187.1; p<0.0001, respectively) . Representative fluorescent images are
presented corresponding to the image analysis of either sham treated with i.t.
vehicle (Figure 2.4 K), CCI treated with i.t. vehicle (Figure 2.4 L), or CCI treated
with AM1241 (Figure 2.4 M).
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It is possible that overall changes in spinal cord cell numbers could dramatically
alter dorsal horn immunofluorescent intensity quantification, as proliferation of
microglia [232], astrocytes [233], or leukocyte CNS extravasation [76] have been
reported. Consequently, cells could simply be constitutively expressing low-levels
of proteins, thus diminishing interpretation that a protein-specific cellular
response has occurred following either CCI and/or i.t. AM1710. However, we
observed no change in cell numbers as assessed by quantification of nuclearspecific DAPI fluorescence intensity as a consequence of either CCI procedures
(ANOVA, F(1,8)=0.1076; p=0.7514, ANOVA, F(1,8)=0.7780; p=0.4035, respectively)
or i.t. drug injections (ANOVA, F(1,8)=0.04328; p=0.8404, ANOVA, F(1,8) =0.06960;
p=0.7986, respectively), (Figure 2.4 I,J).

2.3.5 Microglial and astrocyte activation
2.3.5.1 Iba-1 to identify altered microglial responses
Based on reported evidence that CB2Rs are present on microglia, we examined
whether bilateral dorsal spinal microglial responses during CCI-induced allodynia
were altered subsequent to i.t. administration of AM1241. To examine microglia
in the dorsal horn of the spinal cord, expression of the microglial marker, Iba-1
was examined. Compared to non-neuropathic sham-operated rats given i.t.
AM1241 or equivolume vehicle, CCI-induced neuropathy produced a robust
bilateral increase in spinal cord dorsal horn Iba-1 IR (ANOVA, F(1,8) =212.0;
p<0.0001, ANOVA, F(1,8)=62.28; p<0.0001, respectively), (Figure 2.5 A,B).
Surprisingly, AM1241 did not alter increased levels of spinal dorsal horn Iba-1 IR
in behaviorally reversed rats (ANOVA, F(1,8) =2.767; p=0.1348, ANOVA, F(1,8)
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=0.1346; p=0.7232, respectively), (Figure 2.5 A,B). Representative images taken
from the spinal cord dorsal horn following i.t. vehicle injection in sham and CCI
treated rats are provided (Figure 2.5 C,D).
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Figure 2.5 Glial Immunofluorescent intensity quantification in tissues from rats treated
with AM1241
Immunofluorescent intensity quantification of the spinal cord dorsal horn reveals differences in
astrocyte activation but not microglial activation in neuropathic rats treated with AM1241. A, B,
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Iba-1 expression increased within the ipsilateral and contralateral dorsal horn of the spinal cord
following CCI manipulations compared to control sham treatment, irrespective of i.t. vehicle or
AM1241. C, D, Representative spectrally unmixed images at 20x of Iba-1 fluorescent staining
(red) and DAPI nuclear stain (blue). E, F, GFAP immunofluorescent intensity in the dorsal horn of
the spinal cord was significantly increased in neuropathic rats following CCI given i.t. vehicle,
while GFAP IR in neuropathic rats given i.t. AM1241 was greatly attenuated. G, H, I,
Representative spectrally unmixed images at 20x magnification of GFAP fluorescent labeling
(red) with DAPI nuclear stain (blue). In all images the scale bar is equal to 50 µm. All sections

2.3.5.2 GFAP to identify altered astrocyte responses
In the superficial dorsal horn, where incoming signals from pain fibers are
processed, histological observation reveals that astrocytes make intimate contact
with microglia that express CB2Rs [94]. Prior reports additionally show that
following spinal CB2R activation in neuropathic rats, superficial dorsal horn GFAP
IR is significantly reduced [91]. Therefore, we examined GFAP IR in the dorsal
horn of the spinal cord following i.t. administration of AM1241. Compared to nonneuropathic control animals, neuropathic rats demonstrated a robust bilateral
increase in dorsal horn GFAP IR (ANOVA, F(1,8) =15.00; p=0.0047; ANOVA, F(1,8)
=10.45; p=0.0120, respectively) (Figure 2.5 E,F). In stark contrast, lower values
of bilateral GFAP IR were observed from tissues of rats treated with i.t. AM1241
(ANOVA, F(1,8)=41.38; p=0.0002; ANOVA, F(1,8)=17.63; p=0.0030, respectively)
(Figure 2.5 E,F). Corresponding representative fluorescent images used for
analysis are shown; sham-operated rats treated with i.t. vehicle (Figure 2.5 G,),
or CCI-treated rats injected with either i.t. AM1241 or equivolume vehicle (Figure
2.5 H,I).
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2.3.5.3 MAGL and FAAH
Endocannabinoids known to produce anti-allodynic effects are metabolized via
enzymatic

hydrolysis

by

fatty

acid

amide

hydrolase

(FAAH)

and/or

monoacylglycerol (MAGL) [234]. Inhibition of FAAH or MAGL increases the
bioavailablity of CNS endocannabinoids with a corresponding attenuation of
neuropathic pain rats [151, 152]. Whether FAAH and MAGL IR expression levels
are altered in the dorsal horn following i.t. CB2R agonist injections in neuropathic
rats, is unknown. Therefore, we examined potential changes in MAGL and FAAH
IR in tissue sections from rats given i.t. AM1241. Compared to non-neuropathic
control rats, neuropathic rats showed a robust ipsilateral (ANOVA, F(1,8) =34.19;
p=0.0004) and contralateral (ANOVA, F(1,8) =27.51; p=0.0008) increase in dorsal
horn MAGL IR (Figure 2.6 A,B). In contrast, spinal tissue collected from rats
given an i.t. AM1241 injection revealed significantly lower bilateral MAGL IR
(ipsilateral ANOVA, F(1,8)=8.356; p=0.0202, and contralateral ANOVA, F(1,8)
=4.146; p=0.0761, respectively) (Figure 2.6 A,B). Interestingly, no interpretable or
meaningful change in FAAH IR between non-neuropathic and neuropathic CCI
rats was observed following surgical manipulation (ipsilateral ANOVA, F (1,8)
=8.072; p=0.0218, and contralateral ANOVA, F(1,8) =0.09666; p=0.7638), or
following i.t. AM1241 or vehicle treatment (ANOVA, F(1,8) =0.5436; p=0.4820;
ANOVA, F(1,8) =2.174; p=0.1786, respectively) (Figure 2.6 C,D).
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Figure 2.6 Endocannabinoid degradative enzyme immunofluorescent intensity from rats
treated with AM1241
Immunofluorescent intensity quantification of the spinal cord dorsal horn reveals AM1241 reduces
the expression of the endocannabinoid degragative enzyme, MAGL but does not alter FAAH. A,
B, Compared to control rats, MAGL IR expression was increased ipsilaterally, with strong trends
contralaterally in CCI-treated neuropathic rats that received i.t vehicle of AM1241, while spinal
MAGL IR in CCI-treated rats given i.t. AM1241 was substantially reduced. C, D, No changes in
FAAH IR expression in ipsilateral and contralateral dorsal horn of either sham or CCI-neuropathic

2.3.6 Dorsal Root Ganglia Immunohistochemical analysis: GFAP, IL-1β, pp38MAPK and IL-10
Immunohistochemical detection of GFAP, IL-1β, p-p38MAPK, and antiinflammatory IL-10 in L4-L5 DRG that correspond to the ipsilateral and
contralateral spinal cord segments was quantified. Results revealed that
compared to non-neuropathic control rats, CCI-induced neuropathic rats
displayed a robust bilateral increase in GFAP IR in DRG (ipsilateral ANOVA, F(1,8)
=9.133;

p=0.0165,

and

contralateral

ANOVA,

F(1,8)

=8.443;

p=0.0197,

respectively), (Figure 2.7 A,B). However, i.t. AM1241 injection robustly blocked
bilateral increases in GFAP IR (ipsilateral ANOVA, F(1,8) =27.19; p=0.0008, and
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contralateral ANOVA, F(1,8) =5.223; p=0.0516, respectively), (Figure 2.7 A,B).
Intriguingly, DRG changes in levels of p-p38MAPK IR occurred in the ipsilateral
(ANOVA, F(1,8) =6.885; p=0.0305), but not the contralateral DRG (ANOVA, F(1,8)
=0.2013; p=0.6656) to the sciatic nerve damage (Figure 2.7 C,D), and, i.t.
AM1241 injection revealed p-p38MAPK IR that was similar to controls (ANOVA,
F(1,8) =15.92; p=0.0040, ANOVA, F(1,8) =2.051; p=0.1900, respectively). This
unilateral change was also observed with IL-1β IR due to CCI surgery (ipsilateral
ANOVA, F(1,8) =6.414; p=0.0351; contralateral ANOVA, F(1,8) =0.3111; p=0.5923),
and AM1241 treatment resulted in levels similar to controls (ipsilateral ANOVA,
F(1,8) =52.03; p<0.0001; contralateral ANOVA, F(1,8) =0.2221; p=0.6500) (Figure
2.7 E,F). An intriguing unilateral decrease in IL-10 IR was measured in CCItreated only (ipsilateral ANOVA, F(1,8) =17.42; p=0.0031, and contralateral
ANOVA, F(1,8) =1.583; p=0.2438), while an i.t. AM1241 injection (ipsilateral
ANOVA, F(1,8) =22.83; p=0.0014, and contralateral ANOVA, F(1,8) =1.327;
p=0.2826), (Figure 2.7 G,H) resulted in increased IL-10 IR levels that were
similar to controls. Collectively, these data show that while GFAP-positive
satellite cells in bilateral DRG are a target of AM1241, only ipsilateral IL-1β, pp38MAPK and IL-10 IR levels are altered.
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Figure 2.7 Immunofluorescent intensity quantification DRG
Immunofluorescent intensity quantification of 7 µm in thick sections from the dorsal root ganglion
reveals significant differences in satellite cell activation, phosphorylated p38MAPK, IL-1β and IL10 in i.t. AM1241 injected rats. A, B, GFAP (satellite cell activation) expression was increased in
animals with CCI compared to sham-treated rats, given i.t. vehicle ipsilaterally as well as
contralaterally, and robust bilateral suppression of GFAP IR was observed in rats given i.t.
AM1241. C, D, A small but significant unilateral increase in phospho-p38 (activated) IR was
detected on the side ipsilateral to the CCI treatment with i.t. vehicle , while i.t. AM1241 attenuated
increased p-p38MAPK IR in CCI-treated rats. E, F, Unilateral IL-1β IR was increased in DRG on
the side ipsilateral to the CCI manipulation compared to sham-treated controls, while IL-1β
expression was substantially decreased in CCI-treated rats with i.t. AM1241. G, H, Ipsilateral, but
not contralateral, IL-10 IR was significantly decreased in CCI-treated neuropathic rats given i.t.
vehicle of AM1241 compared to sham controls given either i.t. vehicle or AM1241. However, a
robust increase in IL-10 IR in the DRG of CCI neuropathic rats given i.t. AM1241 was detected.

2.4 Discussion
In the present study, we examined the efficacy of an i.t. CB2R agonist, AM1241,
on chronic bilateral allodynia produced by unilateral sciatic nerve CCI. We
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present evidence that AM1241 produced robust bilateral reversal from allodynia
in a dose-dependent manner that may act via anti-inflammatory mechanisms.
While prior reports show that peripheral administration of AM1241 controls
pathological pain [182, 198, 199, 209], peripheral neuropathy induced by spinal
nerve ligation [182, 211] and cancer chemotherapeutic agents [165, 210], the
current results extend these findings by showing that peri-spinal i.t. AM1241
injection acts to reverse CCI-induced allodynia. Importantly, AM1241 itself did not
alter normal basal sensory threshold responses at any dose when administered
intrathecally, which is distinct from reports showing an anti-nociceptive action at
peripheral nerve terminals following peripheral administration of AM1241 that
produced increased BL sensory thresholds [165, 175, 197].
In this study, we additionally present evidence for distinct profiles of antiinflammatory protein expression patterns in the dorsal horn of the spinal cord and
DRG. In the dorsal horn of neuropathic rats, bilateral IL-10 IR was significantly
lower compared to non-neuropathic rats. While a reduction of peripheral nerve or
DRG IL-10 mRNA or protein has been reported [74, 191, 235, 236], to date, no
prior reports have demonstrated decreased dorsal horn IL-10 IR in adult rats
during chronic allodynia from peripheral neuropathy. Additionally, greater bilateral
p-p38MAPK, astrocyte GFAP, microglial Iba-1 and MAGL IR levels were
measured in neuropathic rats compared to non-neuropathic controls. Further, an
increase in unilateral spinal IL-1β IR was measured on the side ipsilateral to CCI.
However, following an i.t. AM1241 injection, not only was behavioral allodynia
reversed, but IL-10, p-p38MAPK, astrocyte GFAP, MAGL and IL-1β IR levels
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were similar to those observed in non-neuropathic animals. The corresponding
L4-L5 DRG immunofluorescent analysis from neuropathic rats revealed similar
changes in protein expression patterns, however, bilateral DRG changes were
observed only with GFAP IR. These data extend prior reports that AM1241 acts
in a general anti-inflammatory manner by identifying specific in vivo spinal and
DRG changes of elevated IL-10, with concurrently diminished IL-1β and pp38MAPK IR in the dorsal horn of the spinal cord.
The pattern of bilateral allodynia reported in the current study supports a number
of prior reports demonstrating a similar behavioral pattern from CCI [200-203,
217, 226, 237-239]. Bilateral biochemical changes in the spinal cord and the
DRG have been examined that may, in part, characterize underlying contralateral
allodynia from CCI. These studies reported decreased α2-adrenergic receptor
mRNA expression [240], increased neuronal Fos protein [241], increased TNF-α
protein [191], and increased IL-6 mRNA expression [239]. Additionally, very
recent reports have demonstrated increases in unilateral spinal IL-1β mRNA
expression [242], or increased IL-1β spinal immunohistochemical detection [243]
following unilateral sciatic nerve ligation or transection. Further, endogenous IL1β receptor antagonist IL-1RA contributes to the anti-inflammatory effects of
activated CB2 receptors [244]. Here, we demonstrate the unique findings that an
ipsilateral increase in IL-1β IR is observed in anatomically intact spinal cord
following CCI that produces bilateral allodynia. It is notable that the actions of
spinal IL-1β are necessary for allodynia produced from CCI [204, 217]. Together,
these data suggest that ipsilateral IL-1β is important for initiating changes that

79

ultimately spread to the contralateral spinal cord resulting in contralateral
allodynia. Given astrocytes can communicate via gap junctions, it is possible that
ipsilateral IL-1β-to-astrocyte communication leads to the spread of contralateral
astrocyte activation via gap junctions inducing signals that result in contralateral
allodynia. In support of this hypothesis, a model of localized unilateral sciatic
nerve inflammation was demonstrated to critically involve spinal astrocyte gapjunctional communication underlying bilateral allodynia, which was mediated, in
part, by spinal IL-1β [237]. Given the indirect role that ipsilateral IL-1β may play in
contralateral allodynia, the key biochemical difference between ipsilateral and
contralateral spinal cord may be in IL-1β expression patterns.
In the current data reported here, we have identified significant increases of IL-1β
IR in anatomically discrete regions of the spinal cord in CCI-induced neuropathic
rats as a consequence of identifying and omitting autofluorescence and low-level
background emission intensities from tissue samples. This was achieved by
applying relatively straightforward spectral analysis, using the Nuance software,
to quantify immunofluorescent levels in anatomically intact spinal cord that
eliminates unwanted autofluorescence occurring at nearby wavelengths, which is
not discernable using conventional methods of immunofluorescence detection
and quantification. Furthermore, we report that i.t. AM1241 resulted in low-level
immunoreactivity for IL-1β similar to non-neuropathic control levels that
corresponds

to

anti-allodynia.

This

discrete

IL-1β

difference

between

experimental groups was lost when applying standard Image J analysis methods.
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The most striking feature of this approach is that autofluorescent emission-peaks
at nearby wavelengths can be determined from control tissue specimens not
stained for the protein marker under examination. The identified autofluorescent
wavelengths with corresponding intensity can be subtracted from images derived
from tissues that have undergone specific immunohistochemical fluorescence
staining procedures. This feature of subtracting ‘noise’ is advantageous when
considering that sections between animals within a single experimental group
can display variations in peak autofluorescence intensity. Of critical importance is
that low-level fluorescence emission within a discrete 10 nm fluorescent
wavelength range being analyzed (e.g. FITC 575 nm, +/- 5 nm) can occur in the
absence of targeted immunofluorescence protein staining thereby contributing to
background ‘noise’. This noise is detected by applying the consistent use of both
a fixed contiguous pixel number and fluorescent threshold during image capture.
The

identified

endogenous

fluorescent

intensity

is

then

omitted

from

quantification of specific markers in the image. These additional steps ensure
experimenter bias is eliminated. A practical consideration is that the spectral
analysis software is easily learned and fluorescence intensity quantification can
be conducted in a timely manner. An additional advantage applying
immunofluorescent quantification following spectral analysis of intact spinal cord
is greater sensitivity to detect specific protein markers compared to other protein
quantification procedures that require relatively high amounts of tissue samples
(e.g. 100 μg). These traditional methods often translate into the necessity for
greater animal numbers to achieve detectable results.
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Proinflammatory factors were examined in this report that extend beyond IL-1β in
an attempt to provide a broad characterization of the anti-inflammatory effects of
CB2R agonists like AM1241. The mitogen-activated protein kinase (MAPK) family
consists of three major members that includes p38, which as noted above,
contributes to pain sensitization following peripheral nerve injury [27, 34, 192,
193, 195, 232, 245-248] via the actions of spinal IL-1β and other proinflammatory
cytokines [249, 250]. The current data support these prior reports in that
increased p-p38MAPK IR is present in the dorsal horn of the spinal cord and
DRG in neuropathic rats, and extend AM1241 characterization as an antiinflammatory CB2R agonist by demonstrating that AM1241 robustly suppresses
p-p38MAPK IR in pain-reversed rats with peripheral neuropathy.
Microglial and astocytic glial markers in the spinal cord dorsal horn in neuropathic
rats, as assessed by immunofluorescent detection, reveal increased glial
responses in support of prior reports [251, 252]. Dorsal horn spinal cord astrocyte
and microglial responses are recognized to mediate pathological pain in a variety
of animal models via the actions of p-p38MAPK and IL-1β [24, 194, 253]. CB2R
mRNA and immunohistochemically identified protein expression is present
mostly in spinal microglia [94, 135, 139, 212]. CB2Rs in the CNS have been
identified mostly on microglia [94], and prior studies reported decreased
microglial activation following i.t. administration of CB2R agonists [94, 139, 254] .
Studies examining spinal cords of transgenic CB2R knock-out mice exposed to
partial sciatic nerve injury with concurrent neuropathic pain-like behaviors [93]
also revealed increased bilateral dorsal horn microglial activation compared to
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wild-type controls. These results suggest that CB2Rs play a regulatory role in
microglial activation during peripheral neuropathic conditions. However, we
report that i.t. AM1241 does not inhibit dorsal spinal microglial activation, as
assessed by Iba-1 staining, despite full behavioral reversal of CCI-induced
allodynia. Upregulation of Iba-1 is widely known to indicate active microglia [57,
255, 256]. The differences in the data results may be that the aminoalkylindole,
AM1241, acts in a distinctly different manner than other CB 2R agonist
compounds, perhaps by inhibiting general spinal proinflammatory processes
while leaving microglial function intact. Importantly, increased expression of
microglial Iba-1 is indicative of ongoing microglial activity, but cannot distinguish
anti-inflammatory vs. proinflammatory phenotypes. Thus, it is possible that the
increased microglial Iba-1 reported here may be a consequence of increased IL10 and/or mitogen-activated protein-phosphatase production, which are negative
regulators to several proinflammatory MAPKs [91].This notion is supported by a
prior in vitro study that demonstrated CB2R ligands enhance IL-10 release from
immune stimulated macrophages [257].
Intriguingly, microglia are an important additional source of the endocannabinoid,
2-arachidonylglycerol (2-AG) [8]. Endocannabinoids such as anandamide and 2AG are produced and released from neurons and microglia [92]. Increased
endocannabinoid ligand expression and activity in regions such as the spinal
cord are characterized to inhibit pain-like behaviors in rats [208, 258].
In contrast to persistent microglial activity, i.t. AM1241 reduced bilateral GFAP IR
in spinal cord astrocytes and robustly suppressed satellite GFAP-IR in the
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corresponding DRGs. These results support that CB2R activation reverses
chronic bilateral allodynia, in part, by suppressing astrocyte activation. In other
studies using immunohistochemical examination of astrocytes and microglia, it is
notable that astrocyte endfeet frequently make intimate contact with microglia
[259, 260], providing a potential mechanism by which microglia, albeit activated
but in an anti-inflammatory manner, can influence astrocyte activation.
The enzyme, MAGL, has been identified on presynaptic axon terminals in brain,
suggesting it can terminate 2-AG activity following ligand-receptor internalization
in presynaptic neurons [143]. The current report supports, but is not limited to,
the presynaptic localization of MAGL because immunofluorescent levels were
dramatically increased by neuropathy in the superficial dorsal horn where
afferent nociceptive fiber terminals communicate to spinal cord pain processing
neurons. These data extend prior reports by showing a strong decrease in spinal
MAGL IR following i.t. AM1241 that is concurrent with complete reversal of
allodynia.

Indeed,

MAGL

inhibitors

decrease

allodynia

in

CCI-induced

neuropathic mice [151], resulting in an increase in 2-AG accumulation that is
widely characterized to produce analgesia [153]. Microglia also release 2-AG,
and MAGL activity has been described in microglia [145]. Together, these data
support that decreased MAGL IR may be a result of a generalized decrease in
proinflammatory factors following AM1241 treatment.
Surprisingly, an unremarkable unilateral alteration of FAAH was observed
following CCI-neuropathy compared to sham controls, and these levels remained
unchanged following i.t. AM1241 injection. As such, it is not clear from these data
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whether FAAH plays an important role in chronic pain produced by CCIperipheral neuropathy given these levels remained unchanged during pain
reversal. However, only a single biochemical marker was used to ascertain
FAAH expression levels. Further, activity of FAAH may not be reflected in its
levels of expression. In support of this possibility, reports have demonstrated that
blockade of FAAH actions results in anti-allodynia in inflammatory pain models,
or following peripheral nerve transection [146] or CCI [151]. Thus, virtually
unchanged spinal FAAH IR levels should be cautiously interpreted until further
assays verify FAAH expression and activity in models of peripheral neuropathy.
Distinct from data in the current report, increased FAAH IR was observed in large
diameter DRG neurons following sciatic nerve axotomy or L5 spinal nerve
transection [146]. However, animal models of peripheral axotomy can result in
different protein expression profiles in spinal cord and DRG compared to intact
damaged axons, as is the case with CCI. These observed differences are
frequently reported in different animal models of pathological pain [24].
DRG satellite cells form a distinct sheath that completely surround sensory
neurons, and together with the neuron, create a discrete morphological [71] and
a functional unit [69]. Satellite DRG glia have gained increasing recognition for
altering nociceptive transmission by expressing and responding to several
proinflammatory cytokines including IL-1β [69, 72, 261]. Indeed, IL-1β rapidly
activates nociceptive cells in a p38MAPK-dependent manner [80]. The current
report supports these reports, as increased expression of p-p38MAPK and IL-1β,
in addition to GFAP, were present in the DRG of neuropathic animals. We
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demonstrate that ipsilateral DRG IL-10 expression is significantly decreased
during CCI-induced chronic neuropathy. Conversely, i.t. treatment with AM1241
resulted in greater p-p38MAPK, IL-1β and IL-10 IR levels that are similar to nonneuropathic control basal values. No IL-10, IL-1β and p-p38MAPK IR changes in
contralateral DRG were observed during CCI-induced chronic allodynia,
suggesting these immune signals in contralateral DRG do not play a significant
role in CCI-induced contralateral allodynia.
Although AM1241’s behavioral effects occur within a relatively short therapeutic
half-life (~1.5 hr), these data reveal crucial findings which may support the
development of longer lasting, ‘next generation’ CB2R agonists to produce
therapeutic pain control. An advantage of a short therapeutic half-life is the
capability to tightly regulate drug loading doses and potential unwanted sideeffects. Oral formulations easily allow for repeated dosing at discrete intervals.
Additionally, a short half-life for i.t. efficacy localized to the spinal cord may be
advantageous as it may remain localized to spinal canal, avoiding potential
global inhibition of important immune function. Prior reports together with the
data presented here support that the actions of AM1241 are highly effective to
control pathological pain when delivered either peripherally or by i.t.
administration. Additionally, this report supports that pathological pain states,
which can include contralateral allodynia ( “mirror image” body part) is mediated
by significant shifts in ipsilateral and contralateral pro- and anti-inflammatory
spinal cord cytokine milieu, as well as shifts in p38MAPK and the
endocannabinoid degradative enzyme, MAGL. The implication of these results is
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that compounds capable of acting on cytokines in the CNS, can therapeutically
control clinically relevant centrally and peripherally mediated pathological pain
conditions.
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Abstract
Spinal glial and proinflammatory cytokine actions are strongly implicated in
pathological pain. Spinal administration of the anti-inflammatory cytokine
interleukin (IL)-10 abolishes pathological pain and suppresses proinflammatory
IL-1β and tumor necrosis factor alpha (TNF-α). Drugs that bind the cannabinoid
type-2

receptor

(CB2R)

expressed

on

spinal

glia

reduce

mechanical

hypersensitivity. To better understand the CB2R-related anti-inflammatory profile
of key anatomical nociceptive regions, we assessed mechanical hypersensitivity
and protein profiles following intrathecal application of the cannabilactone CB 2R
agonist, AM1710, in 2 animal models; unilateral sciatic nerve chronic constriction
injury (CCI), and spinal application of human immunodeficiency virus-1
glycoprotein 120 (gp120), a model of peri-spinal immune activation. In CCI
animals, lumbar dorsal spinal cord and corresponding dorsal root ganglia (DRG)
were evaluated by immunohistochemistry for expression of IL-10, IL-1β,
phosphorylated

p38-mitogen-activated-kinase

(p-p38MAPK),

a

pathway

associated with proinflammatory cytokine production, glial cell markers, and
degradative endocannabinoid enzymes, including monoacylglycerol lipase
(MAGL). AM1710 reversed bilateral mechanical hypersensitivity. CCI revealed
decreased IL-10 expression in dorsal spinal cord and DRG, while AM1710
resulted in increased IL-10, comparable to controls. Adjacent DRG and spinal
sections revealed increased IL-1β, p-p38MAPK, glial markers, and/or MAGL
expression, while AM1710 suppressed all but spinal p-p38MAPK and microglial
activation. In spinal gp120 animals, AM1710 prevented bilateral mechanical
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hypersensitivity. For comparison to immunohistochemistry, IL-1β and TNF-α
protein quantification from lumbar spinal and DRG homogenates was
determined, and revealed increased DRG IL-1β protein levels from gp120, that
was robustly prevented by AM1710 pretreatment. Cannabilactone CB2R agonists
are emerging as anti-inflammatory agents with pain therapeutic implications.

3.1 Introduction
Spinal sensitization of pain projection neurons is a critical process underlying
pathological pain. Unilateral chronic constriction injury (CCI) of the sciatic nerve
as well as spinal inflammation following i.t. HIV-1 glycoprotein-120 (gp120) are
utilized here as animal models of pathological pain. While distinctly different in
etiology, both models are characterized to involve activated spinal glia and
proinflammatory cytokine activity [262]. Astrocytes and microglia produce
interleukin-1β (IL-1β) and tumor necrosis factor-alpha (TNF-α) which mediate
pathological pain in a variety of animal models [24, 253]. Glia in spinal cord
dorsal horn and dorsal root ganglia (DRG) [80, 250] show increases in
phosphorylated p38 mitogen-activated kinase (p-p38MAPK), a MAPK strongly
associated with IL-1β and TNF-α expression [27]. DRG are home to glial satellite
cells that generate IL-1β and TNF-α, additionally contributing to pathological pain
in response to peripheral injury [69-74, 263]. Conversely, interleukin-10 (IL-10) is
a critical pleiotropic anti-inflammatory cytokine that suppresses IL-1β and TNF-α
actions and blocks phosphorylation of factors that activate MAPK pathways
resulting in the inhibition of MAPK actions [264]. Lumbosacral intrathecal (i.t.)
administration of the IL-10 transgene or protein leads to robust suppression of
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light touch hypersensitivity (allodynia) produced by CCI as well as spinal
inflammation following i.t. gp120 [204, 217, 265].
Two cannabinoid receptor subtypes, CB1R and CB2R, are characterized to
produce analgesic effects [232]. CB1R are present on neurons throughout the
CNS and their activation within the brain corresponds to a variety of effects
beyond pain control [7]. However, CB2R are primarily expressed on microglia
[139] and peripheral immune cells including macrophages [266]. Activation of
CB2Rs lack the known central nervous system (CNS) side effects produced by
CB1R activation [7, 135, 139, 212]. Following peripheral nerve injury, increased
expression of CB2Rs, endocannabinoids, and related degradative enzymes occur
in DRG and spinal cord [92, 107, 146]. Reports demonstrate that the effects of
CB2R activation reduces pathological pain with a corresponding decrease in
activation markers for spinal cord astrocytes, microglia, and factors associated
with proinflammatory pathways [131, 241, 254, 267]. Given the newly
characterized cannabilactone, AM1710, binds CB2R with greater affinity than
CB1R (54-fold CB2R>CB1R) [160, 175], and its antinociceptive action is
selectively blocked by CB2R antagonists [176], i.t. administration of AM1710 was
examined here for its potential actions to reverse or prevent allodynia produced
by CCI and i.t. gp120, respectively. While prior reports reveal that spinal CB2R
activation controls pathological pain responses in neuropathic rats [93, 94, 135,
223, 241], the underlying spinal immunoregulatory signals in parallel with
endocannabinoid degradative enzymes remain unclear.

91

The aim of the present study was to determine alterations in IL-10
immunoreactivty with concurrent reduction in immunoreactivity of CNS glial
activation

markers,

IL-1β,

p-p38MAPK,

and

the

widely

characterized

endocannabinoid degradative enzymes, monoacylglycerol lipase (MAGL) and
fatty acid amine hydrolase (FAAH) in the dorsal horn and DRG in behaviorallyverified CCI neuropathic rats following i.t. application of AM1710 [175, 176].
Bilateral allodynia was examined, as prior reports have documented this change
from normal sensory responses [200, 201, 217, 238]. Following i.t. gp120,
cytokine protein levels surrounding the injection site and DRG were quantified by
enzyme-linked immunosorbent assay (ELISA) procedures.

3.2 Methods
3.2.1 Animals
A total of 76 pathogen-free adult male Sprague Dawley rats (300-400 gram;
Harlan Labs, Madison, WI) were used in all experiments. Rats were doublehoused in a temperature and light-controlled (12 hour light/dark; lights on at 6:00
AM) environment, with standard rodent chow and water available ad libitum. All
procedures adhered to the guidelines of the Committee for Research and Ethical
Issues of the International Association for the Study of Pain and were approved
by the Institutional Animal Care and Use Committee (IACUC) of the University of
New Mexico Health Sciences Center.
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3.2.2 Drugs
The CB2R agonist, 3-1(1’,1’-Dimethylheptyl)-1-hydroxy-9-methoxy-6H-benzo[c]chromene-6-one (AM1710) [160, 175] was used in these experiments. AM1710
was generously gifted by A.M. and G.T. AM1710 was first dissolved in 100%
ethanol and diluted in sterile water (Hospira Inc, Lake Forest, IL) for a final of
concentration 1 mg/ mL containing 5% ethanol. The vehicle of AM1710 was
sterile water containing 5% ethanol. Pilot studies determined the dose range of
AM1710, with a 100-fold dose range tested (10 μg - .1 μg in 10 μl or equivolume
vehicle). Immediately prior to intrathecal (i.t.) injections, frozen (-80°C)
recombinant gp120 (product 1021-2; lot number 7A3I20; ImmunoDiagnostics,
Bedford, MA) was thawed, and diluted to 0.5 μg/μl with 0.1% rat serum albumen
in sterile PBS, pH 7.4 (Life Technologies, Gaithersburg, MD. Three (3) μg in 6 μl
or equivolume vehicle was prepared on ice as detailed in prior reports [196, 215,
237, 268].

3.2.3 Behavioral assessment of allodynia
Baseline (BL) responses to light mechanical touch were assessed using the von
Frey test after animals were habituated to the testing environment, as previously
described [214, 215]. Briefly, rats were placed atop 2 mm-thick parallel bars,
spaced 8 mm apart and habituated for approximately 45 minutes for 5 days. All
behavioral testing was performed during the first half of the light cycle in a sound,
light, and temperature controlled room. The von Frey test utilizes a series of
calibrated monofilaments, (3.61 – 5.18 log stimulus intensity; North Coast
Medical, Morgan Hills, CA) applied randomly to the left and right plantar surface
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of the hindpaw for 8 seconds. Lifting, licking or shaking the paw was considered
a response. For all behavioral testing, threshold assessment was performed in a
blinded fashion by J.L.W.

3.2.4 Chronic constriction injury (CCI) surgery
Following BL behavioral assessment, the surgical procedure for chronic
constriction of the sciatic nerve was completed as previously described [216].
Briefly, in isoflurane- (induction 5% vol. followed by 2.5% in oxygen) anesthetized
rats, the mid- to lower back and the dorsal left thigh shaved and cleaned with
diluted Bacti-Stat AE, (EcoLab HealthCare Division, Mississauga, Ontario,
Canada). Using aseptic procedures, the sciatic nerve was carefully isolated, and
loosely ligated with 4 segments of chromic gut sutures (Ethicon, Somerville, NJ).
Sham surgery was identical to CCI surgery but without the nerve ligation. The
overlying muscle was sutured closed with (2) 3-0 sterile silk sutures (Ethicon,
Somerville, NJ), and animals recovered from anesthesia within approximately 5
minutes. Animal placement into either CCI or sham surgical groups was
randomly assigned.

3.2.5 Chronic indwelling catheter surgery used for i.t. gp120 administration
Following BL assessment for light mechanical touch, chronic indwelling i.t.
catheterization was performed as previously described in experiments utilizing
gp120 for the induction of allodynia [215, 268, 269]. All animals recovered from
this procedure within 5 minutes without overt signs of motor weakness or
discomfort. Verification of lumbar PE-10 catheter placement was conducted at
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the time of tissue collection. One hundred percent of catheters were successfully
placed within the intrathecal L5 lumbar region.

3.2.6 Intrathecal injection for chronic indwelling catheters
For chronic indwelling catheters in gp120 experiments, all drugs were pre-filled
into an ‘i.t. injection catheter’ as detailed previously [269]. A 3-minute i.t. injection
was administered in alert, conscious rats with light towel restraint. No overt motor
weakness was observed. Six microliters of gp120 followed by an 8 µl sterile
saline flush during a 10 second interval was injected.

3.2.7 Acute intrathecal injection used in CCI-related experiments
In rats with CCI, all drugs were administered via acute i.t. catheter placement.
Injections were performed as previously described [215]. Either 10 μl drug or
equivolume vehicle was withdrawn into the injection catheter, which was gently
inserted and threaded rostrally to the 7.7 cm marking to achieve a catheter-tip
position at the i.t. lumbosacral enlargement (~L4-L5). During this time, light tail
twitching and a small amount of cerebrospinal fluid efflux from the 18-gauge
needle was typically observed indicating successful i.t. catheter placement. Drug
or vehicle was injected during a 10 second interval. Drug treatment was
randomly assigned to animals. Upon completion of injection, the PE-10 i.t.
catheter was removed followed by removal of the 18-gauge needle. A 100%
motor recovery rate was observed from this injection procedure.
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3.2.8 Immunohistochemical procedures from CCI-treated rats
Following

behavioral

assessment,

animals

were

overdosed

with

an

intraperitoneal injection sodium phenobarbital (Sleepaway, Fort Dodge Animal
Health, Fort Dodge, IA), then perfused transcardially with saline followed by 4%
paraformaldehyde. Whole vertebral columns with intact spinal cords (cervical 2
through sacral 1 spinal column segments) were removed, and underwent
overnight fixation in 4% paraformaldehyde at 4°C. This tissue collection approach
ensured that all relevant anatomical components, including the spinal cord, DRG,
and overlying meninges, were intact within the vertebral column, allowing
important spatial relationships to remain for examining corresponding functional
interactions at individual and specific spinal cord levels. All specimens underwent
EDTA (Sigma Aldrich, St. Louis, MO) decalcification for 30 days, and spinal cord
sections were subsequently paraffin processed and embedded in Paraplast Plus
Embedding Media (McCormick Scientific, St. Louis, MO) as previously described
[93]. Adjacent tissue sections (7 μm) were mounted on vectabond-treated slides
(Vector Labs, Burlingame, CA), and allowed to adhere to slides overnight at
40°C, followed by deparaffinization, and rehydration via descending alcohols to
PBS (1X, pH 7.4). Sections were then processed with microwave antigen
retrieval procedures (citrate buffer pH 6.0, or tris-based buffer, pH 9.0; BioCare
Medical, Concord, CA).
Slides were incubated with 5% normal donkey serum (NDS), in PBS (pH 7.4) for
2 hours, followed by overnight primary antibody (Table 3.1) incubation in a
humidity chamber at 3° C. Slides underwent secondary antibody incubation
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(Table 3.1) for 2 hours in a humidity chamber at room temperature, rinsed in
PBS, and then coverslipped with Vectashield containing the nuclear stain 4’,6diamidino-2-phenylindole (DAPI ) (Vector Labs, Burlingame, CA). For detection
of MAGL , phosphorylated p38MAPK, and IL-10 protein, sections were incubated
overnight with primary antibodies, incubated with biotinylated secondary antibody
(Table 3.1) for 1 hour, and then treated with Vectastain ABC Elite kit (Vector
Labs, Burlingame, CA) and stained using TSA Plus Fluorescein System
(PerkinElmer Life Sciences, Waltham, MA) and finally coverslipped with
Vectashield containing DAPI. Stained section orientation was kept consistent
throughout for proper identification of ipsilateral and contralateral spinal cord and
DRGs. For lumbar spinal cord, sections were taken from L4-L6, and the dorsal
horn analyzed (Supplemental Figure A-2 A). The intact meninges overlying the
ipsilateral dorsal horn of the spinal cord were analyzed separately to discern
possible immunoreactive changes between surgical and drug treatments groups
that may be different from quantified values obtained for the entire ipsilateral
dorsal horn. For meningeal analysis, those sections revealing clear identification
of the meninges vs.
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Table 3. 1
List of all antibodies used in this study and designated under the appropriate column heading.
Primary antibodies for polyclonal GFAP (astrocyte specific glial fibrillary acidic protein, Millipore,
Billerica, MA, and Abcam, Cambridge, MA), monoclonal GFAP (astrocyte specific glial fibrillary
acidic protein, Progen, Heidelberg, Germany), Iba-1 (microglia, monocyte specific calcium
channel protein, Wako Chemicals, Osaka, Japan), FAAH (fatty acid amide hydrolase
endocannabinoid degredgative enzyme, Cayman Chemicals, Ann Arbor, MI), IL-1β protein
(proinflammatory cytokine, Santa Cruz Biotechnology, Santa Cruz, CA), NF-H 200KDa
(neurofiliament heavy chain clone 3G3, Millipore, Billerica, MA), MAGL (monoacylglyerol lipase
endocannabinoid dregradative enzyme, Abcam, Cambridge, MA), phosphorylated p38MAPK
(activated proinflammatory cytokine signaling pathway, Cell Signaling Technology, Beverly, MA)
and IL-10 protein (anti-inflammatory cytokine, R&D Systems, Minneapolis, MN) were used.
Secondary antibody incubation was performed with the indicated fluorophore conjugated
secondary antibody. For MAGL, phosphorylated p38MAPK, and IL-10 protein, after overnight
primary incubation, sections were instead incubated with biotinylated secondary antibody. *All
secondary antibodies are from Jackson Immunoresearch (West Grove, PA).
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superficial spinal cord were chosen. As such, meninges of tissue sections
comprising complete groups stained for IL-10, Iba-1 and MAGL were analyzed.
For DRG material, sections were taken containing the DRG corresponding to L5
spinal cord segment, and the most distal portion of the DRG was analyzed
(Supplemental Figure A-2 B). Low magnification photomicrographs were
obtained (Supplemental Figure A-2 A, B) using a Nikon Optiphot fluorescent
microscope equipped with a DP2-BSW (Olympus) camera.

3.2.9 Confocal microscopy
All tissue processing, slicing, and procedures for immunohistochemistry were
identical to that described above. However, in these studies more than one
primary antibody was used and examined under confocal microscopy. Therefore,
after the first antibody staining procedure, the slides went through subsequent
staining procedures. This took place over multiple days to account for the times
needed for individual antibody incubation and staining. Confocal microscopy at
63x magnification was then performed on a Zeiss AxioObserver inverted LSM510
META confocal microscope utilizing Zen 2009 software (Carl Zeiss, AG,
Germany). Final images were generated from collapsed z-stacks comprised of
17 images taken 0.393 µm apart on the z axis.

3.2.10 Immunohistochemical spectral image analysis
All images of the spinal cord dorsal horn, overlying meninges and DRGs were
captured by a Zeiss Axioscope Microscope, at 20x magnification, with a Nuance
Spectral Camera (Cambridge Research & Instrumentation, Woburn, MA).
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Utilizing the Nuance computer software, the fluorescent wavelength emission
spectra range was initially determined for each fluorophore utilized in the
detection of the primary antibody of interest (DAPI, 488 nm +/- 10nm; FITC, 575
nm +/- 5nm; Rhodamine Red 600 nm+/- 5nm) by using a control slide with only a
drop of the pure fluorophore. This was performed in the absence of a tissue
specimen that may potentially obscure the measurement of the fluorophore’s
emission spectra. Two sets of additional control slides with tissue sections were
prepared, one with only PBS without primary or secondary antibody treatment,
and the other without primary but with secondary antibody treatment. These
control slides were used to objectively eliminate low intensity fluorescence and
autofluorescence background ‘noise’ from our measurements (Supplemental
Figure A-2 C). Using the control slides, the Nuance software allows the user to
set an acceptable threshold of low-level emission fluorescent intensity (as
opposed to the software “autothreshold” option) within and outside the defined
wavelength range of interest between tissue samples. Emission values that fall
below this acceptable threshold of low-level emission, within and outside the
defined wavelength range of interest, were eliminated from our measurements
(Supplemental Figure A-2 D). The fluorescent intensity threshold for each protein
marker was determined by the user finding the most appropriate threshold that
captures the specific FITC or Rhodamine Red staining for each protein marker
within a tissue (e.g., dorsal horn spinal cord or DRG). Once the optimal level of
fluorescent threshold was determined for a particular protein marker, this level
was held consistent throughout all of the treatment groups for the image analysis
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within each protein marker of interest (Supplemental Figure A-2 D). These steps
were followed by software conversion allowing fluorescent wavelength intensity
for each fluorophore to be converted to a numerical value. Autofluorescence was
defined as that emission outside the defined wavelength of interest (e.g. DAPI,
488 nm +/- 10nm; FITC, 575 nm +/- 5nm; Rhodamine Red 600 nm+/- 5nm) as
well as low-level emission that fell below the acceptable threshold of low-level
emission fluorescent intensity. These specific autofluorescent and low-level
background emission values were subtracted from the image (Supplemental
Figure A-2 E,F), yielding a numerical value of true fluorescent emission intensity
for each fluorophore [219, 220].
Primary antibody staining procedures remained consistent to minimize intensity
variations of each fluorophore (FITC or Rhodamine Red) used to detect the
different primary antibodies of interest. To ensure that fluorophore binding was
not impeded through possible steric hindrance of other proximal fluorophores,
sections were labeled for only one cellular marker of interest on a slide.
The user also determined the minimum number of connected pixels on the
computer screen for image analysis, counted as a region of interest (ROI)
defined in the Nuance software system, which resulted in a software image
containing distinctive morphology (i.e., of cellular bodies and processes, pattern
of protein expression) that was virtually identical to the morphology observed
through the microscope for each protein marker. The minimum number of
connected pixels would therefore be set higher for a protein expressed
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abundantly by a cell (i.e., GFAP) in comparison to a protein expressed sparsely,
leading to a punctuate pattern (e.g., IL-1β). These conditions resulted in a ROI,
and were held consistent for both the ipsilateral and contralateral tissues in every
experimental condition and for each antibody stain. The total area of each ROI,
as measured by mm2, is calculated and is factored into the overall measurement
of fluorescent intensity per second of exposure. The average count of fluorescent
emission intensity per second exposure, per mm 2 is the analyzed value that we
report here. That is, fluorescent intensity average count/second/mm 2, which
takes into account the density as well as the intensity of the fluorophore detected.
A total of 4 sections per animal (N=3) were randomly selected and analyzed in
this manner. By applying this novel method of data acquisition and analysis,
experimenter bias is eliminated, yielding greater consistency and objectivity to
fluorescent quantification.

3.2.11 Protein quantification by ELISA
Twenty minutes after i.t. gp120 and subsequent behavioral verification, rats were
given an overdose i.p. injection (0.8-1.3 cc) of sodium phenobarbital (Sleepaway,
Fort Dodge Animal Health, Fort Dodge, IA) and perfused transcardially with ice
cold saline followed by exposure of the lumbosacral enlargement by
laminectomy. After verifying subdural intrathecal catheter placement and cerebral
spinal fluid (CSF) collection, the dorsal portion of the lumbosacral spinal cord and
the corresponding bilateral L4-L6 dorsal root ganglia were collected separately
into tubes and flash frozen in liquid nitrogen. Tubes were then stored at -80°C
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until assay. ELISA procedures were performed for IL-1β and TNF-α according to
manufacturer’s instructions (R&D Systems, Minneapolis, MN).
Experimental Paradigms
Behavioral efficacy of i.t AM1710 following CCI. Behavioral assessment of BL
thresholds was conducted prior to CCI or sham surgical manipulation. Hindpaw
threshold responses were assessed 3 and 10 days after surgery. Immediately
following behavioral assessment, rats (N=6/group) were given an i.t. injection of
AM1710 or vehicle. Hindpaw threshold responses were reassessed during the
following 24 hr at discrete timepoints.
Immunohistochemical detection of spinal and DRG changes. In a separate group
of rats (N=3/group), identical BL threshold assessment and surgical procedures
were followed, as just described. I.t. AM1710 was injected at the dose (10 ug)
identified to produce maximal reversal from allodynia produced by CCI. At the
time of maximal efficacy (~3 hr), rats were deeply anesthetized followed by
procedures for IHC analysis of tissue sections. Thus, all tissue sections from the
dorsal horn of the spinal cord and the corresponding intact DRG were analyzed
from behaviorally verified rats from different experimental manipulations (sham
vs. CCI + vehicle vs. AM1710).
Behavioral efficacy of i.t AM1710 following i.t. gp120.
A separate group of rats were behaviorally verified for BL thresholds followed by
chronic i.t. catheterization. Threshold values were reassessed 6 days later.
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Immediately thereafter, rats received i.t AM1710 or vehicle, and hindpaw
threshold responses were reassessed 3 hr later (at maximal AM1710 efficacy).
At this time, i.t. gp120 was injected, followed by threshold assessment at 20 min
(N=6 rats/group), and immediately followed by anesthetic overdose and tissue
collection for protein quantification.

3.2.12 Data analysis
Psychometric behavioral analysis was performed as previously described [215]
to compute the log stiffness that would have resulted in the 50% paw withdrawal
rate. Briefly, thresholds were estimated by fitting a Gaussian integral
psychometric function to the observed withdrawal rates for each of the tested von
Frey hairs, using a maximum-likelihood fitting method [221]. For behavioral
statistical analysis to assess the presence of allodynia, a 1-way ANOVA was
used at BL, and a 2-way repeated measures ANOVA was used at 3 and 10 days
after CCI/sham surgery in CCI-related experiments. To determine AM1710 drug
efficacy following i.t. injection on Day 10, a 3-way repeated-measures ANOVA
was applied at 0.5, 1, 2, and 2.95 hr timepoints. For experiments utilizing i.t.
gp120, a 1-way ANOVA was used at BL, and a 2-way repeated-measures
ANOVA was used at 6 days after indwelling catheter surgery, and immediately
prior to i.t. gp120. A two-way repeated-measures ANOVA was applied to assess
AM1710 efficacy 20 minutes after i.t. gp120. All other data analysis was
performed using a one-way ANOVA. A p-value of <0.05 was considered
statistically significant. The computer program GraphPad Prism version 4.03
(GraphPad Software Inc., San Diego, CA) was used in all statistical analyses. All
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data is expressed as mean +/- SEM. For post hoc analysis Bonferroni’s test was
performed.

3.3 Results
3.3.1 Intrathecal injection of AM1710 dose-dependently reverses CCI-induced
allodynia
The CB2R cannabilactone agonist, AM1710, reversed allodynia produced by
CCI. Prior to surgical manipulation, all groups exhibited similar bilateral
(ipsilateral and contralateral) BL behavioral thresholds (Figure 3.1 A,B).
Following CCI, clear bilateral allodynia developed by Day 3 and 10 compared to
sham-operated rats. On Day 10, following i.t. AM1710 or vehicle injection in
sham-operated rats, AM1710 did not alter normal sensory threshold responses to
light touch, as well as throughout the entire timecourse. However, in rats with
CCI, i.t. AM1710 produced reversal from allodynia, with maximal efficacy
observed at 3 hr following the highest dose (10 µg) injected, whereas a 10-fold
lower dose (1.0 µg) attenuated allodynia. The lowest dose examined (0.1 µg) did
not significantly alter threshold responses, with allodynia remaining stable
through the last timepoint tested (24 hr). All CCI-treated rats revealed full
allodynia at 5 hr after i.t. AM1710 treatment.
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Figure 3.1 Selective i.t. cannabinoid 2 receptor agonist AM1710 reverses CCI-induced
allodynia.
Selective i.t. cannabinoid 2 receptor agonist AM1710 reverses CCI-induced allodynia. A, B,
AM1710 reverses CCI-induced allodynia in a dose-dependent manner. A total of 36 animals were
used in this experiment. Prior to surgical manipulation, all groups exhibited similar bilateral
(ipsilateral and contralateral) BL thresholds (ANOVA, F (5,35) =1.982 ; p=0.1124, ANOVA, F(5,35)
=1.142; p=0.3616, respectively). Following CCI, clear bilateral allodynia developed by Day 3 and
continued chronically through Day 10 compared to sham-operated rats. On Day 10, compared to
i.t. control injected rats, AM1710 produced a dose-dependent reversal from allodynia, with
maximal reversal observed at 3 hours following the highest injected dose (10 μg). However,
allodynia fully returned by 5 hours after i.t. AM1710 treatment, with allodynia remaining stable
through 24 hours (ipsilateral paw ANOVA, F(15,84) = 187.6; p<0.0001; and contralateral paw,
ANOVA, F(15,84)=403.7; p<0.0001). While 1.0 μg produced attenuated allodynia, 0.1 μg did not
alter allodynia for either the ipsilateral or contralateral hindpaws. Post hoc analysis revealed that
1μg AM1710 produced a robust reversal from allodynia at 2 hours following i.t. injection, while all
AM1710 treated animals returned to allodynia by 4 hours (p<0.001).

3.3.2 Immunohistochemical analysis of spinal cord dorsal horn
Peak behavioral efficacy after i.t. AM1710 injection was again observed at ~ 3 hr
compared to neuropathic vehicle-injected rats (Figure 3.2 A,B), which is in
support of the behavioral dose-response characterization above (Figure 3.1 A,B).
Bilateral IL-10 immunoreactivity (IR) in the spinal cord dorsal horn is dramatically
decreased in CCI-induced neuropathic rats compared to sham-treated rats
(Figure 3.2 C,D). However, treatment with AM1710 rescued IL-10 IR bilaterally,
similar to levels found in non-neuropathic controls. The intact meninges
surrounding the ipsilateral spinal cord revealed a trend toward decreased IL-10
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IR in CCI animals treated with vehicle, however, no changes between treatment
groups were observed (Inset, Figure 3.2 C). Representative fluorescent images
of either sham treated with i.t. vehicle (Figure 3.2 K), CCI treated with i.t. vehicle
(Figure 3.2 L), or with AM1710 (Figure 3.2 M) corresponding to the quantitative
image analysis data are presented. Moreover, confocal microscope examination
reveals IL-10 expression in astrocytes (Figure 3.6 C,F) within superficial (Lam III) and deeper dorsal horn laminae (Lam III-V), and microglia (Figure 3.6 I; Lam IIII). It is notable that when IL-10 returns to non-neuropathic basal levels,
allodynia is correspondingly reversed.
For IL-1β IR analysis, compared to non-neuropathic sham-operated rats given i.t.
AM1710, or equivolume vehicle, CCI-induced neuropathy produced a robust
unilateral increase in IL-1β IR in i.t. vehicle injected animals (Figure 3.2 E,F).
Conversely, i.t. administration of AM1710 completely suppressed increased
dorsal horn IL-1β IR. Representative fluorescent images are of sham-treated rats
with i.t. vehicle (Figure 3.2 N), CCI-treated rats with i.t. vehicle (Figure 3.2 O), or
CCI treated-rats with AM1710 injection (Figure 3.2 P) that correspond to data
examined by microscopy analysis. Interestingly, in comparison to IL-10 IR in CCI
animals, IL-1β IR observed in the contralateral dorsal spinal cord was not
substantially elevated when compared to non-neuropathic control animals.
We also examined dorsal horn p-p38 MAPK IR. Compared to sham-operated
rats given i.t. AM1710, or equivolume vehicle, CCI-induced neuropathy produced
a robust bilateral increase in the dorsal horn of p-p38MAPK IR (Figure 3.2 G,H).
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Unexpectedly, AM1710 did not alter ipsilateral or contralateral increases in pp38MAPK IR. Again, representative fluorescent images are presented, which
correspond to image analysis of either sham-treated rats with i.t. vehicle (Figure
3.2 Q), CCI-treated rats with i.t. vehicle (Figure 3.2 R), or CCI-treated rats with
AM1710 (Figure 3.2 S).
Upon close examination of the nuclear specific dye, DAPI, no differences in
fluorescence intensity as a consequence of either CCI procedures or i.t. drug
injections were observed, suggesting that local lumbar cellular numbers
remained relatively unchanged (Figure 3.2 I, J).
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Figure 3.2 Immunofluorescent intensity quantification cytokines
Immunofluorescent intensity quantification following AM1710 –induced reversal of allodynia. A
total of 12 animals were used for both the behavioral experiment reported here and tissues from
these animals were analyzed in the reported immunohistochemical experiments. A,B, Prior to
CCI, all groups exhibited similar ipsilateral and contralateral BL thresholds (ANOVA, F (3,11)
=2.396; p=0.1438, and ANOVA, F(3,11) =1.432; p=0.3036, respectively). CCI produced significant
bilateral allodynia at Day 3 and continued to Day 10 compared to sham-treated animals (ANOVA,
F(1,8) =284.8; p< 0.0001, and ANOVA, F(1,8)=222.9; p=0.0001, respectively). Behavioral responses
following i.t. AM1710 (10 μg) produced maximal bilateral reversal of allodynia (ANOVA, F (1,8)=
269.7; p<0.0001 and ANOVA, F(1,8)=146.0; p<0.0001, respectively). At peak reversal, animals
were sacrificed and spinal tissue was collected. C, D, Bilateral IL-10- immunoreactivity (IR) in the
dorsal horn spinal cord was dramatically decreased in CCI-induced neuropathic rats compared to
sham-treated rats. In stark contrast, treatment with AM1710 rescued IL-10 IR to basal levels in
both the ipsilateral and contralateral dorsal spinal cord (ANOVA, F(3,11)=12.36; p=0.0023; ANOVA,
F(3,11)=30.68; p<0.0001, respectively). Inset, C, No changes in expression of meningeal IL-10 IR
between non-neuropathic sham and neuropathic CCI rats following i.t. AM1710 or equivolume
vehicle were observed (ANOVA, F(3,11)=1.109; p=0.4008). E, F, Compared to non-neuropathic
sham-operated rats given i.t. AM1710 or equivolume vehicle, CCI-induced neuropathy produced
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a robust unilateral increase in IL-1β IR in i.t. vehicle injected animals. Conversely, i.t.
administration of AM1710 reversed increased dorsal horn spinal IL-1β IR. IL-1β IR observed in
the contralateral dorsal horn spinal cord was not substantially elevated when compared to nonneuropathic control animals. (ANOVA, F(3,11)= 6.240; p=0.0172; ANOVA, F(3,11)=3.354; p=0.0.760,
respectively). G, H, Compared to non-neuropathic sham-operated rats given i.t. AM1710 or
equivolume vehicle, CCI-induced neuropathy produced a robust p-p38MAPK bilateral IR increase
in dorsal horn spinal cord tissues following i.t. vehicle injection. AM1710 administered i.t. did not
reverse CCI- induced increases in p38MAPK IR. (ANOVA, F(3,11)=4.221; p=0.0459; ANOVA,
F(3,11)=22.26; p=0.0003, respectively). I, J, No differences in DAPI nuclear stain fluorescent
intensity were observed in AM1710 ipsilateral or contralateral dorsal horn (ANOVA, F(3,11)=0.4571;
p=0.7197, ANOVA, F(3,11)=0.0006230; p=1.0, respectively). K, L, M, Representative spectrally
unmixed images at 20x magnification of IL-10 fluorescent staining (green) with DAPI nuclear stain
(blue). N, O, P, Representative spectrally unmixed images at 20x magnification of IL1β
fluorescent staining (red) and DAPI nuclear stain (blue). Q, R, S, Representative spectrally
unmixed images at 20x magnification of phospho-p38 fluorescent staining (green) with DAPI
nuclear stain (blue). In all images the scale bar is equal to 50 µm.

While non-neuropathic sham-operated animals given i.t. AM1710 or equivolume
vehicle exhibited similar Iba-1 IR levels, a marker for altered microglial activity,
AM1710 did not modify the increased dorsal horn Iba-1 IR in CCI-treated rats
during AM1710-induced reversal from allodynia compared to CCI-treated treated
rats with ongoing allodynia (Figure 3.3 A,B). Therefore, despite robust
suppression of dorsal horn IL-1β expression and full reversal of allodynia, local
administration of AM1710 does not inhibit increased levels of spinal Iba-1 IR.
Meningeal Iba-1 IR was significantly elevated in CCI-treated compared to nonneuropathic sham-treated rats (Figure 3.3 A Inset). While a trend toward
decreased Iba-1 IR was observed in meninges of CCI-treated rats given i.t.
AM1710, this decrease was insignificant.
Bilateral dorsal horn GFAP IR expression in adjacent Iba-1 stained sections was
examined. Compared to non-neuropathic sham-operated rats given i.t. AM1710,
or equivolume vehicle, a robust bilateral increase in dorsal horn GFAP was
demonstrated in neuropathic rats (Figure 3.3 C,D). However, clear suppressive
effects of AM1710 on astrocyte activation were observed. Intrathecal AM1710
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strikingly reduced the bilateral increases in dorsal horn GFAP IR seen in CCI
vehicle-treated rats (Figure 3.3 C,D). Corresponding representative fluorescent
images used for analysis are shown; sham-operated rats treated with either i.t.
vehicle or AM1710 (Figure 3.3 E,F), or CCI-treated rats injected with either i.t.
AM1710 or equivolume vehicle (Figure 3.3 G,H).
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Figure 3.3 Immunofluorescent intensity quantification glia
Immunofluorescent intensity quantification of the spinal cord dorsal horn reveals differences in
astrocyte but not microglial activation in neuropathic rats treated with AM1710. A, B, Compared
to non-neuropathic sham-operated rats given i.t. AM1710 or equivolume vehicle, CCI-induced
neuropathy produced a robust bilateral increase in spinal cord dorsal horn Iba-1 IR in rats given
i.t. vehicle (ANOVA, F(3,11)=58.94; p<0.0001, ANOVA, F(3,11)=175.5; p<0.0001, respectively).
Inset, A, significant changes in expression of meningeal Iba-1 IR between non-neuropathic sham
and neuropathic CCI rats following i.t. AM1710 or equivolume vehicle were observed (ANOVA,
F(3,11)=22.55; p=0.0003). C, D, Compared to non-neuropathic sham-operated rats given i.t.
AM1710 or equivolume vehicle, neuropathic rats demonstrated a robust bilateral increase in
dorsal horn GFAP IR given i.t. vehicle (ANOVA, F(3,11)=30.32; p=0.0001, ANOVA, F(3,11)=31.57;
p<0.001, respectively). E, F, G, H, Representative spectrally unmixed images at 20x
magnification of GFAP fluorescent staining (red) and DAPI nuclear stain(blue). In all images the
scale bar is equal to 50 µm.

FAAH and MAGL IR were examined at maximal anti-allodynic efficacy of
AM1710. Surprisingly, no changes were observed in FAAH IR between nonneuropathic sham and neuropathic CCI rats following i.t. AM1710 or equivolume
vehicle (Figure 3.4 A,B). However, the exact opposite was observed with MAGL
IR. That is, neuropathic rats given i.t. vehicle showed a robust bilateral increase
in dorsal horn MAGL IR compared to non-neuropathic sham-operated rats given
i.t. AM1710, or equivolume vehicle (Figure 3.4 C,D). These observed MAGL IR
increases were robustly and ipsilaterally suppressed in spinal cords of rats
treated with i.t. AM1710 (Figure 3.4 C,D). The intact meninges overlying the
ipsilateral spinal cord were also separately analyzed. Different from dorsal spinal
analysis, a significant increase in MAGL IR was observed from non-neuropathic
sham rats given i.t. AM1710 compared to non-neuropathic rats given i.t. vehicle
(Inset, Figure 3.4 C). Like dorsal spinal analysis, a clear increase in MAGL IR
from

CCI-treated

rats

given

vehicle

was

measured.

Representative

corresponding fluorescent images of analyses from whole dorsal horn spinal cord
are shown from sham-operated rats injected with either i.t. vehicle or AM1710
(Figure 3.4 E,F), or CCI-treated rats with either i.t. vehicle or AM1710 (Figure 3.4
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G,H). While MAGL has been identified in neuronal and microglial cultures, we
show that MAGL can be expressed in microglia in vivo (Figure 3.6 J,K,L)
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Figure 3.4 Immunofluorescent intensity quantification endocannabinoid degragative
enzymes
Immunofluorescent intensity quantification of the spinal cord dorsal horn reveals i.t. AM1710
reduces the expression of the endocannabinoid degragative enzyme, MAGL. A, B, No changes in
expression of FAAH IR between non-neuropathic sham and neuropathic CCI rats following i.t.
AM1710 or equivolume vehicle were observed (ANOVA, F(3,11)=1.967; p=0.1976; ANOVA,
F(3,11)=3.068; p=0.0910, respectively) C, D, Compared to non-neuropathic sham operated rats
given i.t. AM1710 or equivolume vehicle, neuropathic rats given i.t. vehicle showed a robust
bilateral increase in dorsal horn MAGL IR. In contrast, an i.t. AM1710 injection robustly
suppressed bilateral increases in dorsal spinal MAGL IR (ANOVA, F(3,11)=11.38; p=0.0029,
ANOVA, F(3,11)=5.444; p=0.00247, respectively). Inset, C, non-neuropathic sham rats given i.t.
AM1710 as well as neuropathic rats given i.t. vehicle showed an increase in meningeal MAGL IR
compared to non-neuropathic rats given i.t. vehicle (ANOVA, F(3,11)=8.153; p=0.0081). E, F, G, H,
Representative spectrally unmixed images at 20x magnification of MAGL fluorescent staining
(green), and DAPI nuclear stain (blue). In all images the scale bar is equal to 50 µm

3.3.3 Immunohistochemical analysis of dorsal root ganglia
Non-neuropathic sham-operated rats given i.t. AM1710, or equivolume vehicle,
revealed low GFAP IR, a marker for satellite cells. In striking contrast, a robust
bilateral increase in GFAP IR was observed in the DRG from CCI-induced
neuropathic rats given i.t. vehicle (Figure 3.5 A,B). However, AM1710 robustly
blocked bilateral GFAP IR increases in DRG (Figure 3.5 A,B). Ipsilateral, and not
contralateral, DRG increases in levels of p-p38MAPK (Figure 3.5 C,D), IL-1β
(Figure 3.5 E,F) and decreases in IL-10 (Figure 3.5 G,H) were observed in
vehicle injected neuropathic rats. However, following i.t. AM1710, these
immunoreactive changes in p-p38MAPK, IL-1β and IL-10 significantly recovered
to non-neuropathic controls levels. Representative corresponding p-p38MAPK
and IL-10 immunofluorescent images of these analyses are shown from
ipsilateral DRG of sham-operated rats treated with i.t. vehicle (Figure 3.5 I,L), or
CCI-treated rats given either i.t. vehicle (Figure 3.5 J,M) or AM1710 (Figure 3.5
K,N).
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Figure 3.5 Immunofluorescent intensity quantification DRG
Immunofluorescent intensity quantification of the dorsal root ganglion reveals differences in
astrocyte activation levels, phosphorylated p38MAPK, IL1β and IL-10. A, B, Compared to nonneuropathic sham operated rats given i.t. AM1710 or equivolume vehicle, CCI-induced
neuropathic rats given i.t. vehicle revealed a robust bilateral increase in GFAP IR. However, i.t.
AM1710 injection robustly blocked bilateral increases in GFAP IR (ANOVA, F(3,11)=28.56;
p=0.0001, ANOVA, F(3,11)=6.067; p=0.0186, respectively). C, D, DRG changes in levels of pp38MAPK IR occurred in the ipsilateral (ANOVA, F(3,11)=8.097; p=0.0083), but not the
contralateral (ANOVA, F(3,11)=0.01644; p=0.9969) spinal cord to the sciatic nerve damage. E, F,
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Unilateral change was also observed with IL-1β IR (ipsilateral ANOVA, F(3,11)=9.291; p=0.0055,
contralateral ANOVA, F(3,11)=0.2395; p=0.8664). G, H, IL-10 IR was also unilaterally decreased in
neuropathic animals following CCI surgery given i.t. vehicle treatment of AM1710 (ipsilateral
ANOVA, F(3,11)=12.01; p=0.0025, contralateral ANOVA, F(3,11)=1.612; p=0.2618). I, J, K,
Representative spectrally unmixed images of phospho-p38 at 20x magnification, phospho-p38
fluorescent staining (green) and DAPI nuclear stain (blue). L, M, N, IL-10 representative
spectrally unmixed images at 20x, IL-10 fluorescent staining (green) and DAPI nuclear stain
(blue). In all images the scale bar is equal to 50 µm.

3.3.4 Identification of IL-10 expressed in dorsal horn astrocytes and microglia
Within the superficial laminae, IL-10 is not co-labeled with GFAP positive cells
(Figure 3.6 A,B,C). However, within the deeper laminae of the dorsal spinal cord,
IL-10 is extensively co-labeled with GFAP, (Figure 3.6 D,E,F) while co-labeling
with NF-H (neurons) was completely absent (data not shown). Additionally, Iba-1
positive cells (macrophages and/or resident microglia) express IL-10 protein in
laminae I-III (Figure 3.6 G,H,I).
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Figure 3.6 Qualitative confocal images of cellular immunostaining of IL-10 in spinal cord.
Qualitative confocal images of cellular immunostaining of IL-10 in spinal cord. A-I, Spinal cord
tissue from rats with CCI-AM1710 treatment. A, B, C, Immunostaining of IL-10 (green) in
meninges and superficial laminae of the spinal cord dorsal horn is not co-labeled with GFAP (red)
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positive cells. DAPI nuclear labeling is blue. Arrows indicate IL-10 in the superficial laminae. D,
E, F, Immunostaining of IL-10 (green) in the deeper laminae of the dorsal horn spinal cord is colabeled yellow with GFAP (red) positive cells, with DAPI nuclear labeling (blue). Arrows indicate
co-labeling of IL-10 and GFAP positive cells. G, H, I, Immunostaining of IL-10 (green) in the
meninges and superficial laminae of the dorsal horn spinal cord is co-labeled (yellow) with Iba-1
(red) positive cells, with DAPI nuclear labeling (blue). Arrows indicate co-labeling of IL-10 and
Iba-1 positive cells. J, K,L, Immunostaining of MAGL (green) in the deeper laminae of the dorsal
horn is co-labeled yellow with Iba-1 (red) positive cells, with NF-H neuronal labeling (blue). An
arrow indicates co-labeling of MAGL and an Iba-1 positive cell. In all images the scale bar is
equal to 20 µm.

3.3.5 Blockade of gp120-induced allodynia and DRG IL-1β production
Pilot data determined the timecourse in which AM1710 blocked the ability of
gp120 to induce allodynia. We found that 10 μg of AM1710 was sufficient in
blocking the initial development of gp120-induced allodynia, with the antiallodynic effects gone by 60 minutes (data not shown). All animals revealed
similar BL responses prior to i.t. lumbar cannula implantation, i.t. AM1710 or
equivolume vehicle injection (Day 6), and immediately prior i.t. gp120 (Figure 3.7
A, B). As expected, a robust bilateral allodynia was observed in animals given i.t.
pretreatment with the vehicle for AM1710 followed ~3 hrs later by i.t. gp120. In
stark contrast, i.t. pretreatment with AM1710 completely prevented the initiation
of the bilateral gp120-induced allodynia (Figure 3.7 A, B). Tissue collected from
these animals 20 minutes after gp120 administration revealed a robust increase
in IL-1β protein levels and a strong trend toward increased TNF-α protein
production in the L4-L6 DRG corresponding to L4-L6 spinal segments exposed to
i.t gp120 compared to controls (Figure 3.7 C, D). However, IL-1β protein was
significantly suppressed in animals given i.t. AM1710 pretreatment followed by
gp120, while a strong trend toward blunted TNF-α protein production was
measured. Expectedly, changes in IL1-β and TNF-α within either the CSF or the
dorsal horn spinal cord was not observed at this early post-i.t. gp120 timepoint.
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Figure 3.7 AM1710 pre-treatment blocks gp120-induced allodynia and IL-1β cytokine
production.
AM1710 pre-treatment blocks gp120-induced allodynia and IL-1β cytokine production. A total of
24 animals were used for both the behavioral experiment reported here and tissues from these
animals were analyzed in the reported ELISA experiments. A, B, Prior to surgical manipulation,
all groups exhibited similar bilateral (ipsilateral and contralateral) BL thresholds (ANOVA, F (3,23)
=1.781; p=0.1833; F(3,23) =2.311; p=0.1072, respectively). Following indwelling catheter
implantation, there was no major effect of surgery on Day 6 after surgery thresholds when
compared to BL thresholds or following the i.t. pretreatment of either AM1710 or vehicle (ANOVA,
F(6,60) = 0.9381; p=0.1311; ANOVA, F(6,60)=2.415 ; p=0.1648, respectively). Animals given i.t.
gp120 developed strong allodynia in both left and right paws at 20 min compared to pre-gp120
threshold values (ANOVA, F(3,20)=61.72; p<0.0001 ANOVA, F(3,20)=75.73; p<0.0001, respectively).
C, Quantification of IL-1β protein by ELISA revealed IL-1β was significantly increased in left DRG
of allodynic rats following i.t. gp120 given a pretreatment with i.t. vehicle of AM1710 (ANOVA,
F(3,13)= 7.785; p=0.0057). D, a trend in the levels of TNF-α protein, although not statistically
significant (ANOVA, F(3,14) = 2.977; p=0.0741).

3.4 Discussion
In this study, we present evidence that a distinct anti-inflammatory response is
induced following spinal (i.t.) administration of the recently characterized
cannabinoid CB2R agonist compound from the cannabilactone class, AM1710,
122

which either prevents or reverses allodynia induced in two distinguishable animal
models. The findings of each animal model will be discussed in turn. In the CCI
model, a transitory bilateral reversal of allodynia from chronic unilateral CCI is
observed following i.t. AM1710 administration. While AM1710 was previously
shown to increase nociceptive thresholds following peripheral administration in
naïve rats [175, 176], this study reports that normal light touch sensory
thresholds are not altered following i.t. AM1710 in non-neuropathic rats.
Additionally, immunoreactivity (IR) for IL-10, significantly decreased in CCItreated rats. In striking contrast, i.t. AM1710 in CCI neuropathic animals reset
bilateral IL-10 IR to basal levels. Overlying meninges revealed similar, albeit
insignificant, trends in IL-10. Furthermore, using confocal microscopy, dorsal
horn localization of IL-10 is observed in astrocytes and microglia in superficial
and deeper laminae (III-V). Together, these findings suggest that spinal
parenchyma IL-10 regulate glia to induce pain relief.
It is critical to note that in response to peripheral nerve injury, CNS cellular
populations can increase by proliferation of microglia [232], astrocytes [270], or
by influx of bone marrow derived perivascular microglia and macrophages [85].
Thus, increased immunoreactivity of specific proteins in the lumbar spinal cord
could simply be due to a general increase in cell numbers constitutively
expressing these markers. However, DAPI IR of cellular nuclei remained
constant in all experimental conditions, supporting the possibility that cellular
specific responses to CCI and AM1710 occurred.

123

Indeed, alterations in several proinflammatory markers were observed in the
spinal cord dorsal horn following CCI. Bilateral increases in p38MAPK IR were
observed, supporting prior work demonstrating that p38MAPK plays a critical role
in mechanical allodynia that involves the action of proinflammatory cytokines
including IL-1β in models of peripheral nerve lesions [27, 194, 271]. While
increased ipsilateral spinal IL-1β mRNA was recently reported following sciatic
nerve ligation [242], the current data in this study is the first demonstration of
increased unilateral IL-1β IR in anatomically intact spinal cord dorsal horn of rats
with CCI-induced allodynia. As with IL-10, AM1710 reset IL-1β to basal levels,
but p-p38MAPK remained completely unaltered by AM1710, suggesting that
basal levels of IL-10 are not sufficient to suppress activated p-p38MAPK IR. In
addition, the data reported here show bilateral increases in GFAP IR were
observed in neuropathic rats. Prior work suggests that increased GFAP
expression may not simply be a cellular marker co-incident with neuropathy, as
has been frequently reported [93, 252, 272], but rather, may play a critical role
mediating neuropathic pain [273]. Interestingly, CB2R activation in neuropathic
rats resulted in significantly reduced superficial dorsal horn GFAP IR [94], which
may occur via microglial alterations because astrocytes make contact with
microglia.
CB2R expression has been identified mostly in spinal microglia [93, 135, 139,
212, 241]. While AM1710 blunted increases in GFAP IR, Iba-1 IR remained
unaltered. Iba-1 is one of several immunohistochemical markers used to identify
active microglia [274, 275]. Spinal cord microglial activation, identified by Iba-1
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IHC staining, was reversed by 3 hours following treatment with a microglialspecific inhibitor [134]. Other markers include the CD11b/CD18 [268], or
translocator protein (TSPO), formerly known as the peripheral benzodiazepine
receptor [276] preferentially expressed in CNS macrophage/microglia. However,
in contrast to prior reports revealing decreased microglial activation following i.t.
CB2R activation [131, 241, 254], we show increased Iba-1 IR persists following
i.t. AM1710 and during reversal from allodynia. However, interpretations of these
results are limited, given only a single microglial marker was used to examine
microglial activation. Nevertheless, microglia produce the anti-inflammatory
endocannabinoid, 2-arachidonyl glycerol (2-AG) during pathological CNS
conditions [8, 144]. Notably, microgla may also be a source of IL-10 [277] in the
spinal cord. Indeed, co-localization of IL-10 in microglia within superficial and
deeper spinal cord laminae (III-IV) in behaviorally reversed CCI-treated rats is
shown in this report.
The bioavailability of endocannabinoids such as anandamide and 2-AG produced
and released from neurons and microglia [8, 144] are primarily controlled through
enzymatic metabolism by FAAH and MAGL [140, 142, 234]. Inhibitors of FAAH
and MAGL that result in increased CNS levels of AEA and 2-AG, suppress
pathological pain [151, 152, 208, 258]. The current study uniquely shows
increased dorsal horn MAGL IR of neuropathic rats that is reduced following i.t.
AM1710 in allodynic-reversed rats. As noted above, microglia are a known
source of 2-AG [8], where the actions of MAGL have been described [145]. We
additionally show that MAGL expression is co-localized in superficial dorsal horn
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microglia using confocal microscopy. Interestingly, no change in FAAH-IR was
observed.
Satellite glial cells in the DRG form a clear sheath around individual large and
small sensory neurons, and when activated under neuropathic conditions, reveal
enriched GFAP and IL-1β expression [69, 72, 80, 81, 273]. IL-1β released from
satellite glia further stimulates sensory neurons. Notably, DRG p-p38MAPK
expression is well-characterized following peripheral nerve injury associated with
pathological pain [84, 85]. Here, examination of DRG revealed increased
unilateral p-p38MAPK, IL-1β, and bilateral peri-neuronal (satellite cells) GFAP-IR
in neuropathic animals, while i.t. AM1710 abolished all of these changes. Like
that observed in spinal cord dorsal horn, DRG IL-10 expression was significantly
diminished during chronic neuropathy, in support of prior reports [191, 208, 273],
and AM1710 resulted in basal IL-10 IR levels.
Bilateral allodynia induced by unilateral sciatic nerve CCI is demonstrated in this
study supporting previous findings [200, 201, 203, 217, 226, 237-239]. Reports
demonstrating bilateral biochemical changes in lumbar spinal cord substantiate
these behavioral observations. Prior demonstrations include, a decrease in α2adrenergic receptor mRNA expression [240], greater Fos protein in neurons [91],
and IL-6 mRNA upregulation [239]. However, unique findings from the present
work reveal unilateral spinal cord dorsal horn IL-1β IR increases. Thus, the spinal
actions of IL-1β must be critical for inducing ipsilateral biochemical changes that
in turn alter contralateral spinal cord activity. One possible mechanism may
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involve ipsilateral IL-1β mediated astrocyte activation that spreads to the
contralateral spinal cord via astrocyte gap-junctional communication. Evidence
for a critical role of spinal gap-junctional communication leading to contralateral
allodynia that is partly mediated by IL-1β has been reported in a model of
localized sciatic nerve inflammation [237].
Intrathecal HIV-1 gp120 is an informative model of pathological pain because the
spinal actions of IL-1β, p38MAPK and other proinflammatory factors are
necessary for allodynia to develop [196, 204, 215, 217, 226, 265, 268, 278].
Here, the onset of gp120-induced allodynia replicated previously characterized
allodynia [67, 196, 204, 215, 217, 226, 265, 268, 278]. However, an early
timepoint analysis of IL1-β reveals no changes in CSF or dorsal horn, in support
of prior reports [268, 278], while increases in DRG IL1-β are observed. Allodynia
and increased protein levels of DRG IL-1β following i.t. HIV-1 gp120 was
completely

prevented

by

i.t.

AM1710

pretreatment,

supporting

immunofluorescent quantitative IL-1β changes observed from DRG in CCI
neuropathic animals. This data supports that rapid changes in allodynia may
primarily be an aspect of altered DRG activity.
CB2Rs can modulate various signal transduction pathways involved in controlling
allodynia in the animal models utilized in this report; CCI and i.t. gp120. While
each model initiates spinal glial responses with subsequent proinflammatory
cytokine production by different pathways, their downstream intracellular
pathways converge. In CCI, enhanced central terminal and dorsal horn
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neurotransmitter (glutamate, substance P), ATP and chemokine release occurs,
activating their cognate receptors on surrounding microglia, astrocytes and
neurons [79, 253, 279-281]. Separately, i.t. gp120 activates microglia and
astrocytes in their role as immunocompetent cells that release neuroactive
substances culminating in allodynia [282]. However, for both models, activated
MAPKs, such as extracellular signal-regulated kinases (ERK1/2), p38 and c-Jun
N-terminal Kinase (JNK), are critical contributors of glial intracellular signaling
leading to IL-1β and TNF-α synthesis and pathological pain [27, 196, 268, 280].
Additionally, spinal nitric oxide (NO), highly reactive through secondary reactions
creating reactive oxygen species, activates MAPKs [283] and mediates allodynia
in both models [67, 196, 280]. CB2R activation impacts signaling pathways
involving cAMP, ERK1/2, JNK, p38-MAPKs and NO production [257, 284] by
several potential mechanisms. First, CB2R activation induces the expression of
MAPK phosphatase-1 (MKP-1) in microglial cells, which acts to de-activate
ERK1/2 and decrease NO production [284]. Second, CB2R activation induces IL10 production that is well-established to suppress IL-1β TNF-α and NO
production [277]. While CB2R-mediated IL-10 production requires p38-, ERK1/2
and

JNK-MAPK

activation

[257],

concurrent

inhibition

of

downstream

translocation to the nucleus of the transcription factor, nuclear factor-kappaB
(NFκB) that triggers IL-1β and TNF-α transcriptional activation, occurs by
disrupting cytoplasmic IkB important for NFκB translocation [257]. The recently
recognized key glial receptor participating in pathological pain, toll-like receptor 4
(TLR4), may become activated not only by its classic ligand, lipopolysaccharaide,
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but also by factors released from i.t. gp120- or CCI-activated glia and damaged
neurons [262, 285]. An intriguing possibility is that CB2R activation may exert
anti-inflammatory effects through the ceramide pathway [286], as ceramide
analogs and TLR4 activation in microglia act synergistically to produce IL-10 via
the p38MAPK pathway [287, 288].
Together, the implication of these results is that CB 2R compounds capable of
acting independently on both the spinal cord and DRG glial cytokines can control
clinically relevant pathological pain conditions.
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Abstract
Chronic constriction injury (CCI) of the rodent sciatic nerve causes light touch
mechanical sensitivity (allodynia) and leads to activation of spinal cord
astrocytes, microglia and dorsal root ganglia (DRG) satellite cells. The
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endocannabinoid system includes the cannabinoid receptor 1 (CB 1R) present on
neurons and the cannabinoid receptor 2 (CB2R) present on immune cells like
microglia. CB2R agonists, like AM1710, are effective in controlling pathological
pain states in animal models. Activation of the CB1R could be responsible for the
analgesic effects of AM1710 through non-specific binding. Thus, we sought to
determine whether spinal or peripheral AM1710 could lead to anti-allodynia and
produce changes in spinal and DRG pro- and anti-inflammatory protein
expression in mice with a CB1R genetic deletion. Following CCI, CB1R KO mice
displayed allodynia similar to their wild-type and heterozygous littermates.
AM1710, given either spinally or peripherally reversed CCI-induced allodynia in
CB1R KO mice to sham control levels. Immunohistochemical procedures followed
by fluorescent microscope analysis were performed for the anti-inflammatory
cytokine IL-10, the pro-inflammatory cytokine IL-1β, and the chemokine
monocyte chemoattractant protein 1 (MCP-1/CCL2) in these tissues. Mouse
macrophage culture supernatants revealed suppressed factors following
exposure to AM1710 under pro-inflammatory stimulating conditions.
Part of this work was presented in abstract form at the 2012 American Pain
Society meeting held in Honolulu, HI.
Perspective
Overall, the results support the selective CB2R agonist AM1710 may act
independently of CB1R actions in spinal cord and DRG. Absence of the CB1R
under neuropathic conditions reveals increases in neuroprotective IL-10 in both
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the DRG and spinal cord. Removal of CB1R actions coupled with CB2R agonists
may produce heightened anti-inflammatory effects, and may be clinically relevant
in the treatment of chronic, neuropathic pain.
Keywords:

cannabinoid;

mouse;

paraffin

immunohistochemistry;

spectral

analysis; MCP-1/CCL-2

4.1 Introduction
Both the dorsal root ganglia (DRG) and dorsal horn of the spinal cord are well
characterized to house neurons critical for processing information underlying
chronic pain. It is well established that glia, (i.e., astrocytes, microglia, as well as
DRG satellite cells) mediate chronic pathological pain signaling [25, 289-292].
Under healthy conditions, glial activation is correlated to immune surveillance,
and is critical for the maintenance of homeostasis. However, unrelenting,
continous activation of glial cells without a homeostatic function often leads to
aberrant, pathological activation, resulting in the release of proinflammatory
cytokines such as tumor necrosis factor alpha (TNF-α), and interleukin (IL)-1β.
Proinflammatory cytokines are known to be a critical components of chronic
neuropathic pain [29, 202]. The chemokine CCL2 (C-C motif ligand 2), also
known as monocyte chemo-attractant protein-1 (MCP-1), exists as a neuron to
glia signal. MCP-1 is released from pre-synaptic neurons in the superficial lamina
of the dorsal horn of the spinal cord, binds to its receptor CCR2 on glia, leading
to glial activation and pathological pain [77, 293-295]. It has been established
that the actions of the anti-inflammatory cytokine IL-10 reverses neuropathic pain
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in several animal models [202, 229, 230, 296, 297]. Although anatomically
distinct, the relative contribution of spinal cord glia compared to DRG glia in the
ongoing maintenance of chronic pain conditions is not well understood.
The most widely understood receptors of the endocannabinoid system are the
cannabinoid 1 receptor (CB1R), predominately found on peripheral nociceptor
cell bodies within the DRG and on pre- and post synaptic neurons in the
superficial lamina of the dorsal horn, including GABA-urgic interneurons [298],
and the cannabinoid 2 receptor (CB2R) predominately found on immune cells
such as microglia. Activation of either the CB1R or CB2R has been extensively
characterized to produce analgesia [91, 94, 139, 148, 155, 162-164, 177, 210,
211, 258, 261, 299-302]. However, actions at the CB1R produce a number of
effects other than analgesia, which diminishes its potential clinical application.
Alternatively, CB2R specific compounds that do not produce the unintended
effects that activation of the CB1R produces, have been pursued. We previously
found that the novel CB2R agonist AM1710 from the cannabilactone classification
[175, 176] was efficacious in preventing and reversing allodynia, light touch
mechanical sensitivity, a significant and frequent manifestation of neuropathic
pain [300]. In correlation with behavioral reversal, we found a distinct antiinflammatory effect after intrathecal administration of AM1710 in both the dorsal
horn spinal cord as well as corresponding DRG. However, CB1Rs may be greater
in number than CB2Rs in the spinal cord. Antibodies for CB2R have been
problematic, leading to difficulty in quanifying numbers of CB1R vs. CB2R under
normal and pathological conditions. Although AM1710 has a ~54-fold greater
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affinity for the CB2R over the CB1R [175], non-specific actions at the CB1R
cannot be dismissed as a major factor contributing to the anti-allodynic effects of
AM1710.
The goal of these studies was to examine whether AM1710 controls pathological
pain via CB2R specific actions that involves a role for cytokines in the spinal cord
and DRG. The use of transgenic animals lacking functional CB1R was employed
to examine the specificity of AM1710. Here we sought to tease out the discrete
anatomical influences of critical protein mediators of chronic pain, such as the
cytokines IL-1β, IL-10 and the chemokine MCP-1 on the reversal of neuropathic
pain. Intriguingly, with the constitutive removal of the CB1R in CB1R KO mice, we
find a novel interplay between the endogenous actions of CB1R and the
expression of the neuroprotective protein IL-10 under neuropathic conditions.

4.2 Methods
4.2.1 Animals
A total of 173 pathogen-free adult male mice on a CD1 genetic background
(24-39 grams) were used in all experiments. The weight difference in the mice
utilized was due to both the age range (1 month to 3 months old) as well as the
genotype differences due to the CB1R KO. That is, with the genetic deletion of
the CB1R, these mice tend to weigh less than age matched controls, but this did
not lead to observable differences in withdrawal responses during behavioral
testing. Mice were housed in a temperature and light-controlled (12 hour
light/dark; lights on at 6:00 AM) environment, with standard rodent chow and

134

water available ad libitum. All procedures adhered to the guidelines of the
Committee for Research and Ethical Issues of the International Association for
the Study of Pain and were approved by the Institutional Animal Care and Use
Committee (IACUC) of the University of New Mexico Health Sciences Center.
Heterozygous CB1R knockout mice were generated on a CD1 background and
were generously gifted from the laboratory of Dr. C. Ledent [303]. Of note, it has
been established that this strain of knockout mice do not display typical
behavioral endpoints observed with CB1R agonists. Heterozygous (CB1R-/+) and
Knockout (CB1R-/-) mice, along with their Wildtype (CB1R+/+) littermates, were
used in all experiments.
The following primer sequences were used in PCR for genotyping:
GGG TGA GGA GAC ATG CCT GGT GA ------------------------ CB1R Wildtype Forward primer
AGA GGT GCC AGG AGG GAA CCC TA ------------------------ CB1R Wildtype Reverse primer
CCT TGC GCA GCT GTG CTC GA -------------------------------- CB1R Knockout Forward primer
GAA CAG TTC GGC TGG CGC GA -------------------------------- CB1R Knockout Reverse primer

4.2.2 Drugs
The CB2R agonist, 3-1(1’,1’-Dimethylheptyl)-1-hydroxy-9-methoxy-6H-benzo[c]chromene-6-one (AM1710) [175, 176, 300, 304] was used in these experiments.
AM1710 was generously gifted by A.M. and G.T. AM1710 was first dissolved in
100% ethanol and diluted in sterile water (Hospira Inc, Lake Forest, IL) for a final
of concentration 1 mg/ mL containing 5% ethanol. The vehicle of AM1710
consisted of sterile water containing 5% ethanol, as described previously [300].
The selective CB2R antagonist, 6-Iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1Hindol-3-yl](4-methoxyphenyl)methanone, (AM630) was purchased (cat # 1120,
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Tocris Bioscience, Minneapolis, MN). As described for AM1710, AM630 was first
dissolved in 100% ethanol and diluted in sterile water (Hospira Inc, Lake Forest,
IL) for a final of concentration 1 mg/ mL containing 5% ethanol. The vehicle of
AM630 was made up of sterile water containing 5% ethanol.

4.2.3 Behavioral assessment of allodynia
Baseline (BL) responses to light mechanical touch were assessed using the von
Frey test after animals were habituated to the testing environment, as described
elsewhere [305]. Briefly, mice were placed atop 2 mm-thick parallel bars, covered
with a wire mesh screen, with spaces 1 mm apart and habituated for
approximately 30 minutes for 4 days. Mice were unrestrained, and were singly
placed under an inverted wire mesh basket to allow for unrestricted air flow. All
behavioral testing was performed during the first half of the light cycle in a sound,
light, and temperature controlled room. The von Frey test utilizes a series of
calibrated monofilaments, (2.83 – 4.31 log stimulus intensity; North Coast
Medical, Morgan Hills, CA) applied randomly to the left and right plantar surface
of the hindpaw for 3 seconds. Lifting, licking or shaking the paw was considered
a response. For all behavioral testing, threshold assessment was performed in a
blinded fashion by J.L.W.

4.2.4 Chronic constriction injury (CCI) surgery
Following BL behavioral assessment, the surgical procedure for chronic
constriction of the sciatic nerve was completed as previously described [216], but
modified for mouse [305, 306]. Briefly, in isoflurane- (induction 5% vol. followed
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by 2.0% in oxygen) anesthetized mice, the mid- to lower back and the dorsal left
thigh shaved and cleaned with 75% ethanol. Using aseptic procedures, the
sciatic nerve was carefully isolated, and loosely ligated with 3 segments of 5-0
chromic gut sutures (Ethicon, Somerville, NJ). Sham surgery was identical to CCI
surgery but without the loose nerve ligation. The overlying muscle was sutured
closed with (1) 4-0 sterile silk suture (Ethicon, Somerville, NJ), and animals
recovered from anesthesia within approximately 5 minutes. Animal placement
into either CCI or sham surgical groups was randomly assigned.

4.2.5 Acute intrathecal injection
In mice with intrathecal injections, all drugs were administered via acute i.t.
catheter placement. Injections were performed via a lumbar puncture in between
L5-L6. Briefly, an ‘injection catheter’ made from a 27-gauge needle with the
plastic hub removed was fitted into polyethylene (PE) 20 tubing, and the needle
portion of another 27-gauge needle was inserted at the other end, with the hub of
this needle connected to a 10 μl Hamilton syringe, closely resembling the
‘injection catheter’ previously described [202, 217, 226, 297]. Using prior
publications as a guideline, a dose of 5 μg AM1710 [300] or 3 μg of the selective
CB2R antagonist, AM630 [307] was used. Drug or equivolume vehicle was drawn
into the injection catheter, and the tip of the 27-gauge needle was gently inserted
in between L5-L6. During this time, light leg twitching and a tail flick was typically
observed indicating successful i.t. catheter placement. Drug or vehicle was
injected during a 5 second interval. Drug treatment was randomly assigned to
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animals. Upon completion of injection, the 27-gauge needle was removed. A
100% motor recovery rate was observed from this injection procedure.

4.2.6 Acute intraperitoneal injection
An acute IP injection of either AM1710 or equivolume vehicle was used, in CCIinduced neuropathic mice or sham-operated non-neuropathic mice. Prior reports
[176] indicate an efficacious dose of 25 mg/kg/ ml (5 mg/ kg) AM1710, which was
administered in these studies.

4.2.7 Immunohistochemical procedures from CCI-treated mice
Following

behavioral

assessment,

animals

were

overdosed

with

an

intraperitoneal injection sodium phenobarbital (Sleepaway, Fort Dodge Animal
Health, Fort Dodge, IA), then perfused transcardially with saline followed by 4%
paraformaldehyde. Whole vertebral columns with intact spinal cords (cervical 2
through sacral 1 spinal column segments) were removed, and underwent
overnight fixation in 4% paraformaldehyde at 4°C. This tissue collection approach
ensured that all relevant anatomical components, including the cervical, thorasic,
and lumbosacral spinal cord, DRG, and overlying meninges, were intact within
the vertebral column, allowing important spatial relationships to remain for
examining corresponding functional interactions at individual and specific spinal
cord levels. All specimens underwent EDTA (Sigma Aldrich, St. Louis, MO)
decalcification for approximately 2 weeks, and spinal cord sections were
subsequently paraffin processed and embedded in Paraplast Plus Embedding
Media (McCormick Scientific, St. Louis, MO) as previously described [218, 300,
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301, 308]. Adjacent tissue sections (7 μm) were mounted on Superfrost Plus
slides (VWR, Radnor, PA), and allowed to adhere to slides overnight at 40°C,
followed by deparaffinization, and rehydration via descending alcohols to PBS
(1X, pH 7.4). Sections were then processed with microwave antigen retrieval
procedures (citrate buffer pH 6.0, or tris-based buffer, pH 9.0; BioCare Medical,
Concord, CA).
Slides were incubated with 5% normal donkey serum (NDS), in PBS (pH 7.4) for
2 hours, followed by overnight primary antibody incubation in a humidity chamber
at 3° C. Slides underwent secondary antibody incubation for 2 hours in a
humidity chamber at room temperature, rinsed in PBS, and then coverslipped
with Vectashield containing the nuclear stain 4’,6-diamidino-2-phenylindole
(DAPI) (Vector Labs, Burlingame, CA). All antibody methods were as previously
described [300, 301]. For the detection of MCP-1/CCL2 an Armenian hamster
anti-rat monoclonal antibody was used (clone 2H5, cat. # NB100-78196, Novus
Biologicals, Littleton, CO), with a primary antibody dilution of 1:100, and detected
with a Donkey- anti-hamster FITC tagged secondary antibody (Jackson
Immunoresearch, (West Grove, PA).

4.2.8 Immunohistochemical spectral image analysis
All images of the spinal cord dorsal horn, overlying meninges and DRGs were
captured by a Nikon inverted fluorescent microscope (Melville, NY), at 20x
magnification, with a Nuance Spectral Camera (Cambridge Research &
Instrumentation, Woburn, MA), as previously described [300, 301]. Briefly,
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utilizing the Nuance computer software, the fluorescent wavelength emission
spectra range was initially determined for each fluorophore utilized in the
detection of the primary antibody of interest (DAPI, 488 nm +/- 10nm; FITC, 575
nm +/- 5nm; Rhodamine Red 600 nm+/- 5nm) by using a control slide with only a
drop of the pure fluorophore. The fluorescent intensity threshold for each protein
marker was determined by the user finding the most appropriate threshold that
captures the specific FITC or Rhodamine Red staining for each protein marker
within a tissue (e.g., dorsal horn spinal cord or DRG). Once the optimal level of
fluorescent threshold was determined for a particular protein marker, this level
was held consistent throughout all of the treatment groups for the image analysis
within each protein marker of interest. These steps were followed by software
conversion allowing fluorescent wavelength intensity for each fluorophore to be
converted to a numerical value.
Primary antibody staining procedures remained consistent to minimize intensity
variations of each fluorophore (FITC or Rhodamine Red) used to detect the
different primary antibodies of interest. To ensure that fluorophore binding was
not impeded through possible steric hindrance of other proximal fluorophores,
sections were labeled for only one cellular marker of interest on a slide.
The average count of fluorescent emission intensity per second exposure, per
mm2 is the analyzed value that we report here. That is, fluorescent intensity
average count/second/mm2, which takes into account the density as well as the
intensity of the fluorophore detected. A total of 4 sections per animal (N=3) were
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randomly selected and analyzed in this manner. By applying this novel method of
data acquisition and analysis, experimenter bias is eliminated, yielding greater
consistency and objectivity to fluorescent quantification.

4.2.9 RAW264.7 cell culture, AM1710 incubation, and Lipopolysaccharide
stimulation
The mouse macrophage-like RAW 264.7 cells were obtained from American
Type Culture Collection (cat# TIB-71; ATCC Manassas, VA) and cultured in
Dulbecco’s

Modified

Eagle’s

Medium

(Sigma-Aldrich,

St.

Louis,

MO)

supplemented with 10% heat-inactivated fetal bovine serum and 100 U/ml
penicillin and 100 μg/ml streptomycin (Gibco-Life Technologies, Grand Island,
NY) at 37°C under humidified 5% CO2 atmosphere. Cells were seeded at
150,000 cells/mL in 24 well plates and grown overnight. The following day, cells
were treated with 0 (no treatment control), 10 pg/mL, 1 ng/mL, 10 ng/mL, and
100 ng/mL AM1710 for 10 minutes without any other treatment, or 4 hours after
10 minutes exposure to the gram negative cell wall protein lipopolysaccharide
(LPS) at the concentration of 500 ng/mL, (E. coli #055:B5, Sigma Aldrich, St.
Louis, MO). Cells were washed with fresh media after treatments and incubated
for 4 or 24 hours followed by collection of supernatants and cells for RNA (4
hours post treatment) or total cellular protein (24 hours post treatment). All
treatments were conducted in quadruplicates and extracellular proteins
(supernatants) or total cell lysates were used for protein as outlined below.
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4.2.10 Cell culture protein quantification by ELISA
RAW 264.7 treated cell supernatants (50 µL) or 10 ug total cellular protein in
quadruplicates were collected separately into tubes and flash frozen in liquid
nitrogen. Tubes were then stored at -80*C until assayed for extracellular or
intracellular protein quantification. ELISA procedures were performed for IL-10,
and

TNF-α,

according

to

manufacturer’s

instructions

(R&D

Systems,

Minneapolis, MN, USA).

4.2.11 Data analysis
Psychometric behavioral analysis was performed as previously described [221]
to compute the log stiffness that would have resulted in the 50% paw withdrawal
rate. Briefly, thresholds were estimated by fitting a Gaussian integral
psychometric function to the observed withdrawal rates for each of the tested von
Frey hairs, using a maximum-likelihood fitting method [90]. For behavioral
statistical analysis to assess the presence of allodynia, a 1-way ANOVA was
used at BL, and a 2-way repeated measures ANOVA was used at 3 and 10 days
after CCI/sham surgery in CCI-related experiments. All other data analysis was
performed using a one-way ANOVA. A p-value of <0.05 was considered
statistically significant. The computer program GraphPad Prism version 4.03
(GraphPad Software Inc., San Diego, CA) was used in all statistical analyses. All
data is expressed as mean +/- SEM. For post hoc analysis Bonferroni’s test was
performed.
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4.3 Results
4.3.1 CB1R KO Mice display similar allodynia profiles to their WT and Het
littermates
The functional knockout of the CB1R produced no overt changes in the bilateral
allodynia profiles obtained with CCI. Prior to surgical manipulation, all groups
exhibited similar bilateral (ipsilateral and contralateral) BL behavioral thresholds
(ANOVA,

F(5,40)

=1.661;

p=0.1693

ANOVA,

F(5,40)

=1.659;

p=0.1697,

respectively), (Figure 4.1 A,B). Following CCI, clear bilateral allodynia developed
regardless of the CB1R genetic profile by Day 3 compared to sham-operated
mice (ANOVA, F(17,72) =9.755; p<0.0001 ANOVA, F(17,72) =20.09; p<0.0001,
respectively). Bilateral allodynia remained reliable until Day 27 post surgical
manipulation, when allodynia started to spontaneously resolve (ANOVA, F(77,395)
=2.956; p<0.0001 ANOVA, F(77,395) =5.483; p<0.0001, respectively). All groups of
sham-operated mice exhibited thresholds similar to baseline responses.
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Figure 4.1 Characterization of length and severity of bilateral allodynia in CB 1R KO, Het
and WT mice.
Characterization of length and severity of bilateral allodynia in CB1R KO, Het and WT mice. A, B,
Mice develop and maintain CCI-induced allodynia regardless of functional CB1R copy number.
Before surgical manipulation, all experimental groups exhibited similar ipsilateral and contralateral
BL thresholds. CCI surgery produced significant bilateral allodynia at day 3 post CCI through day
27 post CCI compared to sham-treated animals.
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4.3.2 Intrathecal injection of AM1710 reverses CCI-induced allodynia
independently of actions due to the CB1R and is dependent on CB2R
actions
The CB2R cannabilactone agonist, AM1710, reversed allodynia produced by
CCI. Pilot experiments determined i.t. administration of 5 μg AM1710 produced
maximal behavioral pain reversal by 1.5 hours, with allodynia fully returning by 5
hours after drug administration (data not shown). Prior to surgical manipulation,
all groups exhibited similar bilateral (ipsilateral and contralateral) BL behavioral
thresholds (ANOVA, F(8,52) =1.199; p=0.3214 ANOVA, F(8,52) =1.172; p=0.3369,
respectively), (Figure 4.2 A,B). Following CCI, clear bilateral allodynia developed
by Day 5 and 12 compared to sham-operated mice (ANOVA, F(15,89) =137.4;
p<0.0.0001 ANOVA, F(15,89) =207.3; p<0.0001, respectively). On Day 12,
following i.t. AM1710 injection in sham-operated mice, AM1710 did not alter
normal sensory threshold responses to light touch, as well as throughout the
entire timecourse. However, in mice with CCI, i.t. AM1710 produced reversal
from allodynia, with maximal efficacy observed at 2 hr following injection in CB1R
wildtype (WT), heterozygous (Het) or homozygous gene deleted knockout (KO)
mice. Neuropathic mice lacking functional CB1Rs and pretreated intrathecally 30
minutes in advance with the selective CB2R antagonist AM630 failed to
behaviorally reverse from allodynia when treated with i.t. AM1710, and revealed
response thresholds similar to control mice with CCI (ANOVA, F(3,19) =0.9822;
p=0.3918 ANOVA, F(3,19) =1.729; p=0.2029, respectively), (Figure 4.2 C,D).
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Figure 4.2 Intrathecal AM1710, a cannabinoid 2 receptor agonist reverses CCI-induced
allodynia in a CB2R dependent manner.
Intrathecal AM1710, a cannabinoid 2 receptor agonist reverses CCI-induced allodynia in a CB2R
dependent manner. A, B, AM1710 reverses CCI-induced allodynia independent of CB1R actions.
Before surgical manipulation, all experimental groups exhibited similar ipsilateral and contralateral
BL thresholds and CCI surgery produced significant bilateral allodynia at days 5 and 12 following
injury compared to sham-treated animals. Responses from AM1710 (5 μg) maximally reversed
CCI-induced allodynia at ~2 hours after intrathecal administration. C, D, Intrathecal pre-treatment
with the CB2R selective antagonist AM630 30 minutes before i.t. administration of AM1710 blocks
the anti-allodynia effects of AM1710 in CB1R KO mice.

4.3.3 Immunohistochemical analysis of spinal cord dorsal horn and DRG
cytokines from mice receiving i.t. AM1710
Bilateral IL-10 (IR) in both the ipsilateral and contralateral spinal cord dorsal horn
is dramatically decreased in CCI-induced neuropathic mice compared to shamtreated mice (CB1R WT, Het or KO), (Figure 4.3 A, Supplemental Figure A-3 A,
respectively). While not significant, a trend is observed of increased IL-10 IR in
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CB1R Het or KO mice compared to CB1R WT. However, treatment with AM1710
increased IL-10 IR bilaterally, with levels similar to those found in nonneuropathic controls (ANOVA, F(8,26) =16.55; p<0.0001 ANOVA, F(8,26) =5.756;
p=0.0010, respectively). Fluorescent images of ipsilateral dorsal horn spinal cord
from wild type mice with either sham treatment with i.t. AM1710 (Figure 4.3 B),
CCI treatment with i.t. vehicle (Figure 4.3 C), or with AM1710 (Figure 4.3 D)
corresponding to the quantitative image analysis data are presented.
Similarly, bilateral IL-10 IR in corresponding ipsilateral and contralateral DRG is
dramatically decreased bilaterally in CCI-induced neuropathic mice (CB1R WT,
Het, or KO) compared to sham-treated mice (CB1R WT, Het or KO), (Figure 4.3
E, Supplemental Figure A-3 B, respectively). Interestingly, a similar DRG trend,
as seen in the dorsal horn of the spinal cord, was additionally observed with
regard to IL-10 IR increases in neuropathic CB1R Het and KO, in comparision to
CB1R WT mice. However, treatment with AM1710 significantly increased IL-10 IR
bilaterally, to control levels of non-neuropathic mice (ANOVA, F(8,26) =15.59;
p<0.0001 ANOVA, F(8,26) =6.605; p=0.0004, respectively).
For IL-1β IR analysis, compared to non-neuropathic sham-operated mice (CB1R
WT Het KO) given i.t. AM1710, CCI-induced a robust bilateral increase in IL-1β
IR within the dorsal horn of the spinal cord in control injected animals (Figure 4.3
F, Supplemental Figure A-3 C, respectively). Conversely, i.t. administration of
AM1710 completely suppressed increased dorsal horn IL-1β IR within 2 hours of
administration of the drug (ANOVA, F(8,26) =22.94; p<0.0001 ANOVA, F(8,26)
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=21.56; p<0.0001, respectively). Representative fluorescent images are of shamtreated mice with i.t. AM1710 (Figure 4.3 G), CCI-treated rats with i.t. vehicle
(Figure 4.3 H), or CCI treated-rats with AM1710 injection (Figure 4.3 I) that
correspond to data examined by microscopy analysis.
In corresponding DRG, bilateral IL-1β immunoreactivity (IR) is additionally
increased in CCI-induced neuropathic mice compared to sham-treated mice
(Figure 4.3 J, Supplemental Figure A-3 D, respectively). However, 2 hours after
treatment with AM1710 suppressed IR increases in IL-1β were observed
(ANOVA,

F(8,26)

=14.40;

p<0.0001

ANOVA,

respectively).
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F(8,26)

=16.17;

p<0.0001,

Figure 4.3 Ipsilateral immunofluorescent intensity quantification cytokines
Ipsilateral immunofluorescent intensity quantification from 7 µm thick sections of dorsal horn
spinal cord and corresponding DRG from behaviorally verified CB1R KO, Het, WT mice, following
i.t. vehicle or AM1710. A, IL-10 expression in dorsal horn spinal cord was decreased in CCItreated mice that received i.t. vehicle compared to control sham-treated mice given AM1710,
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while IL-10 IR recovered to sham levels in CCI neuropathic mice given i.t. AM1710. B, C, D,
Representative spectrally unmixed images at 20x magnification of IL-10 fluorescent labeling
(green) with DAPI nuclear stain (blue) in dorsal horn spinal cord. In all images the scale bar is
equal to 50 µm. E, IL-10 expression in DRG was decreased in CCI-treated mice that received i.t.
vehicle compared to control sham-treated mice given AM1710, while IL-10 IR recovered to sham
levels in CCI neuropathic mice given i.t. AM1710. F, Compared to sham controls, IL-1β
expression was increased in the dorsal horn spinal cord of CCI-treated animals given i.t. vehicle
of AM1710. However, i.t. AM1710 in CCI-treated mice robustly suppressed increases in IL-1β IR.
G, H, I, Representative spectrally unmixed images at 20x magnification of IL-1β fluorescent
labeling (red) with DAPI nuclear stain (blue) in dorsal horn spinal cord. J, Compared to sham
controls, IL-1β expression was increased in the DRG of CCI-treated animals given i.t. vehicle of
AM1710. However, i.t. AM1710 in CCI-treated mice robustly suppressed increases in IL-1β IR.

4.3.4 Intraperitoneal injection of AM1710 reverses CCI-induced allodynia in CB1R
knockout mice
In pilot studies we examined an AM1710 i.p. dose of 25 mg/kg/ ml based on prior
reports [176]. This dose of AM1710 was sufficient in reversing bilateral allodynia
with maximal reversal occurring at 0.5 hours that continued to 1 hour after
administration, with the anti-allodynic effects gone by 2 hours (data not shown).
Prior to surgical manipulation, all groups exhibited similar bilateral (ipsilateral and
contralateral) BL behavioral thresholds (ANOVA, F(8,52) =2.085; p=0.0574
ANOVA, F(8,52) =1.341; p=0.2486, respectively), (Figure 4.4 A,B). Clear bilateral
allodynia developed by Day 5 through 12 in all CCI treated mice compared to
sham-operated mice (ANOVA, F(15,89) =182.4; p<0.0001 ANOVA, F(15,89) =143.5;
p<0.0001, respectively). On Day 12, following i.p. AM1710 injection in shamoperated mice, AM1710 did not alter normal sensory threshold responses to light
touch. However, in mice with CCI, i.p. AM1710 produced reversal from allodynia,
regardless of the CB1R copy number.
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Figure 4.4 Intraperitoneal AM1710, a cannabinoid 2 receptor agonist reverses CCI-induced
allodynia in a CB1R independent manner.
Intraperitoneal AM1710, a cannabinoid 2 receptor agonist reverses CCI-induced allodynia in a
CB1R independent manner. A, B, AM1710 reverses CCI-induced allodynia independent of CB1R
actions. Before surgical manipulation, all experimental groups exhibited similar ipsilateral and
contralateral BL thresholds and CCI surgery produced significant bilateral allodynia at days 5 and
12 following injury compared to sham-treated animals. Responses from AM1710 (25 mg/kg/ml)
maximally reversed CCI-induced allodynia at ~ 30 minutes after intraperitoneal administration.

4.3.5 Immunohistochemical analysis of spinal cord dorsal horn and DRG IL-10,
IL-1β and microglial Iba-1
Bilateral IL-10 IR in the spinal cord dorsal horn is dramatically decreased in CCIinduced neuropathic mice compared to sham-treated mice (ANOVA, F(8,26)
=6.211; p=0.0006 ANOVA, F(8,26) =6.810; p=0.0004, respectively), (Figure 4.5
A,Supplemental Figure A-4 A, respectively). Surprisingly, treatment with i.p.
AM1710 did not alter spinal IL-10 IR. As observed previously, a trend for
increased spinal IL-10 in CCI-treated Het and KO mice when compared to WT
mice persisted in this data set.
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Figure 4.5 Ipsilateral immunofluorescent intensity quantification
Ipsilateral immunofluorescent intensity quantification from 7 µm thick sections of dorsal horn
spinal cord and corresponding DRG from behaviorally verified CB1R KO, Het, WT mice, following
i.p. vehicle or AM1710. A, IL-10 expression in dorsal horn spinal cord was decreased in CCItreated mice that received i.p. vehicle compared to control sham-treated mice given AM1710, and
IL-10 IR remained unchanged at neuropathic levels in CCI neuropathic mice given i.p. AM1710.
B, IL-10 expression in DRG was decreased in CCI-treated mice that received i.p. vehicle
compared to control sham-treated mice given AM1710, while IL-10 IR recovered to sham levels in
CCI neuropathic mice given i.p. AM1710. C, Compared to sham controls, IL-1β expression was
increased in the dorsal horn spinal cord of CCI-treated animals given i.p. vehicle of AM1710.
Intraperitoneal AM1710 in CCI-treated mice did not alter increases in IL-1β IR. D, Compared to
sham controls, IL-1β expression was increased in the DRG of CCI-treated animals given i.p.

152

vehicle of AM1710. However, i.p. AM1710 in CCI-treated mice robustly suppressed increases in
IL-1β IR. E, Iba-1 IR expression increased within the ipsilateral dorsal horn of the spinal cord
following CCI manipulations compared to control sham treatment, irrespective of i.p. vehicle or
AM1710.

While bilateral IL-10 IR in corresponding DRG is diminished in CCI-induced
neuropathic mice (WT, Het, KO) compared to sham-treated mice (Figure 4.5 B,
Supplemental Figure A-4 B, respectively), treatment with i.p. AM1710 raised IL10 IR bilaterally. These levels were similar to those found in non-neuropathic
sham mice (ANOVA, F(8,26) =20.80; p<0.0001 ANOVA, F(8,26) =11.31; p<0.0001,
respectively).
IL-1β IR analysis, compared to non-neuropathic sham-operated mice given i.p.
vehicle, revealed that CCI-induced neuropathy produced a bilateral increase in
IL-1β IR within the dorsal horn spinal cord in i.p. vehicle injected animals
(ANOVA, F(8,26) =145.2; p<0.0001 ANOVA, F(8,26) =172.3; p<0.0001, respectively)
(Figure 4.5 C, Supplemental Figure A-3 C, respectively). Surpisingly, i.p.
administration of AM1710 did not alter dorsal horn IL-1β IR in mice (CB1R WT,
Het, KO) reversed from allodynia.
Supporting the

previous

data,

bilateral IL-1β

immunoreactivity (IR)

in

corresponding DRG is again increased in CCI-induced neuropathic mice (CB1R
WT, Het, KO) compared to sham-treated mice (Figure 4.5 M, Supplemental
Figure A-4 D, respectively). Treatment with i.p. AM1710 suppress IL-1β IR with
bilateral effects resulting in levels comparible to non-neuropathic controls
(ANOVA,

F(8,26)

=25.30;

p<0.0001

ANOVA,

F(8,26)

=11.08;

p<0.0001,

respectively). Non-neuropathic sham-operated animals (CB1R WT, Het and KO
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mice) given i.p. vehicle exhibited similar Iba-1 IR levels. Iba-1 is a marker for
altered microglial activity, and increased dorsal horn Iba-1 IR in CCI-treated mice
during AM1710-induced reversal from allodynia remained unchanged compared
to CCI-treated treated mice with ongoing allodynia (ANOVA, F(8,26) =15.37;
p<0.0001 ANOVA, F(8,26) =8.777; p=0.0001, respectively), (Figure 4.5 E,
Supplemental Figure A-4 E, respectively). Similarly, while non-neuropathic shamoperated animals given i.p. vehicle exhibited similar GFAP IR levels, a marker for
altered astrocyte activity, AM1710 did not modify the observed increased dorsal
horn GFAP IR in CCI-treated mice during AM1710-induced reversal from
allodynia compared to CCI-treated treated mice with ongoing allodynia (data not
shown).

4.3.6 Immunohistochemical analysis of MCP-1 in DRG and dorsal horn spinal
cord
Bilateral MCP-1 IR in corresponding DRG is dramatically increased in CCIinduced neuropathic mice (WT, Het, KO) compared to sham-treated mice
receiving i.p. vehicle (Figure 4.6 A, Supplemental Figure A-5 A, respectively).
However, treatment with i.p. AM1710 significantly decreased MCP-1 IR
bilaterally, with levels similar to non-neuropathic controls (ANOVA, F(8,26) =13.39;
p<0.0001

ANOVA,

F(8,26)

=7.566;

p=0.0006,

respectively).

Peripheral

administration of AM1710 (i.p.) leads to profound suppression of vehicle-treated
MCP-1 in the DRG, with a modest reduction in MCP-1 in the spinal cord. Like
peripheral administration, i.t. AM1710 results in dramatically reduced MCP-1 IR
in DRG. However, unlike i.p. administration of AM1710, i.t. injection substantially
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suppresses MCP-1 IR in the spinal cord of neuropathic rats. In DRG, bilateral
MCP-1 IR is dramatically increased in CCI-induced neuropathic mice (WT, Het,
KO) receiving i.t. vehicle compared to sham-treated mice (WT, Het, KO) with i.t.
AM1710 (Figure 4.6 B, Supplemental Figure A-5 B, respectively). Treatment with
AM1710 reduced MCP-1 IR bilaterally (ANOVA, F(8,26) =4.677; p=0.0032 ANOVA,
F(8,26) =8.242; p=0.0001, respectively).
CCI-induced neuropathy, in all mice (WT, Het, KO), produced a robust bilateral
increase in MCP-1 IR within the spinal cord dorsal horn when compared to sham
control mice (WT, Het, KO), (Figure 4.6 C, Supplemental Figure A-5 C,
respectively). Unlike the unremarkable actions of i.p. AM1710 on dorsal horn
spinal cord levels of either IL-10 or IL-1β IR, i.p. administration of AM1710
decreased dorsal horn MCP-1 IR within 30 minutes. (ANOVA, F(8,26) =27.94;
p<0.0001 ANOVA, F(8,26) =21.29; p<0.0001, respectively). A similar overall effect
on MCP-1 IR was observed with i.t. AM1710. Compared to non-neuropathic
sham-operated mice (WT, Het, KO) given i.t. AM1710, CCI-induced neuropathy
produced reliable bilateral increases in MCP-1 IR within the dorsal horn,
independently of genetic copy number of CB1R (Figure 4.6 D, Supplemental
Figure A-5 D, respectively). Meanwhile, i.t. administration of AM1710 completely
suppressed increased dorsal horn MCP-1 IR (ANOVA, F(8,26) =11.46; p<0.0001
ANOVA, F(8,26) =7.243; p=0.0003, respectively).
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Figure 4.6 Ipsilateral immunofluorescent intensity quantification MCP1
Ipsilateral immunofluorescent intensity quantification of DRG and spinal cord dorsal horn reveals
both i.p. and i.t. AM1710 administration reduces the expression of the chemokine MCP-1. A, B,
Compared to control mice, DRG MCP-1 IR expression was increased in CCI-treated neuropathic
mice that received either i.p. or i.t vehicle of AM1710, while DRG MCP-1 IR in CCI-treated mice
given either i.p. or i.t. AM1710 was substantially reduced. All sections were 7 µm in thickness. C,
D, Compared to control mice, dorsal horn spinal cord MCP-1 IR expression was increased in
CCI-treated neuropathic mice that received either i.p. or i.t vehicle of AM1710, while dorsal horn
spinal cord MCP-1 IR in CCI-treated mice given either i.p. or i.t. AM1710 was substantially
reduced. All sections were 7 μm in thickness.

4.3.7 AM1710 abolishes Lipopolysaccharide effects in RAW264.7 Cells
Macrophage like RAW264.7 cells were were stimulated with 500 ng of the gram
negative bacteria cell wall protein lipopolysaccharide (LPS) for 10 minutes, and
then treated with either 10 ng AM1710, 100 ng AM1710 or equivolume vehicle for
10 minutes, 30 minutes or 1 hour. Compared to the no treatment controls, LPS
stimulation produced a robust increase of both IL-10 and TNF-α protein in cell
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supernatants (ANOVA, F(7,31) =95.89; p<0.0001 ANOVA, F(7,31) =654.3;
p<0.0001, respectively), (Figure 4.7 A, B, respectively). At both doses, and all
sampled timepoints, AM1710 was able to abolish LPS stimulated protein
production, back to basal levels.

Figure 4.7 Alone AM1710 abolishes Lipopolysaccharide effects in RAW264.7 cells.
Alone AM1710 abolishes Lipopolysaccharide effects in RAW264.7 cells. A, B, LPS stimulation of
RAW264.7 cells produced robust increases in both IL-10 and TNF-α protein, and AM1710
treatment dramatically diminished both proteins back to basal levels.

4.4 Discussion
Together these data support an anti-inflammatory mechanism of AM1710 that is
selective for the CB2R, and is not reliant on actions of CB1R. AM1710 in a cell
culture model of macrophage stimulation dramatically modulated both the proand anti-inflammatory cytokines TNF-α and IL-10 to unstimulated basal levels.
Peripheral or peri-spinal (i.t.) administration of AM1710 markedly reduced
elevated MCP-1 IR, in both spinal cord and DRG. Interestingly, although i.p.
AM1710 produced robust behavioral reversal of allodynia within 30 minutes of
administration, yet changes in IL-1β and IL-10 IR were only observed in the
DRG, not spinal cord. In all groups of mice peri-spinal delivered AM1710
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produced changes in both spinal cord as well as DRG, with corresponding relief
from allodynia in IL-10, IL-1β, as well as MCP-1. The CB1R reduced copy
number did not alter MCP-1 or IL-1β IR. We characterized the length and severity
of CCI-induced neuropathy in CB1R KO, Het, and WT mice on a CD1 genetic
background. Clear bilateral allodynia persisted for approximately 30 days
regardless of CB1R genetic deletion. These data are the first demonstration
evaluating the severity and duration of allodynia due to CCI in CB 1R knockout
and heterozygous mice. However, several models of neuropathic pain have been
used to examine the role of CB1R in other pain models, as discussed below.

4.4.1 The role of CB1R in neuropathic pain
The finding of a behavioral lack of effect on chronic pain symptoms with respect
to the CB1R copy number in CB1R KO mice may be specific to allodynia. The
observation that CB1R knockout mice display similar severity and duration of
allodynia compared to their heterozygous and wild type litermates was not
expected

based

on

prior

evidence

[309-311].

Previous

reports

detail

pharmacological blockade of CB1R with the selective CB1R antagonist
Rhimanobant/SR141716/AM251 has an effect on reversing allodynia. In rats
given oral doses of AM251, the compound reversed CCI-induced allodynia [310].
In separate studies, AM251 attenuated mechanical allodynia in diabetic mice
[309]. Additionally, acute i.t. delivery of AM251, in a dose-dependent manner,
reversed formalin induced pain [311]. Allodynia vs. other measures of sensory
responses like hyperalgesia, may be less sensitive to the genetic deletion of
CB1R. CCI-treated CB1R KO and WT mice both developed the same levels of

158

thermal hyperalgesia [310]. KO mice with sciatic nerve ligation (SNL) developed
unilateral allodynia that was comparable to WT littermates, and allodynic
behavior between groups was nearly identical through the measured timecourse
[312]. These data suggest that under WT conditions antagonism of CB1R is
conducive for anti-allodynia. However, in CB1R KO mice, there must be
compensatory mechanisms that allow for allodynia to be produced to levels
corresponding to WT mice.

4.4.2 Specificity of AM1710’s behavioral and cytokine effects
To verify the spinal CB2R actions of AM1710 following pain reversal, we
examined the effects of i.t. AM1710 in mice with a CB1R genetic deletion,
compared to heterozygous and wildtype littermates. Furthermore, pre-treatment
with AM630, a selective CB2R antagonist, in CB1R KO mice with CCI, blocked
the effects of AM1710. This provides further in vivo evidence that AM1710 acts
on CB2R to suppress allodynia. In support of work in rats [300], intrathecal
AM1710 reset both spinal and DRG levels of IL-10 and IL-1β IR to basal levels in
neuropathic mice in the presence of behavioral reversal, independent of CB1R.
To verify the peripheral CB2R actions of AM1710 to produce anti-allodynia we
examined AM1710 given i.p. in CB1R knockout mice. Again, we compared the
behavioral outcomes to CB1R heterozygous and wild type mice with CCI, and
found that the activation of the CB1R is not necessary for the anti-allodynia
effects of AM1710. Further, peripheral AM1710 produced changes in only DRG
IL-10 and IL-1β at an early 30 minute timepoint. These data support prior findings
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that detail that AM1710 does not effectively cross the blood brain barrier, and
effects of i.p. AM1710 are fast acting (<30 min after administration) [176].
Peripheral AM1710 may act at either nociceptive terminals and/or nociceptors
neuronal cell bodies within the DRG. These data additionally support that CB2R
may be found on peripheral nerve terminals, especially under neuropathic
conditions [313]. Although not significantly different, the CB1R KO displayed the
least amount of reversal. In support of peripherally restricted actions of i.p.
AM1710, we show robust effects at the level of the DRG on both IL-10 and IL-1β
IR. Additionally, reduced IL-10 and increased IL-1β IR as well as glial GFAP and
IBA-1 IR, persisted in the spinal cord concurrent with acute relief from allodynia,
which suggests that spinal mechanisms do not necessarily drive acute
neuropathic pain. No change in spinal IL-1β and IL-10 following i.p. AM1710
suggest that the spinal changes of cytokine expression requires additional time to
catch up following DRG alterations. These short term effects, with allodynia
returning by 2 hours after i.p. administration, could be due to clearance of
AM1710 from peripheral circulation to unmodified IL-10 levels in the spinal cord.

4.4.3 Separation of spinal and DRG mechanisms in neuropathic pain
Very few publications have looked at dorsal horn spinal cord changes with a
peripheral injection, or DRG changes with an intrathecal injection [300, 301].
Here, the reported anatomically distinct protein profiles have not been widely
examined. Both spinal cord and DRG IR are altered with an i.t. injection.
However, following i.p. injection only, DRG at a 30 minute timepoint, reveal IL-10
and IL-1β IR changes that correspond to allodynia reversal. It may be under
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these conditions that an existing and dynamic neuron to glial component is
important in mediating acute actions.

4.4.4 Role of MCP-1 in neuropathic pain
The chemokine MCP-1 is known to be released by neurons in the dorsal horn of
the spinal cord, is bound by its receptor, CCR2, found on immune cells
(macrophage and microglia), and resulting CCR2 signaling cascades are
characterized to attract monocyte-derived cells to areas of tissue injury and
insult. MCP-1 regulation is highly dynamic, and is well characterized to be
upregulated in spinal and DRG neuronal cell bodies in numerous animal models
of neuropathic pain [49, 78, 79, 294, 295, 314-318] as well as in spinal astrocytes
[33]. These data support prior reports demonstrating increased MCP-1
expression in both spinal cord superficial nociceptive neurons as well as
interneurons, astrocytes and DRG nociceptive neuronal cell bodies with CCIinduced neuropathy [33, 49, 318-322]. However, we have extended the findings
of these prior reports and show dynamic regulation of MCP-1 with either i.p. or i.t.
administration of the anti-inflammatory CB2R agonist AM1710. I.t. AM1710 led to
a significant decrease of MCP-1 in both the spinal cord and DRG. I.p. AM1710
led to decreases in not only DRG MCP-1 IR, but also in dorsal horn spinal cord
MCP-1 IR. This early alteration of spinal MCP-1 after peripheral administration of
AM1710 suggests that it may be the driving factor regulating neuropathic pain.
Indeed, under pathological conditions it has been found that the actions of CCR2,
due to MCP-1 binding on either resident spinal microglia or infiltrating bone
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marrow microglia is sufficent for the development of neuropathic pain behaviors
after peripheral nerve ligation [318]. Pharmacological suppression of MCP-1
under neuropathic conditions blocks the development of pain [323]. Additionally,
overexpression of MCP-1 was capable of producing allodynia in otherwise naïve
animals [324]. It has been shown that release of MCP-1 leads directly to the
upregulation of IL-1β [323]. One critical factor in controlling neuropathic pain may
be increased MCP-1 actions Importantly, CB2R agonists may participate in
regulating MCP-1 mediated pain.

4.4.5 Constitutive CB1R modulation of inflammatory factors
The endocannabinoid system is emerging as a critical mediator of inflammation
and pain signaling. Activation of the CB1R can produce pain relief in animal
models of pain, which may have inflammatory components, and as such blocking
the actions of the CB1R to mediate pain may seem counter-intuitive. However,
anti-inflammatory actions are well known to facilitate eduring pain relief, and
blocking CB1R may prove to enhance anti-inflammation. Here, under
inflammatory neuropathic conditions, the functional deletion of CB1R produces
increases of the anti-inflammatory cytokine IL-10 over wild-type in both spinal
cord and DRG tissue, in the presence of stable allodynia.
Evidence exists that antagonism of CB1R, or reducing the effects of constitutive
CB1R, may be beneficial in lowering pro-inflammatory factors. Chronic oral
administration of AM251 reduces CCI-induced increases in prostaglandin in
blood, nitric oxide in sciatic nerve, and spinal TNF-α to basal levels [310]. In
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another study, chronic oral treatment with AM251 lowered the amount of spinal
TNF-α in streptozotocin-induced diabetes [325]. Several reports show decreased
TNF-α and IL-1β following LPS administration in rats when rats were treated with
AM251 [326, 327].
We propose an endocannabinoid mediated form of neuroprotection. Normal,
constitutive
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pain/inflammatory conditions may serve to be neuroprotective [261, 284, 299,
328]. However, with this vital component of the endocannabinoid system
removed, as in CB1R knockout mice, neurons no longer have the same
supported protection. Microglia may compensate, thereby becoming activated
upon insult, as presented in the spectral analysis data of Iba-1 IR. This increased
activation did not increase pro-inflammatory IL-1β IR, but increased IR of the
neuroprotective cytokine, IL-10 [227]. Although speculative, the current findings
may be due to higher endocannabinoid ligand binding to the CB 2R expressed on
microglia.
An inverse role for CB1R and IL-10 expression can be made from prior literature
where studies pharmacologically block the CB1R. Adipocites from obese Zucker
rats treated for 3 weeks with AM251 had lower TNF-α and correspondingly
higher IL-10 levels [329]. Additionally, AM251, when given peripherally or spinally
in mice, lowered circulating pro-inflammatory cytokines with increased IL-10 [330,
331]. Given this evidence, there may be additional therapeutic, anti-inflammatory
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synergism with the administration of CB1R antagonists coupled with CB2R
agonists [332].
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Figure 4.8 Diagram of proposed DRG and dorsal horn spinal cord interplay in the
regulation and maintenance of neuropathic pain.
Diagram of proposed DRG and dorsal horn spinal cord interplay in the regulation and
maintenance of neuropathic pain. A, Under neuropathic conditions increases in both spinal and
DRG MCP-1 (blue lightening bolt) from neurons leads to glial activation (red many sided
polygon), and upregulation of pro-inflammatory factors (yellow oval), such as the proinflammatory cytokines IL-1β and TNF-α. Further, this cycle is continued by steady aberrant pain
signaling from the DRG into the dorsal horn spinal cord (red trace from DRG to spinal cord). B,
During acute peripheral pain relief, such as with i.p. AM1710, decreased DRG pro-inflammatory
factors and MCP-1 are observed, leading to abolished pain signaling to the dorsal horn spinal
cord. This in turn lowers neuronal production of spinal MCP-1. However, due to the acute
mechanisms at play, lower spinal MCP-1 does not immediately translate to diminished glial proinflammatory signaling. This allows for aberrant chronic pain signaling to be rapidly re-instated
once peripheral drug effects start to wear away.

4.4.6 Spinal CB2R agonists as attractive therapeutics
Both i.p. and i.t. AM1710 administration is effective in reversing CCI-induced
neuropathy independent of CB1R actions. However, i.p. injection produced a
more transient reversal from allodynia than spinal injection, and supports that
spinal administration of CB2R agonists may be more efficacious in long term pain
control. This may be due to opponent systems at play with an i.p. injection that
an i.t. injection does not encounter. I.p. injection of AM1710 is able to produce
acute pain relief, but does not cross the blood brain barrier, and therefore, must
be circulated through the periphery to ultimately reach sites of action, such as
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peripheral nerve terminals, and does not produce spinal protein changes in either
IL-10 or IL-1β.
Importantly, it has been shown that under pathological pain there is increased
MCP-1 expression in neuronal cell bodies within the DRG, which correspond to
abbarent pain singaling into the superficial laminae within the dorsal horn spinal
cord. This elevated DRG MCP-1 is typically observed with elevated levels of
DRG IL-1β, and influx of monocytes into the DRG. The primary nerve afferents
located within the spinal cord dorsal horn superficial lamina pre-synaptically
release MCP-1 upon repeated and sustained abberent pain signaling input from
the DRG. Astrocytes additionally release MCP-1 under pathological conditions
[33]. As in the DRG, this elevated MCP-1 is typically observed with elevated
levels of spinal IL-1β and activated microglia (Figure 4.8, A). These spinal
proteins have been shown to be critical in the mediation of enduring chronic pain
relief. However, in the absence of alterations of either cytokine in the spinal cord,
we show that IR levels of both proteins are reset to basal levels in DRG, and a
reduction in both spinal and DRG MCP-1 IR. Further these restricted changes
were sufficient to produce acute (approximately 1 hour) allodynia reversal. Acute
pain relief may require glial alterations leading to changes in pain processing at
either the spinal cord, or the DRG. Although actions in the DRG may produce
initial pain reversal, it is not sufficient to diminish ongoing chronic glial
inflammatory events within the spinal cord, and thus ultimately spinally driven
pain signaling is unmasked and pathological pain signaling is re-established
(Figure 4.8, B). Therefore, targeting the spinal cord may be necessary to produce
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long term relief from chronic pain. AM1710, as well as other CB2R selective
compounds, has the ability to produce a robust anti-inflammatory effect and
holds promise for the treatment of neuropathic pain.
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5. Discussion
5.1 The endocannabinoid system in chronic pain
The bioavailability of endocannabinoids such as anandamide and 2-AG in
neurons and microglia [8, 92] are primarily controlled through enzymatic
metabolism by FAAH and MAGL [140, 142, 234]. Increased endocannabinoid
expression and activity in regions such as the spinal cord are characterized to
inhibit pain-like behaviors in rats [208, 258]. The enzyme, MAGL, has been
identified on presynaptic axon terminals in brain, suggesting it can terminate 2AG activity following ligand-receptor internalization by presynaptic neurons [141,
143]. The current studies reported in this thesis supports, but is not limited to, the
presynaptic localization of MAGL because MAGL immunofluorescent levels were
dramatically increased by neuropathy in the superficial dorsal horn of the spinal
cord where afferent nociceptive fiber terminals communicate to pain processing
neurons. These data extend prior reports by showing a strong decrease in spinal
MAGL immunoreactivity (IR) following either i.t. AM1241 or AM1710 that is
concurrent with complete reversal of allodynia. Indeed, MAGL inhibitors decrease
allodynia in CCI-induced neuropathic mice [151], resulting in an increase in 2-AG
accumulation that is widely characterized to produce analgesia [153]. Microglia
also produce and release 2-AG, and MAGL activity has been described in
microglia [145]. In support of these prior reports, studies presented in this
dissertation (Chapter 3) reveals MAGL staining colocalized with Iba-1 positive
microglia in spinal parenchyma and infiltrating monocytes within spinal meninges.
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Surprisingly, an unremarkable minor increase of FAAH was observed following
CCI-neuropathy compared to sham controls, and these levels remained
unchanged following either i.t. AM1241 or AM1710 injection. As such, it is not
clear from these data whether FAAH plays an important role in chronic pain
produced by CCI-peripheral neuropathy given these levels remained unchanged
during pain reversal. However, only a single biochemical marker was used to
ascertain FAAH expression levels. Further, activity of FAAH may not be reflected
in its levels of expression. The data presented here as part of my dissertation
represents the only known reports addressing pain suppression concurrent with
spinal modulation of endocannabinoid degradative enzymes following treatment
with CB2R agonists under neuropathic conditions.

5.2 Chronic Pain and Cannabinoid 2 Receptor Agonists
The effects of two structurally distinct CB2R agonists, AM1241 and AM1710, on
chronic bilateral allodynia produced by unilateral sciatic nerve CCI was examined
in this body of work. The pattern of bilateral allodynia reported here in both mice
and rats supports a number of prior reports demonstrating a similar behavioral
pattern from CCI [200, 201, 203, 217, 237-239]. Bilateral biochemical changes in
the spinal cord and the DRG have been examined that may, in part, characterize
underlying contralateral allodynia from CCI. These studies reported bilateral
increases in neuronal Fos protein [241], TNF-α protein [191], and IL-6 mRNA
expression [239]. Additionally, very recent reports have demonstrated increases
in unilateral spinal IL-1β mRNA expression [242], or increased IL-1β spinal IHC
IR [243] following unilateral sciatic nerve ligation or transection. Further, the
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endogenous IL-1β receptor antagonist, IL-1RA, contributes to the antiinflammatory effects of activated CB2 receptors [244]. Here I have presented
evidence that both CB2R agonists, AM1241 and AM1710 produced robust
bilateral reversal from allodynia in a dose-dependent manner that may act via
anti-inflammatory mechanisms. This will be discussed in greater detail below. I
additionally investigated intraperitoneal drug efficacy of AM1710 and discovered
that the compound’s anti-allodynia and anti-inflammatory effects were not reliant
on CB1R actions. While prior reports show that peripheral administration of either
AM1241 or AM1710 suppresses pathological pain induced by numerous
methods, [176, 182, 198, 199, 209], such as peripheral neuropathy induced by
spinal nerve ligation [182, 211] and cancer chemotherapeutic agents [176, 177,
198, 210], the current results extend these findings by showing that peri-spinal
(intrathecal; i.t.) AM1241 or AM1710 injection acts to reverse CCI-induced
allodynia. Intrathecal efficacy of AM1710 was not dependent on spinal CB 1R
mechanisms. Importantly, neither i.t. AM1241 nor AM1710 themselves did not
alter normal baseline (BL) sensory threshold responses at any dose, which is
distinct from reports showing an anti-nociceptive action at peripheral nerve
terminals following peripheral administration of AM1241 or AM1710 that
produced increased BL sensory thresholds [165, 175, 176, 197].

5.2.1 Dorsal horn spinal cord and dorsal root ganglia IL-10
This thesis presents evidence for distinct profiles of anti-inflammatory cytokine
protein expression patterns in the dorsal horn of the spinal cord and DRG. In
both the dorsal horn and DRG of neuropathic rats and mice, bilateral IL-10 IR
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was significantly lower compared to non-neuropathic rats and mice. While a
reduction of peripheral nerve or DRG IL-10 mRNA or protein has been reported
[74, 191, 236], to date, no prior reports have demonstrated decreased dorsal
horn IL-10 IR in adult mice or rats during chronic allodynia from peripheral
neuropathy.

5.2.2 Glial, cytokine and p38MAPK alterations in dorsal root ganglia
DRG satellite cells form a distinct sheath that completely surround sensory
neurons, and together with the neuron, create a discrete morphological [71] and
a functional unit [69]. Satellite DRG glia have gained increasing recognition for
altering nociceptive transmission by expressing and responding to several
proinflammatory cytokines including IL-1β [69, 72]. Proinflammatory factors
examined in this thesis include IL-1β to provide a characterization of the antiinflammatory effects of CB2R agonists. In addition to IL-1β, the mitogen-activated
protein kinase (MAPK) family consists of three major members that includes p38,
contributes to pain sensitization following peripheral nerve injury [27, 34, 192,
195, 232, 245-248] via the actions of spinal IL-1β and other proinflammatory
cytokines [249, 250]. These cytokines produce changes at the levels of both the
dorsal horn spinal cord and the dorsal root ganglion, which are critical for chronic
pain processing. Indeed, IL-1β rapidly activates DRG nociceptive cells in a
p38MAPK-dependent manner [80]. The data in this thesis supports these reports,
as increased expression of p-p38MAPK and IL-1β, in addition to GFAP, were
present in the DRG of neuropathic animals. The corresponding L4-L5 DRG
immunofluorescent analysis from neuropathic rats and mice revealed similar
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changes in protein expression patterns. However, bilateral rat DRG changes
were observed only with GFAP IR. This difference may be due to a higher
sensitivity in the contralateral side of mice compared to rats as a consequence of
the immune stimulus from CCI surgery. The data presented here support these
prior reports in that increased p-p38MAPK IR is present in the DRG in
neuropathic rats. In addition, allodynia and increased protein levels of DRG IL-1β
following spinal immune activation (i.t. HIV-1 gp120) was completely prevented
by i.t. AM1710 pretreatment, as measured by quantitative ELISA protein
analysis. Thus immunofluorescent quantitative IL-1β changes observed from
DRG in CCI neuropathic animals using IHC procedures is supported. These data
extend prior reports that CB2R agonists act in a general anti-inflammatory
manner by identifying specific in vivo DRG changes of elevated IL-10 with
concurrently diminished IL-1β.

5.2.3 Alterations in dorsal horn spinal cord
In dorsal horn spinal cord, greater bilateral astrocyte GFAP and microglial Iba-1
IR levels were quantified in neuropathic mice and rats, compared to nonneuropathic controls. Additionally, increased bilateral p-p38MAPK was assessed
only in neuropathic rats. Further, an increase in unilateral spinal IL-1β IR was
measured on the side ipsilateral to CCI in rats, and a bilateral increase in spinal
IL-1β IR was measured in mice. However, following an i.t. AM1241 or AM1710
injection, not only was behavioral allodynia reversed, but IL-10 and IL-1β IR
levels were similar to those observed in non-neuropathic animals.
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Increased microglial and astocytic glial markers in the spinal cord dorsal horn in
neuropathic rats and mice, as assessed by immunofluorescent detection, was
detected supporting prior reports [251, 252]. Dorsal horn spinal cord astrocyte
and microglial responses are recognized to participate in pathological pain found
with a variety of animal models via the actions of p-p38MAPK and IL-1β [24, 194,
253].
CB2R mRNA and immunohistochemically identified protein expression is
present mostly in spinal microglia [93, 94, 135, 139, 212]. CB2Rs in the CNS
have been identified mostly on microglia [94], and prior studies reported
decreased microglial activation following i.t. administration of CB 2R agonists [94,
131, 139]. Studies examining spinal cords of transgenic CB2R knock-out mice
exposed to partial sciatic nerve injury with concurrent neuropathic pain-like
behaviors [93] also revealed increased bilateral dorsal horn microglial activation
compared to wild-type controls. These results suggest that CB2Rs play a
regulatory role in microglial activation during peripheral neuropathic conditions.
However, here I have shown that neither i.t. AM1241 nor AM1710 inhibits dorsal
spinal microglial activation, as assessed by Iba-1 staining, despite full behavioral
reversal of CCI-induced allodynia. Upregulation of Iba-1 is widely known to
indicate active microglia [57, 255, 256]. Other markers for activated microglia
include the CD11b/CD18 [268], or translocator protein (TSPO), formerly known
as the peripheral benzodiazepine receptor [276] preferentially expressed in CNS
macrophage/microglia. The differences in the data results from prior reports may
be that these compounds act by inhibiting general spinal proinflammatory
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processes while leaving microglial function intact. Importantly, increased
expression of microglial Iba-1 is indicative of ongoing microglial activity, but
cannot distinguish anti-inflammatory vs. proinflammatory phenotypes. Thus, it is
possible that the increased microglial Iba-1 reported here may be a consequence
of increased IL-10 and/or MAP-phosphatase production, which are negative
regulators to several proinflammatory MAPKs [91]. This notion is supported by a
prior in vitro study that demonstrated CB2R ligands enhance IL-10 release from
immune stimulated macrophages [257]. However, interpretations of these results
are limited, given only a single microglial marker was used to examine microglial
activation. Microglia are also well characterized to become activated in a
proinflammatory manner due to abberant neuronal signaling under pathological
conditions.

5.3 Neuron to glia link – MCP-1
The chemokine MCP-1/CCL2 is known to be released by neurons, and binds its
receptor, CCR2, found on immune cells, microglia, and possibly GABAergic
spinal neurons [321], and CCL2 is characterized to attract monocyte-derived
cells to areas of tissue injury and insult. Its regulation is highly dynamic, and is
well characterized to be upregulated in spinal and DRG neuronal cell bodies in
numerous animal models of neuropathic pain [49, 78, 79, 294, 295, 314-318].
Either pharmacological or genetic suppression of MCP-1’s actions under
neuropathic conditions blocks the development of pain [315, 318]. We confirm
prior reports demonstrating increased MCP-1 expression in both spinal cord and
DRG with CCI-induced neuropathy. We show dynamic regulation of MCP-1 with
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either i.p. or i.t. administration of the anti-inflammatory CB2R agonist AM1710. I.t.
AM1710 led to a significant decrease of MCP-1 in both the spinal cord and DRG
neurons. I.p. AM1710 led to decreases in not only DRG MCP-1 IR, but also
dorsal horn spinal cord MCP-1 IR. This early alteration of spinal MCP-1 after
peripheral administration of AM1710 suggests that it may an initial driving factor
regulating neuropathic pain as previously demonstrated [49, 318-322]. It has
been shown that release of MCP-1 leads directly to the upregulation of IL-1β
[323]. One critical factor in controlling neuropathic pain may be diminished MCP1. Furthermore, the ability to decrease MCP-1 may be neuroprotective, as
increases in MCP-1 are found in neurodegenerative diseases, such as multiple
sclerosis and ALS [333].

5.4 Constitutive CB1R modulation of inflammatory factors and a
neuroprotectve endocannabinoid mechanism
As previously discussed, activation of the CB1R on neurons is well characterized
to produce relief from pathological pain signaling. Although counter-intuitive,
given activation of CB1R can produce pain relief, blocking CB1R may prove to
enhance anti-inflammation. Here, under inflammatory neuropathic conditions, the
functional deletion of CB1R produces increases of the anti-inflammatory cytokine
IL-10 compared to wild-type in both spinal cord and DRG tissue, in the presence
of stable allodynia. These data suggest that constitutive CB1R expression may
suppress IL-10 expression. Indeed, evidence exists that antagonism of CB1R, or
reducing the effects of constitutive CB1R, may be beneficial in lowering proinflammatory factors. Chronic oral administration of AM251 reset CCI-induced
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increases in inflammatory prostaglandin in blood, nitric oxide in sciatic nerve, and
spinal TNF-α to basal levels [310]. In another study, chronic oral treatment with
AM251 lowered the amount of spinal TNF-α in streptozotocin-induced diabetes,
an inflammatory pain condition following induction of type II diabetes in rats [325].
Several reports show decreased TNF-α and IL-1β in an in vivo LPS inflammatory
rat model whereby rats were treated with AM251 [326, 327]. Thus, in
combination, these reports suggest reducing CB1R may lead to anti-inflammatory
conditions.
Constitutive
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pain/inflammatory conditions may serve to be neuroprotective [261, 284, 299,
328]. However, with this vital component of the endocannabinoid system
removed, as in CB1R knockout mice, neurons are no longer protected under
inflammatory conditions. Under these altered conditions, microglia may
compensate, becoming more activated upon insult, as seen in the present
spectral analysis data of Iba-1 IR. This increased activation did not increase proinflammatory IL-1β IR, but increased IR of the neuroprotective cytokine, IL-10.
Although speculative, the current findings may be due to endocannabinoid
binding to the CB2R, presumably on microglia, as the CB1R is removed.

5.5 Clinical
CB2R agonists are emerging as favorable therapeutics over CB 1R for the
treatment of chronic pain, as these compounds produce relief from pain
symptoms without the commonly reported CB1R-related side-effects, like
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catalepsy and motor ataxia. CB2R agonists may exert their actions independently
from μ-opioid receptor actions, and no evidence currently exists related to the
development of tolerance or addiction following CB2R agonist administration.
While CB2R agonists appear to be highly promising as a new avenue for pain
therapeutics, the actual direct CNS and DRG effects of CB 2R agonists on the
endocannabinoid system are largely unknown. In addition, the CNS role in pain
modulation of the endocannabinoid system is itself not fully understood.
My dissertation research has added to this understanding. Although both CB 2R
agonist compounds, AM1710 and AM1241, exhibited behavioral effects which
occurred within a relatively short therapeutic half-life (~3 hours and ~1.5 hours,
respectively in rats), these data reveal crucial findings which may support the
development of longer lasting, ‘next generation’ CB2R agonists to produce
therapeutic pain control. An advantage of a short therapeutic half-life is the
capability to tightly regulate drug loading doses and potential unwanted sideeffects. Oral formulations easily allow for repeated dosing at discrete intervals.
Additionally, a short half-life for i.t. efficacy localized to the spinal cord may be
advantageous as it may remain localized to spinal canal, avoiding potential whole
body global inhibition of important immune function. Prior reports together with
the data presented here support that the actions of both AM1710 and AM1241
are highly effective to control pathological pain when delivered either peripherally
or by i.t. administration. Additionally, this report supports that pathological pain
states, which can include contralateral allodynia (“mirror image” body part) is
mediated by significant shifts in ipsilateral and contralateral pro- and anti-
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inflammatory spinal cord cytokine milieu, as well as shifts in p38MAPK, MCP-1
and the endocannabinoid degradative enzyme, MAGL. The implication of these
results is that compounds capable of acting on cytokines in the CNS, or
specifically on corresponding DRG can therapeutically control clinically relevant
centrally and peripherally mediated pathological pain conditions.
Although speculative, spinal CB2R activation in humans may be necessary to
reverse ongoing chronic pathological pain. This approach would preferentially
target pathologically activated glia which are critical modulators of chronic
neuropathic pain. Targeting glial cells including microglial cytokines, using CB2R
ligands may hold the key to unlocking an efficacious treatment for chronic pain
patients.

5.6 Experimental Limitations
Chronic pain is a complex disease and is comprised of both a physiological and
emotional component. As such, there are multiple alterations in sensory
perceptions that change behavioral outcomes. Here I only tested one behavioral
measure of chronic pain, allodynia. Therefore, the behavioral results discussed
may not fully reflect behavioral outcomes of other tests commonly used to assess
chronic pain symptoms in animals. Other reasonable animal behavioral tests that
could have been performed include, but are not limited to: Hargreave’s test/ Hot
plate test, for heightened nociceptive responses. Although not necessarily
indicative of pathological pain, depression, or depressive-like outcomes are often
correlated to chronic pain conditions. Additionally, the forced swim test could
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have been applied to examine depressive-like behavioral outcomes. However,
the von Frey test is very reliable, and the results obtained and described here did
not contain ambiguity regarding the effects of the compounds tested.
Additionally, I relied heavily on the use of novel spectral microscopy quantitation
for much of my protein analysis work. It must be acknowledged that this method
is only semi-quantitative, as I do not measure the florescent intensity output to
any known protein concentration curve. These measurements do not provide the
actual concentration of the proteins tested in the sample, rather the ability to say
that one tissue sample has more protein than another. The other alternative
protein quantitation methods that could have been employed here are either
ELISA or Western Blot protein analysis. However, both of these methods rely on
the grinding of tissue, which eliminates the ability to spatially observe the
expression of a given protein within the tissue directly involved in an analysis.
Further, I am able to discern ipsilateral vs. contralateral spinal cord dorsal horn,
and as reported, the ipsilateral meningeal layer of the spinal cord dorsal horn
(Chapter 3). This ability to distinguish and quantify discrete anatomical protein
changes would be very difficult to reproducibly achieve with the human error
associated with dissection techniques, for either ELISA or Western blot analysis.

5.7 Future Directions
It has been found that both endocannabinoids and CB 2R agonists can bind to the
ligand-gated ion channel TRPV-1 [235]. TRPV-1 belongs to the family of
transient receptor potential (TRP) ionic channel family, which includes TRPV-1,
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TRPV-2, TRPV-4, TRPM-8 and TRPA-1 that are expressed by nociceptors.
When activated, these channels are known to generate an inward flow of cations,
such as Ca2+. TRPV-1’s are widely characterized in the periphery on nociceptive
(C and Aδ fiber) nerve terminals within the skin, and cell bodies in DRG, and
within the CNS [235, 334]. Activation is known to occur under noxious chemical
stimulation, such as with capsaicin, the active ingredient in chili peppers,
forskolin, and mustard seed oil [335]. When these compounds bind to and
activate the TRPV-1, this inward flow of Ca2+ depolarizes neuronal signaling,
leading to stimulus transduction ultimately producing the sensation of burning
pain via the pain signaling pathway previously described [335]. Cross-talk also
exists within the TRPV family, and it is known that activation of a TRPV-1 can not
only desensitize itself, but also neighboring TRP’s. It has been speculated that
CB2R agonists at least in part, exert its actions as a weak agonist for the TRPV-1
receptors

generating

small

inward

currents

and

Ca2+

accumulation.

Consequently, threshold levels to produce action potentials in nociceptors are not
generated [235, 336]. By potentially acting weakly as a TRPV-1 agonist, it has
been speculated that CB2R agonists are able to “desensitize” the receptor
without producing pain [235, 336]. Indeed, in vitro, it has been demonstrated that
if a TRPV-1 is bound by a CB2R agonist, a reduction in Ca2+ signaling events can
occur [336]. However, no report clearly demonstrates that CB2R agonists act via
TRPV-1 in vivo. With the use of TRPV-1 knockout mice, my future research will
examine whether TRPV-1 is required for the in vivo efficacy of the CB2R selective
agonist AM1710. I will additionally verify wether glial activation profiles, cytokine
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and chemokine expression are altered in the absence of TRPV-1 (TRPV-1
knockout mice).
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Appendix A: Supplemental Figures

Supplemental Figure A.1
Chemical structures of CB2R agonists and antagonist utilized in all experiments.
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Supplemental Figure A.2
Anatomical location of images acquired and spectral analysis allows for discrete fluorescence
signal detection and analysis. A, Hematoxylin and eosin staining of the dorsal horn of the spinal
cord and B, dorsal root ganglion (area within black box) is displayed in context to relevant
anatomical structures (the entire spinal cord and partial cauda equina, respectively)at 4x
magnification, and then at 20x magnification. C, Representative fluorescent emission for DAPI
(blue) FITC (light green), GFP (dark green) Rhodamine Red (red) and autofluorescence (double
black). Selection of narrow fluorescent peak emission bands (dotted black box around FITC
wavelength) allows for analysis of only FITC signal, without autoflourescent or GFP signal
contaminating fluorescent analysis. D, Representative fluorescent emission threshold level of
FITC defined and expanded from dotted black box in A, with the fluorescent threshold of intensity
set (dashed black line), above autofluorescent levels. E, Representative spectral image of dorsal
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root ganglion as stained for IL-10 (green), with autofluorescent signal defined in pink. F, Same
image in E, with autofluorescent signal removed. In all images the scale bar is equal to 50 µm.
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Supplemental Figure A.3
Contralateral immunofluorescent intensity quantification from 7 μm thick sections of dorsal horn
spinal cord and corresponding DRG from behaviorally verified CB1R KO, Het, WT mice, following
i.t. vehicle or AM1710. A, IL-10 expression in contralateral dorsal horn spinal cord was decreased
in CCI-treated mice that received i.t. vehicle compared to control sham-treated mice given
AM1710, while IL-10 IR recovered to sham levels in CCI neuropathic mice given i.t. AM1710. B,
Contralateral IL-10 expression in DRG was decreased in CCI-treated mice that received i.t.
vehicle compared to control sham-treated mice given AM1710, while IL-10 IR recovered to sham
levels in CCI neuropathic mice given i.t. AM1710. C, Compared to sham controls, IL-1β
expression was increased in the contralateral dorsal horn spinal cord of CCI-treated animals
given i.t. vehicle of AM1710. However, i.t. AM1710 in CCI-treated mice robustly suppressed
increases in IL-1β IR. D, Compared to sham controls, IL-1β expression was increased in the
contralateral DRG of CCI-treated animals given i.t. vehicle of AM1710. However, i.t. AM1710 in
CCI-treated mice robustly suppressed increases in IL-1β IR.
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Supplemental Figure A.4
Contralateral immunofluorescent intensity quantification from 7 µm thick sections of dorsal horn
spinal cord and corresponding DRG from behaviorally verified CB1R KO, Het, WT mice, following
i.p. vehicle or AM1710. A, IL-10 expression in contralateral dorsal horn spinal cord was
decreased in CCI-treated mice that received i.p. vehicle compared to control sham-treated mice
given AM1710, and IL-10 IR remained unchanged at neuropathic levels in CCI neuropathic mice
given i.p. AM1710. B, IL-10 expression in contralateral DRG was decreased in CCI-treated mice
that received i.p. vehicle compared to control sham-treated mice given AM1710, while IL-10 IR
recovered to sham levels in CCI neuropathic mice given i.p. AM1710. C, Compared to sham
controls, IL-1β expression was increased in the contralateral dorsal horn spinal cord of CCItreated animals given i.p. vehicle of AM1710. Intraperitoneal AM1710 in CCI-treated mice did not
alter increases in IL-1β IR. D, Compared to sham controls, IL-1β expression was increased in the
contralateral DRG of CCI-treated animals given i.p. vehicle of AM1710. However, i.p. AM1710 in
CCI-treated mice robustly suppressed increases in IL-1β IR.
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Supplemental Figure A.5
Contralateral immunofluorescent intensity quantification of DRG and spinal cord dorsal horn
reveals both i.p. and i.t. AM1710 administration reduces the expression of the chemokine MCP-1.
A, B, Compared to control mice, contralateral DRG MCP-1 IR expression was increased in CCItreated neuropathic mice that received either i.p. or i.t vehicle of AM1710, while DRG MCP-1 IR in
CCI-treated mice given either i.p. or i.t. AM1710 was substantially reduced. All sections were 7
C, D, Compared to control mice, contralateral dorsal horn spinal cord MCP-1 IR
expression was increased in CCI-treated neuropathic mice that received either i.p. or i.t vehicle of
AM1710, while dorsal horn spinal cord MCP-1 IR in CCI-treated mice given either i.p. or i.t.
AM1710 was substantially reduced.
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